,processed_text
0,introduction clear asthma frequent chronic disease childhood risk severe sars cov- infection pediatric population sars cov- infection affect lung function patient purpose aim investigate course consequence sars cov- infection child asthma determine risk factor decline lung function test method retrospective study asthmatic child coronavirus disease  covid- compare random control group asthmatic patient covid- addition clinical course effect lung function test covid- child asthma evaluate result eighty patient covid-  include study fever fatigue cough frequent symptom covid- severity covid-  patient .% mild clinical condition  moderate disease .% severe disease critically ill disease patient diagnose multisystem inflammatory syndrome child mis c patient suffer pneumothorax lung function test patient covid- infection analyze significant difference find fev .% vs .% p=. fvc% .% vs .% p=. fev fvc .% vs .% p=. value .% vs .% p/=% decrease fef- covid- infection conclusion covid- infection lead dysfunction small airway asthmatic child obesity independent risk factor decrease fef- long term effect covid- infection especially small airway require close monitoring child asthma article protect
1,march world health organization declare coronavirus disease  covid- pandemic till affect million spain million person world total million death spain observe hospitalize covid- patient covid- associate comorbidity show people underlie chronic illness likely grow seriously ill individual covid- past medical history cardiovascular disorder cancer obesity chronic lung disease diabetes neurological disease bad prognosis likely develop acute respiratory distress syndrome pneumonia covid- affect respiratory system variety way spectrum level disease severity depend person immune system age comorbiditie symptom range mild cough shortness breath fever critical disease include respiratory failure shock multi organ system failure covid- infection cause overall worsening previous respiratory disease asthma chronic obstructive pulmonary disease copd interstitial lung disease etc review aim provide information impact covid- disease pre exist lung comorbiditie
2,objective coronavirus disease  covid- pandemic emergency department utilization hospitalization rate allergic disease decline severity allergy admit patient low study aim determine prevalence allergic disease adolescent change trend covid- pandemic compare precede  year subject method analyze datum nationwide web base self report korea youth risk behavior survey  adolescent age year participate survey survey period divide pre pandemic period ii iii iv pandemic period period v current prevalence asthma allergic rhinitis atopic dermatitis allergic morbidity have condition change prevalence covid- pandemic analyze result datum participant analyze weight study population mean age year male .% prevalence asthma allergic rhinitis atopic dermatitis allergic morbidity .% .% .% .% respectively prevalence allergic morbidity increase periods iv decline significantly periods iv v. periods iv prevalence asthma decrease prevalence allergic rhinitis increase prevalence atopic dermatitis remain unchanged period v prevalence condition decrease conclusion necessary update management measure develop relevant policy response altered prevalence allergic disease outbreak covid-
3,importance sars cov- entry require tmprss cell surface protease antiandrogen therapy reduce expression tmprss objective determine temporary androgen suppression induce degarelix improve clinical outcome inpatient hospitalize covid- design setting participant hormonal intervention treatment veteran covid- requiring hospitalization hitch phase placebo control double blind randomized clinical trial compare efficacy degarelix plus standard care vs placebo plus standard care clinical outcome man hospitalize covid- require invasive mechanical ventilation inpatient enrol  department veterans affairs hospital july april datum analyze august  october intervention patient stratify age history hypertension disease severity centrally randomized degarelix subcutaneous dose  mg saline placebo standard care include limit supplemental oxygen antibiotic vasopressor support peritoneal dialysis hemodialysis intravenous fluid remdesivir convalescent plasma dexamethasone main outcomes measures composite primary end point mortality ongoing need hospitalization requirement mechanical ventilation day  randomization secondary end point time clinical improvement inpatient mortality length hospitalization duration mechanical ventilation time achieve temperature reference range maximum severity covid- composite end point  day result trial stop futility plan interim analysis time  evaluable patient include  patient randomize degarelix group  patient placebo group  initially plan median range age year common comorbiditie include chronic obstructive pulmonary disorder patient hypertension patient cardiovascular disease patient asthma patient diabetes patient chronic respiratory failure require supplemental oxygen baseline prior covid- patient primary end point significant difference degarelix placebo group patient vs  patient p similarly difference observe degarelix placebo group secondary end point include inpatient mortality patient vs  patient cause mortality patient vs  patent difference degarelix placebo group overall rate adverse event patient vs  patient adverse event patient vs  patient unexpected safety concern conclusion relevance randomized clinical trial androgen suppression vs placebo usual care man hospitalize covid- degarelix result amelioration covid- severity trial registration clinicaltrials.gov identifier nct
4,background chronic condition associate high risk severe coronavirus disease  covid- include asthma conflict conclusion risk severe disease population objective understand impact asthma covid- outcome cohort hospitalize patient association asthma severity bad outcome method identify hospitalize patient covid- confirmatory polymerase chain reaction testing n asthma n international classification diseases tenth revision code march  december determine asthma maintenance medication pulmonary function test high historical absolute eosinophil count immunoglobulin e. primary outcome include death mechanical ventilation intensive care unit icu admission icu hospital length stay analysis adjust demographic comorbiditie smoking status timing illness pandemic result unadjusted analysis find difference primary outcome patient asthma patient asthma adjust analysis patient asthma likely mechanical ventilation odd ratio confidence interval ci .- p icu admission odd ratio ci p long hospital length stay risk ratio ci p high mortality hazard ratio ci p compare non asthma cohort inhale corticosteroid use eosinophilic phenotype associate considerabledifference interestingly patient moderate asthma bad outcome patient severe asthma conclusion asthma associate severe covid- control factor
5,background high risk covid- infection severity man compare woman describe beginning pandemic role androgens recently highlight control key step coronavirus infection mediate transmembrane protease serin  tmprrs angiotensin convert enzyme  ace receptor lung tissue furthermore high incidence androgenic alopecia male covid- disease report objective study aim evaluate telogen effluvium te prevalence relationship clinical immunologic parameter sample patient consecutively evaluate recovery covid- pneumonia northern italy method overall  patient recruit month covid- pneumonia recovery  hospitalize respiratory intensive care unit remain one treat home extent te assess visual analogic scale thick bundle hair demographic clinical datum systemic inflammation biomarker evaluate result thirty patient report history te mean te vas score range woman high risk odd complain te compare male ci p association strong adjust covid- severity hospital admission vs home care ci p mg l oradj ci p il beta  ng l oradj ci p significantly associate te.conclusion exploratory study raise hypothesis hair shed strictly relate severity covid- disease underlie inflammation patient hormonal status key messagesthe presence telogen effluvium te significantly common woman high severity covid- disease play critical role important hormonal influence development te.the severity inflammation relate te covid- play role suggest high level crp platelet ilbeta
6,introduction current evidence indicate severity coronavirus disease  covid- low pediatric population local datum limited objective characterize clinical epidemiological aspect covid- infection patient young  year argentina population method cross sectional observational analytical study confirmed covid- patient age year see march  march   referral child hospital argentina multivariate analysis identify predictor severe case result total  covid- case include .% live metropolitan area buenos aires .% male patient median age year see epidemiological week .% history contact covid- patient .% family setting .% respiratory symptom .% general symptom .% gastrointestinal symptom .% neurological symptom .% symptom .% asymptomatic addition .% patient hospitalize .% severe critical course total  patient develop multisystem inflammatory syndrome history asthma bronchopulmonary dysplasia congenital heart disease moderate severe malnutrition obesity chronic neurological disease and/or age young  month independent predictor severity live vulnerable neighborhood protective factor conclusion half case refer history contact covid- patient family setting hospitalization base clinical criterion severity severity associate presence certain comorbiditie
7,background study aim compare outbreak coronavirus disease  covid- belgium tomographic biological clinical aspect artificial intelligence ai methodology perform observational retrospective study adult patient symptomatic seven day covid- infection diagnose chest compute tomography ct and/or reverse transcription polymerase chain reaction include study wave pandemic last march second wave last october december wave subgroup define depend respiratory failure occur course disease quantitative estimation covid- lung lesion perform ai radiologist radiology resident chest ct severity score calculate ai result  patient include study find statistically significant difference obesity hypertension asthma difference predominant second wave mixed distribution central peripherical pulmonary lesion note second wave difference note mortality respiratory failure complication radiological biological element chest ct severity score risk factor mortality respiratory failure mild agreement ai visual evaluation pulmonary lesion extension k conclusion march december cohort majority parameter analyze record significant change wave ai reduce experience performance gap radiologist well establish hospitalization criterion
8,background inhale corticosteroid establish long term treatment inflammatory respiratory disease asthma chronic obstructive pulmonary disease investigate treatment coronavirus disease  covid- anti inflammatory action inhale corticosteroid potential reduce risk severe illness result hyperinflammation covid- objective assess inhale corticosteroid effective safe treatment covid- maintain currency evidence living systematic review approach search method search cochrane covid- study register include central pubmed embase clinicaltrials.gov ictrp web science science citation index emerging citation index covid- global literature coronavirus disease identify complete ongoing study  october selection criterion include randomised control trial rct evaluate inhale corticosteroid covid- irrespective disease severity age sex ethnicity include follow intervention type dose inhale corticosteroid include follow comparison inhale corticosteroid plus standard care versus standard care placebo exclude study examine nasal topical steroid data collection analysis follow standard cochrane methodology risk bias assessment cochrane rob  tool rate certainty evidence grade approach outcome mortality admission hospital death symptom resolution time symptom resolution adverse event adverse event infection main result inhale corticosteroid plus standard care versus standard care placebo people confirm diagnosis moderate severe covid- find study include people confirm diagnosis moderate severe covid- people confirm diagnosis asymptomatic sars cov- infection mild covid- include rct allocate  participant  confirm mild covid- analyse subset total number participant recruit study female trial platform design participant allocate treatment group simultaneously include study community base recruit people able use inhaler device deliver steroid rely remote assessment self reporting outcome people old  year co morbidity hypertension lung disease diabetes study conduct high income country prior wide scale vaccination programme total  participant analyse inhaled corticosteroid arm budesonide  participant ciclesonide  participant  participant control arm study include people asymptomatic sars cov- infection respect follow outcome inhale corticosteroid compare standard care result little difference cause mortality day risk ratio rr confidence interval ci  participant low certainty evidence absolute term mean death  people receive inhale corticosteroid death  people receive intervention ci    people probably reduce admission hospital death  day rr ci  participant moderate certainty evidence probably increase resolution initial symptom day  rr ci  participant moderate certainty evidence reduce duration symptom resolution day day ci control group rate  day  participant low certainty evidence evidence uncertain effect adverse event study period rr ci  participant low certainty evidence result little difference adverse event day rr ci  participant low certainty evidence result little difference infection study period rr ci  participant low certainty evidence study report outcome subgroup e.g. age ethnicity sex perform subgroup analysis author conclusion people confirmed covid- mild symptom able use inhaler device find moderate certainty evidence inhale corticosteroid probably reduce combine endpoint admission hospital death increase resolution initial symptom day low certainty evidence suggest corticosteroid little difference cause mortality day  decrease duration symptom resolution know inhale corticosteroid increase decrease adverse event heterogeneity way report study low certainty evidence inhale corticosteroid decrease infection evidence identify come study high income setting budesonide ciclesonide prior vaccination roll out identify lack evidence concern quality life assessment adverse event people asymptomatic infection moderate severe covid-  ongoing complete unpublished rct identify trial registry address similar setting research question current body evidence expect incorporate finding study future version review monitor newly publish result rct inhale corticosteroid weekly basis update review evidence certainty evidence change
9,background severe acute respiratory syndrome coronavirus  sars cov- cause coronavirus disease  covid- challenge healthcare globally acute increase number hospitalize patient necessitate rigorous reorganization hospital care create circumstance previously identify facilitate prescribe error pes e.g. demanding work environment high turnover doctor prescribe expertise hospitalized covid- patient risk pes potentially result patient harm determine prevalence severity risk factor pe post covid- patient hospitalize wave covid- netherlands  month discharge method prospective observational cohort study recruit patient visit post covid- outpatient clinic academic hospital netherlands  month covid- hospitalization june  october  patient appointment eligible inclusion prevalence severity pes assess multidisciplinary consensus meeting odd ratio ors calculate univariate multivariate analysis identify independent risk factor pes result ninety patient include pe experienced medication relate harm require immediate change medication therapy prevent detoriation overall identify pes covid- relate hospitalization multivariate analysis identify icu admission ci medical history copd asthma ci independent risk factor pes conclusion pes occur frequently sars cov- pandemic patient admit icu covid- hospitalization medical history copd asthma risk pes risk factor identify high risk patient implement targeted intervention awareness prescribe safely crucial prevent harm new patient population
10,background coronavirus disease  covid- account  million case million death globally affect population nation develop transitional gender age extent specific involvement known study aim analyze determine different second wave covid- pandemic assess compute tomography severity score ct ss methodology retrospective cross sectional observational study perform tertiary care institution include  patient undergo ct chest june october  patient undergo ct chest february april include patient symptomatic confirm covid- positive compare ct ss dataset addition analyze distribution ct ss concern age comorbiditie gender difference wave covid- analysis perform spss version  ibm corp. armonk ny usa artificial intelligence platform u net architecture xception encoder analysis result study datum reveal mean ct ss differ statistically wave covid- age group affect second wave decade young overall disease predilection affect male finding show female afflict second wave covid- compare wave particular disease increase severity case comorbiditie hypertension diabetes mellitus bronchial asthma tuberculosis conclusion assessment demonstrate significant difference radiological severity score wave covid- secondary objective reveal wave show demographical difference iterate demographical subset population consider low risk disease manifestation heterogeneous
11,purpose acute respiratory syndrome coronavirus  sars cov- pandemic high impact patient chronic disease literature different perspective asthma comorbidity risk factor covid- severity patient method aim retrospective study  allergy department spain determine severity covid- asthmatic adult follow allergy department relationship atopy clinical demographic characteristic phenotype laboratory datum addition lung function test asthma control test act covid- analyze datum obtain electronic medical record march  april result asthmatic patient diagnose covid- infection validate detection test patient admit bilateral pneumonia advanced age elevated d dimer low number lymphocyte eosinophil heart disease hypertension associate severe covid- allergic mixed allergic eosinophilic phenotype biomarker total ige aeroallergens sensitization allergic rhinitis blood eosinophilia relate few hospital admission poor control lower forced expiratory volume second fev relate bad prognosis covid- conclusion asthmatic patient allergic eosinophilic phenotype well evolution covid- low risk admission old patient cardiovascular comorbiditie aerd eosinopenia relate severity covid-
12,management patient asthma coronavirus disease  covid- pandemic concern especially asthma predispose patient respiratory problem interestingly asthma characterize type  inflammation know t helper type endotype display cellular molecular profile confer protective effect covid- result experimental clinical study establish action immunoglobulin e ige induce airway hyperreactivity weaken interferon mediate antiviral response follow respiratory viral infection robust evidence support beneficial effect anti ige biologic treatment omalizumab reduce respiratory virus induce asthma exacerbation reduce frequency duration severity respiratory viral illness patient asthma accumulate report patient severe asthma treat omalizumab pandemic reassuringly show continue omalizumab treatment covid- safe fact help prevent severe course covid- accordingly guidance issue global initiative asthma recommend patient asthma continue take prescribed asthma medication include biologic therapy covid- pandemic impact biologic treatment patient asthma covid- well understand evidence emerge
13,background prospective population base study investigate multiple determinant pre vaccination antibody response sars cov- lack method prospective population base study sars cov- vaccine naive uk adult recruit  november positive swab test result sars cov- prior enrolment information  potential sociodemographic behavioural nutritional clinical pharmacological risk factor obtain online questionnaire combined igg iga igm response sars cov- spike glycoprotein determine dry blood spot obtain november april logistic linear regression estimate adjusted odd ratio aors adjust geometric mean ratio agmrs potential determinant sars cov- seropositivity participant antibody titre seropositive participant respectively result participant  .% seropositive factor independently associate high risk sars cov- seropositivity include frontline health care occupation aor ci international travel .- number visit shop indoor public place  vs. .- p trend body mass index bmi /=  vs. /= vs.  unit week light physical exercise associate low risk .-  vs. h week seropositive participant high titre anti spike antibody associate factor include bmi /=  vs. /=  vs. .- p trend association substantially attenuate adjustment covid- disease severity conclusion high alcohol consumption low light physical exercise represent new modifiable risk factor sars cov- infection recognise association south asian ethnic origin obesity high risk sars cov- seropositivity independent sociodemographic behavioural nutritional clinical pharmacological factor investigate seropositive participant high titre anti spike antibody people south asian ancestry obese people explain great covid- disease severity group
14,objective yupingfeng powder ypf kind preventative patent medicine choose treatment coronavirus disease  covid- high frequency application respiratory tract disease chronic obstructive pulmonary disease asthma respiratory tract infection pneumonia advantage reduce relapse rate severity active component ypf mechanism component affect covid- unclear study aim determine active constituent elucidate potential mechanism method ultra performance liquid chromatography quadrupole time flight mass spectrometry uplc q tof ms liquid chromatography triple quadrupole mass spectrometry lc qqq ms determine component absorbable constituent ypf secondly tcmsp drugbank swiss pharmmapper search target absorbable bioactive constituent ypf target covid- identify base genecards omim database string database filter possible inter protein interaction thirdly gene ontology enrichment analysis kyoto encyclopedia genes genomes kegg pathway analysis perform identify molecular function systemic involvement target gene result total  component ypf  absorbable constituent identify uplc q tof ms wogonin prim o glucosylcimifugin -o methylvisamminol astragaloside iv -o methylvisamminol hydroxylation vital constituent treatment covid- rela tnf il- mapk mapkere recognize key target ypf major metabolic reaction absorb constituent ypf demethylation hydroxylation sulfation glucuronidation kegg pathway analysis show important function ypf t cell activation response molecule bacterial origin cytokine receptor binding receptor ligand activity cytokine activity il- signal pathway chagas disease lipid atherosclerosis etc conclusion approach combine uplc q tof ms network pharmacology effective tool identify potentially bioactive constituent ypf key target treatment covid-
15,background coronavirus disease  covid- global health issue especially people pre existing health condition patient deal asthma presume high risk covid- cause severe respiratory distress main body initial stage pandemic clinical trial study assess association covid- asthma significant association report fact asthma case remain undiagnosed overlap respiratory feature difficult differentiate disease pathomechanism condition immune response generate response condition suggest presence condition likely influence presence severity condition far specific treatment know covid- use plasma therapy broad spectrum antiviral drug initial phase pandemic widespread vaccination phase give positive outcome reduce covid- case disease severity short conclusion take asthma increase risk factor covid- morbidity article aim provide comprehensive insight risk proper management asthma patient covid- pandemic common medication asthma patient suppress respiratory immune response facilitate cytokine storm covid- patient similarly risk viral induce asthma exacerbation different social issue shortage medicine sdoh delay clinical trial asthma patient inconvenience primary focus point reduce probable asthma attack severity prevent hospitalization asthma patient well management asthma patient maintain asthma action plan healthy lifestyle ensure nutritious diet develop self management intervention play crucial role
16,background chronic illness report poor prognostic factor associate severe illness mortality coronavirus disease  covid- infection association asthma limited controversial especially mild asthma method territory wide retrospective study conduct investigate association asthma prognosis covid- patient laboratory confirm hong kong covid-  january  september  include study severe disease define develop respiratory complication systemic complication death result  patient include analysis  asthma  have mild asthma patient asthma significantly likely require invasive mechanical ventilation incidence odd ratio p oxygen therapy incidence .% p intensive care unit admission incidence .% p systemic steroid treatment incidence .% p develop shock incidence .% p acute kidney injury incidence .% p secondary bacterial infection incidence .% p significantly long length stay similar finding find patient asthma global initiative asthma gina step   subgroup analysis conclusion asthma regardless severity independent prognostic factor covid- associate severe disease respiratory systemic complication
17,background coronavirus disease  covid- important global issue december clinical course covid- know mild child adult associate hospitalization child increase emergence contagious severe acute respiratory syndrome coronavirus  sars cov- variant achievement high vaccination rate adult consider global domestic situation believe risk stratification child covid- urgently need decision making hospitalization priority child infect sars cov- vaccination priority covid- method systematic review meta analysis perform comprehensively search pubmed embase scopus koreamed database august criterion enrollment severe covid- poor outcome intensive care unit admission invasive mechanical ventilation and/or death underlie comorbiditie sars cov- infection result  screen study  article include systematic review  article include meta analysis neonate risk ratio rr confidence interval ci .- prematurity young infant rr ci .- obesity rr ci .- diabetes rr ci .- chronic lung disease rr ci .- heart disease rr ci .- neurologic disease rr ci .- immunocompromised status rr ci .- significant risk factor severe covid- child subgroup analysis age young  month rr ci .- asthma rr ci .- neurodevelopmental disorder rr ci .- risk factor severe covid- conclusion child comorbiditie obesity diabetes heart disease chronic lung disease asthma seizure disorder immunocompromised status high prevalence severe covid- neonate premature infant high risk severe covid- define high risk group severe covid- help guide hospital admission priority vaccination sars cov-
18,controversial chronic lung inflammation increase risk covid- risk factor acquire covid- level expression sars cov- entry receptor ace tmprss lung tissue clear lung tissue inflammation affect expression level receptor aim determine level sars cov- receptor lung tissue asthmatic relative age gender asthma severity investigate factor regulate gene expression datum set know asthmatic cohort sarp u biopred evaluate association ace tmprss age gender asthmatic patient type underlie lung tissue inflammatory cytokine notably ace extent tmprss expression upregulate lung tissue asthmatic compare healthy control differential expression ace tmprss observe relative age moderate severe asthma group datum suggest age key regulatory factor expression type tissue inflammation associate significantly ace tmprss expression level follow adjust age gender oral corticosteroid use patient type cytokine ifn gamma il- il- associate increase expression type ii cytokine il- il- low expression ace lung tissue airway epithelium and/or lung biopsy moderate severe asthmatic patient note il- associate ace expression il- associate tmprss expression sputum asthmatic subject vitro treatment bronchial fibroblast il- il- cytokine confirm regulatory effect cytokine sars cov- entry receptor result suggest type inflammation regulate ace tmprss expression lung tissue asthmatic affect susceptibility sars cov- infection
19,patient coronavirus disease  covid- develop eosinopenia eosinophil function include immunoregulation antiviral activity addition modulation inflammatory reaction benralizumab anti interleukin ralpha monoclonal antibody selectively deplete eosinophils enhance antibody dependent cell mediate cytotoxicity eosinophil depletion affect covid- prognosis elucidate present case -year old patient severe asthma benralizumab therapy test positive acute respiratory syndrome coronavirus  sars cov- infection patient experience asymptomatic covid- course deterioration asthma control eosinophil depletion contribute deterioration clinical status comorbiditie play major role severity covid- patient asthma finding case literature review reveal benralizumab therapy associate significant negative impact disease course covid- patient
20,outbreak coronavirus disease  covid- cause novel severe acute respiratory syndrome coronavirus  sars cov- evolve global health crisis currently number risk factor identify potential impact increase morbidity covid- adult include old age male sex pre existing comorbiditie racial ethnic disparity addition factor change laboratory index pro inflammatory cytokine possible complication indicate progression covid- severe critical stage child predominantly suffer mild illness covid- similar adult main risk factor pediatric patient include age pre existing comorbiditie contrast supplementation healthy diet sufficient nutrition covid- vaccination atopic condition act protective factor infection sars cov- covid- vaccination protect vulnerable individual sars cov- infection importantly reduce development severe disease death covid- currently therapy covid- label empiric impact severity mortality covid- unclear interaction asthma covid- bidirectional need clarify study review highlight clinical evidence support rationale risk protective factor morbidity severity mortality covid-
21,damaging inflammatory response implicate pathogenesis severe coronavirus disease  covid- mechanism contribute response unclear prospective cohort early non neutralizing afucosylated immunoglobulin g igg antibodie specific severe acute respiratory syndrome coronavirus  sars cov- associate progression mild severe covid- study biology afucosylated igg immune complex develop vivo model reveal human igg fc gamma receptor fcgammar interaction regulate inflammation lung afucosylated igg immune complex isolate patient covid- induce inflammatory cytokine production robust infiltration lung immune cell contrast antibody structure associate disease progression antibody elicit messenger rna sars cov- vaccine highly fucosylate enrich sialylation modification reduce inflammatory potential igg. vaccine elicit igg promote inflammatory lung response result human igg fcgammar interaction regulate inflammation lung define distinct lung activity mediate igg associate protection progression severe covid-
22,introduction impact acute covid- people asthma appear complex moderate multiple interact disease specific demographic environmental factor research long term effect group limited aim assess impact covid- predictor persistent symptom people asthma method datum online uk wide survey  people asthma median age year female conduct october undertake mixed method analysis characteristic experience report having covid- result covid- group n= .% report increase inhaler use bad asthma management compare report covid- differ gender ethnicity household income covid- group .% report have long covid .% unsure long covid likely long covid describe breathing bad bad initial illness .% vs .% p increase inhaler use .% vs .% p bad bad asthma management .% vs .% p have long covid associate age gender ethnicity uk nation household income analysis free text survey response identify key theme variable covid- severity duration recovery symptom overlap interaction covid- asthma barrier access healthcare conclusion persist symptom common people asthma follow covid- measure need ensure appropriate healthcare access include clinical evaluation investigation distinguish covid- symptom asthma
23,objective association vitamin d concentration respiratory disease assess large rapidly expand literature observational study numerous randomized trial datum source medline embase cochrane central register controlled trials web science clinicaltrials.gov international standard randomized controlled trials number registry  vitamin d play essential role maintain bone health regulate calcium concentration body development vitamin d deficiency associate deteriorate bone health severe case hypocalcemia ricket osteomalacia child adult great risk vitamin d deficiency include patient chronic illness e.g. chronic kidney disease cystic fibrosis asthma sickle cell disease dark pigmented skin poor nutrition infant exclusively breastfe primary source vitamin d sunlight exposure nutritional intake composite literature confusing lead heat debate optimal concentration vitamin d related guideline supplementation accord period research impact vitamin d actively discuss correct functioning immune system establish participate formation innate adaptive immune response year appear datum control trial confirm d hypovitaminosis correlation infection systemic review randomized control trial meta analysis show effectiveness vitamin d supplementation reduce morbidity respiratory disease literary source impact vitamin d consider influence duration severity pneumonia author note case severe complicated pneumonia concentration vitamin d significantly low control case propose activation vitamin d receptor vdr signal pathway generate beneficial effect ards cause sars cov- decrease cytokine chemokine storm regulate reninangiotensin system modulate neutrophil activity systemic review randomized control trial meta analysis show effectiveness vitamin d supplementation reduce morbidity respiratory disease researcher conclude datum remain uncertain require confirmation far design randomized control trial
24,background coronavirus disease  covid- generally asymptomatic mild healthy child severe case occur study report clinical characteristic child classify critical covid- korea provide insight risk factor management child method study retrospective case series child  infant overweight bmi patient fever patient dyspnea cough accompany symptom include sore throat headache lethargy myalgia radiologic finding show pneumonia day symptom onset pneumonia progress child day improve day diagnosis critical case remdesivir administer case steroid provide case inotropic administer case case treat noninvasive mechanical ventilator require mechanical ventilator case require ecmo acute respiratory distress syndrome case admit intensive care unit admission period range day critical covid- case  year age fatal case conclusion develop appropriate policy child covid- pandemic important monitor assess clinical burden population
25,objective summarize current literature psychological impact coronavirus disease  covid- people allergic disease identify gap need future research data source ovid medline(r embase classics embase  present october search search strategy include follow keyword allergic disease covid psychological disorder study selection primary manuscript abstract online telephone survey mixed method study capture patient caregiver experience case study publish guideline allergic disease specific expert group include result people asthma chronic respiratory condition high risk negative psychological outcome risk factor include asthma severity female sex previous history anxiety depression likely owe perceive risk severe disease covid- study identify people allergic rhinitis significantly high anxiety depression score compare healthy control p psychological impact food allergy covid- strongly feel parent caregiver similarly parent child asthma experience substantial psychological burden conclusion covid- considerable psychological impact patient asthma limited datum publish mental health impact covid- patient allergic rhinitis food allergy covid- research continue evolve literature capture later stage pandemic important physician aware potential coincidence mental illness chronic allergic disease refer patient caregiver appropriate resource continue manage allergic disease(s
26,background novel disease cause new coronavirus sars cov- cause unprecedented global pandemic care provider asthmatic child increasingly con cerned viral infection primary trigger asthma flare effect sars cov- generate worldwide lockdown asthmatic child unknown objective aim study analyze effect pandemic sars cov- pediat ric asthma control material method retrospective open transversal study perform ter tiary hospital recruit patient aged year physician diagnose asthma information   season provide result datum collect  child age range year mean age  year control asthma observe  .% patient  versus   patient poorly control asthma  versus  .% decrease exacerbation cause allergy pollen dust mite mold cause relate sars cov- infection observe increase exacerbation observe animal dander stress physical exercise sarscov- infection child reduce need asthma control medication few visit healthcare provider less need treatment oral corticosteroid compare season conclusion pediatric asthma control improve need controller medication decline few visit healthcare provider pandemic compare  season
27,understanding risk factor intervention influence outcome coronavirus disease  covid- continue evolve reveal advance emerge hypothesis form start pandemic epidemiologic study show asthma control diagnosis asthma determinant covid- severity clinical outcome patient primary immunodeficiency impaired cellular immunity variable il- emerge reliable biomarker covid- severity large clinical trial show potential improve outcome inhibition il- signal patient study genetic risk factor severe covid- reveal importance interferon homeostasis defense severe acute respiratory syndrome coronavirus covid- vaccine constitute primary tool end pandemic strategy develop address potential allergic immune mediate reaction discuss advance understanding covid- risk factor outcome context allergic immunologic mechanism
28,
29,acute asthma remain frequent cause child access healthcare asthma exacerbation essential define characteristic severity respiratory infection entail increase risk exacerbation potential hospitalization literature contradictory finding report risk severity severe acute respiratory syndrome coronavirus  sars cov- infection patient affect asthma implication management anti ige monoclonal antibody therapy mean patient affect severe persistent allergic asthma adequate control treatment biological therapy omalizumab add treatment step  global initiative asthma report severe asthma benefit include reduction frequency exacerbation good knowledge report case adolescent severe allergic asthma treat omalizumab switch self administration home sars cov- infection base peculiar experience physician consider switch self administration omalizumab home coronavirus disease  pandemic extensive research datum future study need confirm finding
31,background conflicting evidence effect asthma different therapeutic option covid- severity clinical outcome aim study aim investigate relationship inhale corticosteroid ics asthmatic patient severity covid- materials method retrospective observational study conduct march  october  include datum covid- asthmatic patient n= king abdulaziz medical city patient exclude poor medication history documentation ics non asthma indication ordinal logistic regression determine clinical variable affect covid- severity clinical outcome ics non ics user compare result sample n=  ics therapy significant difference find ics non ics user disease severity p=. mortality p=. icu admission p=. occurrence complication number day ventilation significantly increase ics user p=. prescribe ics laba combination adj p=. hypertensive adj p=. have cancer adj p=. have diabetes adj p=. increase risk severe disease conclusion overall ics therapy alter covid- severity mortality asthmatic patient continued use ics pandemic encourage prevent asthma exacerbation
32,world face coronavirus disease  covid- pandemic severe acute respiratory syndrome coronavirus  sars cov- infection concern raise asthma patient increase risk sars cov- infection disease severity appear asthma independent risk factor furthermore asthma represent hospitalise patient severe pneumonia sars cov- infection increased risk asthma exacerbation trigger sars cov- accumulate evidence asthma phenotype comorbiditie important factor evaluate risk sars cov- infection disease severity finding suggest th high inflammation reduce risk sars cov- infection disease severity contrast increase risk patient th low asthma use inhale corticosteroid ics safe asthma patient sars cov- infection furthermore propose ics confer degree protection sars cov- infection development severe disease reduce expression angiotensin convert enzyme- transmembrane protease serine lung contrast chronic recurrent use systemic corticosteroid sars cov- infection major risk factor poor outcome bad survival asthma patient conversely biological therapy severe allergic eosinophilic asthma increase risk infect sars cov- have bad covid- severity present review summarise current literature asthma covid-
33,background treatment coronavirus disease cause severe acute respiratory syndrome coronavirus- sars cov- urgently need remain limited sars cov- infect cell interaction spike s protein angiotensin convert enzyme  ace transmembrane protease serine  tmprss host cell multiple cell organ target particularly airway epithelial cell om- standardized lysate human airway bacteria strong immunomodulating property impeccable safety profile widely prevent recurrent respiratory infection find airway om- administration inhibit ace tmprss transcription mouse lung suggest om- hinder sars cov-/host cell interaction objective seek investigate om- treatment protect nonhuman primate human epithelial cell sars cov- method ace tmprss mrna protein expression cell binding sars cov- s protein cell entry sars cov- s protein pseudotype lentiviral particle sars cov- cell infection measure kidney lung intestinal epithelial cell line primary human bronchial epithelial cell ace transfecte hekt cell treat om- vitro result om- significantly downregulate ace tmprss transcription surface ace protein expression epithelial cell line primary bronchial epithelial cell om- strongly inhibit sars cov- s protein bind sars cov- s protein pseudotype lentivirus entry sars cov- infection epithelial cell effect om- appear depend sars cov- receptor downregulation conclusion om- inhibit sars cov- epithelial cell infection vitro downregulate sars cov- receptor expression study warrant assess om- prevent and/or reduce severity coronavirus disease
34,background conflict datum regard impact respiratory allergic comorbiditie course novel coronavirus disease  covid- child objective study aim investigate relationship allergic disease covid- severity pediatric patient method seventy pediatric patient covid- classify accord clinical severity evaluate allergy immunology pulmonology department   month infection resolve blood collect patient complete blood cell count assessment immunoglobulin total immunoglobulin e ige level skin prick test spirometry test perform result total  patient age year evaluate covid- asymptomatic mild  patient moderate severe critical  patient base allergy evaluation allergic rhinitis diagnose  patient .% asthma  patient atopic dermatitis  patient aeroallergen sensitivity detect  patient .% covid- infection asymptomatic mild  patient allergic rhinitis .%  aeroallergen sensitivity p p respectively difference severity patient asthma p median interquartile range total ige level significantly high asymptomatic mild group p difference term spirometry parameter conclusion aeroallergen sensitization allergic rhinitis child associate mild course covid- knowledge atopy associate severe covid- outcome child guide clinical risk classification
35,background patient hereditary angioedema hae postulate increase risk coronavirus disease  covid- infection inherent dysregulation plasma kallikrein kinin system limited datum available explore hypothesis objective assess interrelationship(s covid- hae method self report covid- infection complication morbidity mortality survey online questionnaire participant include subject hae c inhibitor cinh deficiency hae cinh subject hae normal c inhibitor hae nl cinh household control normal control impact hae medication examine result total  participant complete survey analyze include  subject hae cinh  subject hae nl cinh  normal control incidence report covid- significantly different normal control subject hae cinh great subject hae nl cinh p obesity positively correlate covid- overall population p similar nonsignificant trend subject hae cinh comorbid autoimmune disease risk factor covid- subject hae cinh p covid- severity complication similar group report covid- reduce subject hae cinh receive prophylactic subcutaneous cinh .% p demand icatibant .% p subject hae cinh hae medication increase risk covid- compare normal control .% p conclusion subject hae cinh take hae medication significantly high rate report covid- infection subcutaneous cinh icatibant use associate significantly reduce rate report covid- result implicate potential role complement cascade tissue kallikrein kinin pathway pathogenesis covid- patient hae cinh
36,background aim dyspnea common symptom associate covid- cause novel coronavirus sars cov- study aim assess prevalence dyspnea observe co variable find predictor dyspnea  month recovery covid- method total  patient include study base response clinical finding initial admission hospital covid- exclude deceased patient total  patient interview telephone -point dyspnea scale relevant question gauge patient clinically interview carry train physician response record store analysis carry statistical programming language r. result total  participant study state suffer respiratory symptom  month covid- study demonstrate patient oxygen saturation level spo p d dimer p serum ferritin p presence severity dyspnea significantly correlate addition patient smoking history p comorbiditie chronic obstructive pulmonary disease copd p find statistically significant group conclusion finding study useful predict manage long term complication covid-
37,coronavirus disease  covid- pandemic cause severe acute respiratory syndrome coronavirus  sars cov- rapidly global health challenge lead unprecedented social economic consequence mechanism pathogenesis sars cov- unique complex omics scale study emerge rapidly offer tremendous potential unravel puzzle sars cov- pathobiology move forward diagnostic potential drug target risk stratification therapeutic response vaccine development therapeutic innovation review summarize aspect understand multiomic integration base molecular characterization covid- date include integration transcriptomic proteomic genomic lipidomic immunomic metabolomic explore virus target develop suitable therapeutic solution system biology tool furthermore review cover abridgment omic investigation relate disease pathogenesis virulence role host genetic variation broad array immune inflammatory phenotype contribute understand covid- trait insight review combine exist strategy multiomics integration profiling help advance knowledge covid-
38,background clinical presentation coronavirus disease  covid- child asthma rarely investigate study aim assess clinical manifestation outcome covid- child asthma use asthma medication associate outcome interest method global asthma network gan conduct global survey gan center datum collection november  april result fourteen gan center  country provide datum  child asthma infect severe acute respiratory syndrome coronavirus  sars cov- covid- asymptomatic  .% mild  .% moderate  .% severe critical  .% thirty .% patient exacerbation asthma  .% hospitalize median  day interquartile range moderate severe covid- significantly likely exacerbation asthma compare asymptomatic mild covid- adjusted odd ratio adjor ci inhale bronchodilator significantly likely change asthma medication adjor ci compare child inhale corticosteroid ics differ use ics regard symptomatic severity covid- asthma exacerbation hospitalization conclusion dependence inhaled bronchodilator inappropriate use ics safe continue child asthma pandemic covid-
39,severe acute respiratory syndrome coronavirus cause coronavirus disease  covid- infect  million lead death million people know risk factor severe disease asthma initially hypothesize risk factor severe disease give association asthma exacerbation respiratory viral illness general fortunately clinical outcome patient asthma overall similar patient asthma convince evidence asthma risk factor severe disease explain decrease gradient angiotensin convert enzyme- receptor upper low respiratory epithelium aeroallergen sensitize patient asthma reduction angiotensin convert enzyme- receptor expression vaccination patient asthma recommend clear contraindication covid specific treatment option available depend severity disease caution use systemic corticosteroid patient asthma require supplemental oxygen give association bad outcome postacute covid- syndrome long haul covid appear prevalent population asthma multidisciplinary approach care reasonable option
40,background study aim assess baseline characteristic clinical outcome coronavirus disease  covid- pediatric patient rheumatic musculoskeletal disease rmd identify risk factor associate symptomatic severe disease define hospital admission intensive care admission death method observational longitudinal study conduct year sars cov- pandemic march -march pediatric patient attend rheumatology outpatient clinic tertiary referral hospital madrid spain diagnosis rmd covid- include main outcome symptomatic disease hospital admission covariate sociodemographic clinical characteristic treatment regimen run multivariable logistic regression model assess associated factor outcome result study population include  pediatric patient mean age year  patient .% asymptomatic  .% mild moderate covid-  patient .% require hospital admission median length hospital admission  day patient require intensive care death previous comorbiditie increase risk symptomatic disease hospital admission compare outpatient factor independently associate hospital admission previous use glucocorticoid p statistically significant risk factor symptomatic covid- find final model conclusion difference covid- outcome accord childhood onset rheumatic disease type find result suggest associate comorbiditie treatment glucocorticoid increase risk hospital admission
41,objective prospectively quantify community level change asthma symptom control morbidity index asthmatic schoolchildren response coronavirus disease  covid- lockdown measure method spring  spring prospectively assess monthly change pediatric asthma control test c act asthma medication usage infection unscheduled visit asthma schoolchildren active asthma cyprus greece compare asthma symptom control morbidity index lockdown measure participant time spend home objectively assess wearable sensor result total  asthmatic child participate study spring compare mean baseline pre covid- lockdown c act score adjust mean increase confidence interval ci p ci p nd rd monthly assessment observe implementation lockdown measure mean increase c act score ci p note increase time spend home improvement profound child severe asthma significant reduction infection asthma medication usage unscheduled visit asthma observe spring  child participate study absence lockdown measure change c act index disease severity observe conclusion clinically meaningful improvement asthma symptom control asthmatic schoolchildren observe covid- lockdown measure spring improvement independently associate time spend home profound child severe asthma
42,asthma heterogenous disease prevalence severity different male versus female age child boy increase prevalence asthma adult woman increase prevalence severity asthma sex hormone genetic epigenetic variation social environmental factor response asthma therapeutic important factor sex difference observe asthma incidence prevalence severity woman fluctuation sex hormone level puberty menstrual cycle pregnancy associate asthma pathogenesis sex difference gene expression epigenetic modification response environmental factor include sars cov- infection associate difference asthma incidence prevalence symptom review role sex hormone genetic epigenetic interaction environment clinical manifestation therapeutic response asthma
43,coronavirus disease  covid- pandemic cause overwhelming number hospitalization death significant socioeconomic impact vast majority study indicate asthma allergic disease represent risk factor covid- susceptibility cause severe course disease raise opportunity investigate underlie mechanism interaction allergic background severe acute respiratory syndrome coronavirus  sars cov- infection majority patient asthma atopic dermatitis allergic rhinitis chronic rhinosinusitis food allergy drug allergy exhibit expression type  immune inflammatory pathway contribution epithelial cell innate lymphoid cell dendritic cell t cell eosinophil mast cell basophils type  cytokine interleukin il)- il- il- il- il- potential impact type  inflammation relate allergic disease susceptibility covid- severity course report review prevalence asthma common allergic disease covid- patient address impact allergic non allergic asthma different severity control status currently available asthma treatment inhale oral corticosteroid short- long act beta agonist leukotriene receptor antagonist biological outcome covid- patient addition possible protective mechanism asthma type  inflammation covid- infection expression sars cov- entry receptor antiviral activity eosinophil cross reactive t cell epitope discuss potential interaction allergic disease covid- postulate include recommendation management
44,background pediatric study asthma covid- date ecological offer limited insight evaluate association asthma covid- individual level method datum prospective clinical registry conduct nested case control study compare group child covid- underlying asthma a+c case child covid- underlie disease c+ control child asthma covid- a+ control result cohort include  a+c case  c+ control  a+ control a+c case likely c+ control present dyspnea wheezing receive pharmacologic treatment include systemic steroid p hospitalize .% vs. .% p adjust analysis a+c case nearly  time likely hospitalize c+ control adjust ci length stay respiratory support level differ group a+c case .% present asthma exacerbation .% develop acute exacerbation symptom shortly test positive sars cov- compare historic a+ control a+c case severe asthma likely controller medication well asthma symptom control p conclusion cohort asthma risk factor hospitalization child covid- bad covid- outcome sars cov- strong trigger pediatric asthma exacerbation asthma severity associate high risk covid-
45,background transmission dynamic sars cov- vary depend social distancing measure circulate sars cov- variant host factor environmental factor seek investigate clinical epidemiological characteristic sars cov- outbreak occur highly dense population area colombo sri lanka april methodology principal finding carry rt qpcr sars cov assess sars cov- specific total neutralize antibody nabs densely pack underserved settlement n identification index case th april individual detect infect rt qpcr secondary attack rate close contact ci  asymptomatic individual find covid- base presence sars cov- specific antibody .% initially seropositive sars cov- detectable total antibody   day .% detectable nabs .% rt qpcr positive individual completely asymptomatic  .% experience symptom classify have mild illness  .% age  .% diabetes cardiovascular disease  .% asthma virus sequence b. b. lineage carry dg mutation discussion conclusion infect individual develop mild asymptomatic illness despite presence comorbid illness majority underserved settlement infect despite circulation dg variant important study environmental host factor lead disease severity transmission
46,introduction aim study compare number pediatric emergency department ped visit young allergic patient respiratory cutaneous symptom wave coronavirus disease  covid- pandemic  period evaluate percentage positive case severe acute respiratory syndrome coronavirus  sars cov- carry retrospective analysis datum young patient visit ped cutaneous respiratory symptom period th february th year  datum allergy covid- nasal swab collect observe ped visit allergic patient respiratory cutaneous symptom period th february th year  ninety ped visit time frame year  p=. month old child  patient non allergic respiratory cutaneous symptom result positive sars cov- specifically find ped visit  .%  vs  .%  patient urticaria angioedema atopic dermatitis p=.  .%  vs  .%  patient anaphylaxis p=.  .%  vs  .%  asthma p=. .%  vs .%  low respiratory disease exclude asthma p=. .%  vs  .%  upper respiratory disease urd p=. show substantial decrease ~% ped visit compare time frame  absolute number  vs respectively ped visit significant reduction find urd .%  vs  .% p=. total number ped visit allergic patient respiratory cutaneous symptom drop precipitously tricky estimate protective action allergy fear contagion lockdown reduction air pollution keep child allergy visit ped study need well understand impact underlie allergy covid- susceptibility disease severity
47,introduction obstructive lung disease asthma chronic obstructive pulmonary disease copd smoking associate great risk respiratory infection hospitalisation conflicting datum exist association severity covid- study evaluate association differ age objective examine association asthma copd smoking severity covid- cohort hospitalise patient test effect modification age method perform retrospective analysis electronic health record datum patient admit massachusetts general hospital assign maximal clinical progression scale score patient  day follow hospital admission order logistic regression measure association maximal severity score asthma copd smoking interaction age measurement main result  patient hospitalise covid- find increase risk severe disease patient copd prior smoking independent age find evidence effect modification age asthma current smoking particular asthma associate decrease covid- severity old adult current smoking associate decrease severity young patient conclusion cohort study identify age modify factor association asthma smoke severity covid- finding highlight complexity determine risk factor covid- severity suggest effect risk factor vary age spectrum
48,aim identify spectrum disease child covid- risk factor admission paediatric intensive care unit picus conduct multicentre prospective study child sars cov- infection  spanish hospital include child covid- multi inflammatory syndrome mis c young  year old attend year pandemic enrol  child total  .% hospitalise  .% require admission picu frequent major clinical syndrome cohort mild syndrome include upper respiratory tract infection flu like syndrome skin mucosa problem asymptomatic .% bronchopulmonary syndrome include pneumonia bronchitis asthma flare .% fever source .% mis c .% gastrointestinal syndrome hospitalise child proportion .% .% .% .% respectively risk factor associate picu admission age month ci mis c ci chronic cardiac disease ci asthma recurrent wheezing ci exclude mis c patient moderate severe liver disease ci asthmatic child admit picu mis c pneumonia asthma flare conclusion hospitalised child covid- usually present major clinical phenotype decrease severity risk factor picu include mis c elevation inflammation biomarker asthma moderate severe liver disease cardiac disease know study suggest child susceptible sars cov- infection compare adult study describe symptom presentation remain unclear symptom group clinically identifiable syndrome severity associate new gather primary diagnosis major syndrome decrease severity mis c bronchopulmonary syndrome gastrointestinal syndrome fever source mild syndrome classification child syndrome unique help assess risk critical illness define spectrum disease instead describe symptom sign
49,objective investigate experience people continue unwell acute covid- refer long covid term symptom interaction healthcare design conduct mixed method analysis response survey access uk online post covid- support information hub april december people experience have acute covid- participant  respondent female .% white ethnicity median age range year .% hospitalise complete survey   week onset symptom .%   week  .% week result ongoing symptom frequently report breathing problem .% fatigue .% muscle weakness joint stiffness .% sleep disturbance .% problem mental ability .% change mood include anxiety depression .% cough symptom appear relate severity acute illness presence pre existing medical condition analysis free text response reveal main theme experience live covid- physical psychological symptom fluctuate unpredictably interaction healthcare unsatisfactory implication future condition society healthcare system need research conclusion consideration patient perspective experience assist planning service address problem persist people remain symptomatic acute phase covid-
50,background remain unclear patient allergic rhinitis ar and/or asthma susceptible corona virus disease  covid- infection severity mortality objective investigate role ar and/or asthma covid- infection severity mortality assess long term ar and/or asthma medication affect outcome covid- method demographic clinical datum adult participant complete sars cov- testing march  december uk biobank analyze rate covid- infection hospitalization mortality relation pre exist ar and/or asthma assess base adjust generalized linear model analyze impact long term ar and/or asthma medication risk covid- hospitalization mortality result patient ar age low positive rate sars cov- test relative risk rr confidence interval ci p low susceptibility male rr ci p female rr ci p similar effect asthma covid- hospitalization major participant age rr ci p instead elderly contrast patient asthma test positively high risk hospitalization rr ci p ar asthma impact covid- mortality conventional medication ar asthma example antihistamines corticosteroid beta adrenoceptor agonist show association covid- infection severity conclusion ar age asthma aged act protective factor covid- infection asthma increase risk covid- hospitalization long term medication significant association infection severity mortality covid- patient ar and/or asthma
51,background observation patient hospitalize coronavirus disease covid- lead note low prevalence patient affect chronic respiratory disease particular asthmatic patient compare general population aim paper evaluate possible protective role corticosteroid therapy patient chronic lung disease risk contract severe covid- main body sars cov- use angiotensin convert enzyme  ace receptor enter cell consider high number receptor patient affect asthma chronic obstructive pulmonary disease copd evidence patient high risk hospitalization covid- need study understand possible protective factor patient particular finding study reduce coronavirus replication cell line treat steroid molecule commonly treat chronic lung disease need attention short conclusion hypothesis corticosteroid commonly treat airways disease modify severity sars cov- disease key point possible predictive factor positive outcome covid- patient treat everyday molecule
54,background covid- pandemic rapidly emergence december belong coronavirus family virus strike time history datum base previous research etiology epidemiology virus family help play vital role formulate prevention precaution strategy initial stage pandemic datum relate covid- pakistan initially document large scale addition weak health care system low economic condition pakistan population general suffer comorbiditie severely affect outcome patient infect covid- objective covid- infection couple manifestation notable outcome document characterize clinically aim study examine clinical manifestation serve indicator early detection severity prognosis covid- infection especially high risk group method retrospective observational study involve abstraction demographic feature present symptom adverse clinical outcome  patient covid- conduct patient admit major hospital rawalpindi islamabad region pakistan study conduct february august multivariate regression analysis carry identify significant indicator covid- severity intensive care unit icu admission ventilator aid mortality study relate covid- infection comorbiditie examine related factor age gender result study identify fever .% cough .% shortness breath .% time hospital admission prevalent symptom patient covid- symptom common conclusive outcome infection  patient n= require icu admission n= require ventilator aid point disease progression stay hospital .% n= patient die analysis reveal relationship present symptom comorbiditie progression disease severity patient old adult patient comorbiditie hypertension diabetes chronic kidney disease asthma significantly affect high proportion result requirement icu admission ventilator aid case case mortality conclusion old adult patient comorbiditie hypertension diabetes asthma chronic obstructive pulmonary disorder chronic kidney disease increase risk develop severe covid- infection increased likelihood adverse clinical outcome
55,coronavirus disease  covid- sweep world information covid- evolve rapidly interim guidance multiple organisation constantly update expand early discovery covid report pregnancy affect progress disease severity recently centres disease control prevention cdc report pregnancy risk factor covid- severity current case report present peripartum covid- positive mortality case
56,background controversial evidence association asthma chronic obstructive pulmonary disease copd risk outcome coronavirus disease  covid- aim evaluate effect asthma copd susceptibility severity covid- method datum nationwide covid- cohort database korea national health insurance corporation utilize total  covid- patient january   june match control regard age sex income asthma copd define diagnostic code icd- medication claim code conditional unconditional multivariate logistic regression apply analyze susceptibility severity covid- associate asthma copd result prevalence mild severe asthma copd differ covid- control patient multivariate analysis total  covid- patient  .% severe covid-  .% total covid- patient die outcome covid- mild severe asthma associate severity mortality covid- adjust variable severe copd significant risk factor severe covid- odd ratio confidence interval ci p mortality covid- multivariate analysis ci p conclusion korean nationwide cohort asthma copd associate covid- severe copd associate severity mortality covid-
57,background age sex race comorbiditie insufficient explain individual remain asymptomatic sars cov- infection die sense increase risk cause long term exposure air pollution investigate understand high heterogeneity covid- infection course objective aim assess underlie effect long term exposure pm severity mortality covid- method retrospective observational study conduct  patient suffer covid- infection build set multivariate predictive model assess relationship long term exposure pm covid- outcome probability death severe covid- outcome predict function clinical variable pollutant exposure mean regularize logistic regression subsequently regularize linear regression construct predict percentage dead severe patient finally odd ratio effect estimate calculate result find long term exposure pm important variable state comorbiditie i.e. copd asthma diabetes obesity prediction covid- severity mortality pm show high effect estimate ci covid- severity mortality high effect estimate correspond age ci follow pm ci finally increase  microg m pm concentration cause increase ci patient suffer covid- severe disease increase ci death discussion result demonstrate long term pm burden guideline exacerbate covid- health outcome guideline air quality standard establish directive epa update accordingly protect human health
58,rationale study suggest patient asthma risk severe coronavirus disease covid- limit datum asthma phenotype consider risk specific covid- objective determine effect asthma phenotype level covid- outcome compare hospitalization rate influenza pneumonia method electronic medical record identify patient asthma match general population patient level datum link public health england severe acute respiratory syndrome coronavirus  sars cov- test datum hospital mortality datum asthma phenotype medication exacerbation history type  inflammation risk outcome adjust major risk factor measure cox regression measurement main result total patient asthma match patient include patient asthma significantly increase risk general practice diagnosis covid- asthma regular inhaled corticosteroid ics use hazard ratio hr confidence interval ci .- intermittent ics plus add asthma medication use hr ci .- regular ics plus add use hr ci .- frequent exacerbation hr ci .- significantly associate hospitalization phenotype significantly associate influenza pneumonia hospitalization patient regular ics plus add asthma therapy hr ci frequent exacerbation hr ci significantly high risk icu admission death atopy blood eosinophil count associate severe covid- outcome conclusion severe asthma associate severe covid- outcome type  inflammation risk covid- hospitalization appear similar risk influenza pneumonia
59,background coronavirus disease  covid- associate coagulopathy cac venous thromboembolism vte report complication covid- infection early publication show cac thromboembolism predictor mortality covid- patient severe disease materials method prospective study conduct intensive care unit icu confirm covid- patient enrol follow death icu discharge cac vte comorbiditie record predictor mortality determine univariate multivariate regression result  patient covid- .% survive .% die cac present .% .% survivor non survivor respectively p  patient .% vte p=.  patient .% arterial thrombosis p=. survivor nonsurvivor age year p=. male gender p=. cac p comorbiditie like chronic kidney disease ckd p=. chronic obstructive pulmonary disease copd p=. asthma p=. significant predictor mortality conclusion severe complication covid- cac sepsis induce coagulopathy overt disseminate coagulopathy vte old age comorbiditie e.g. copd ckd asthma cac vte pulmonary embolism coagulation parameter critical severity score d dimer platelet prothrombin time sofa sequential organ failure assessment score significant predictor mortality covid- patient
60,background late coronavirus infection sars cov- start china december announce pandemic world health organization march epidemiological datum far sars cov- infection child adult allergic asthma common chronic disease child usually relate great risk severity covid- pediatric population report research asthma covid- child far comforting come asthma patient low airway infection attention give evaluate asthma control level possibility sars cov- infection case report report rare adolescent case covid relate pneumonia development underlying asthma -year old male patient follow pediatric allergy outpatient clinic diagnosis asthma  year think typical clinical laboratory finding sars cov- infection combine underlie pediatric allergic asthma pulmonary ct show finding consistent covid related pneumonia discharge  week complaint regress examination normal -day favipiravir treatment complete conclusion physician come asthma patient low airway infection attention give evaluate asthma control level possibility sars cov- infection
61,background little know clinical factor associate covid- disease severity child adolescent method conduct retrospective cohort study  child hospital april  september  pediatric patient discharge primary diagnosis covid- assess factor associate hospitalization factor associate clinical severity eg admission inpatient floor admission intensive care unit icu admission icu mechanical ventilation shock death hospitalize result covid- encounter .% patient discharge emergency department ed  .% hospitalize clinical severity distribution hospitalize moderate .% severe .% severe .% factor associate hospitalization vs discharge ed include private payor insurance adjust odd ratio aor ci .- obesity type  diabetes mellitus type  dm aor ci .- asthma aor ci .- cardiovascular disease aor ci .- immunocompromised condition aor ci .- pulmonary disease aor ci .- neurologic disease aor ci child adolescent hospitalize covid- great disease severity associate black non white race age great  year obesity type  dm cardiovascular neuromuscular pulmonary condition conclusion child adolescent present child hospital eds covid- hospitalize receive care icu old child adolescent low risk hospitalization severe illness hospitalize difference disease severity race ethnicity presence select comorbiditie factor take consideration prioritize mitigation vaccination strategy
62,background novel coronavirus disease  covid- infect .% world population previous study examine risk factor mortality severity base hospitalize individual population base cohort study call provide evidence extrapolate general population aim examine association comorbiditie mortality disease severity individual covid- diagnose  ontario canada method finding conduct retrospective cohort study individual covid- ontario canada diagnose january  december case link health administrative database maintain ice cover resident ontario primary outcome cause -day mortality covid- diagnosis secondary outcome composite severity index contain death hospitalization examine risk factor outcome employ cox proportional hazard regression model logistic regression model adjust demographic socio economic variable comorbiditie result stratify age group total individual diagnose covid-  include study half .% n comorbidity median follow period  day common comorbiditie hypertension n asthma n diabetes .% n individual comorbidity high risk mortality compare hr ci p risk substantially elevate ci .- ci time number comorbiditie increase significant predictor mortality include comorbiditie solid organ transplant hr ci p dementia hr ci p chronic kidney disease hr ci p severe mental illness hr ci% p cardiovascular disease cvd hr ci .- diabetes hr p chronic obstructive pulmonary disease copd hr ci p cancer hr ci p hypertension hr ci p compare effect old age group comorbiditie associate high risk mortality severity individual  year old individual comorbiditie  year age group ci .- p time high risk mortality compare limitation include datum collect  new variant concern predominant ices database contain detailed individual level socioeconomic racial variable conclusion find solid organ transplant dementia chronic kidney disease severe mental illness cvd hypertension copd cancer diabetes rheumatoid arthritis hiv asthma associate mortality severity study highlight number comorbiditie strong risk factor death severe outcome young individual covid- finding suggest addition prioritize age vaccination priority group include young population multiple comorbiditie
63,objective study explore hospital journey patient intellectual disability id compare general population admission covid- wave pandemic demand inpatient resource high identify disparity treatment outcome design match cohort study id cohort  patient match base age sex ethnicity control group ratio compare outcome international severe acute respiratory emerge infections consortium clinical characterisation protocol uk setting admission covid- uk hospital datum symptom severity access intervention complication mortality length stay extract intervention non invasive respiratory support intubation tracheostomy ventilation admission intensive care unit icu result subjective present symptom loss taste smell frequently report id patient indicator severe disease altered consciousness seizure common control high rate cardiovascular risk factor asthma rheumatological disorder smoking id patient admit high respiratory rate median= range=- likely require oxygen therapy .% vs .% despite id patient ci likely receive non invasive respiratory support ci likely receive intubation ci likely admit icu hospital ci increase risk die covid- hospitalise die time fast ci compare control conclusion significant disparity healthcare people id general population covid- pandemic contribute excess mortality group
64,background conduct systematic review evaluate asthma increase risk severe disease adverse outcome subject covid- method query pubmed embase database study index december include study provide datum severe disease hospitalization icu care need mechanical ventilation mortality subject covid- asthma calculate relative risk report outcome interest random effect model summarize datum result retrieve citation include  study review publication report datum retrieve electronic record retrospective subject cohort  study judge high quality subject asthma covid- marginally high risk hospitalization summary relative risk ci severe disease summary relative risk ci icu admission summary relative risk ci mechanical ventilation summary relative risk ci mortality summary relative risk ci compare subject covid- asthma conclusion comorbid asthma increase risk covid relate hospitalization severe disease adverse outcome subject covid-
65,covid- pandemic continue case report publish patient severe asthma biological agent survive mild course illness encourage continuation biological therapy patient severe asthma contrary previous information severe course covid- recently report severe asthmatic biological therapy compare general population evaluate covid- rate disease severity severe asthmatic biological agent retrospective study conduct patient severe asthma treat biological agent datum concern subject contract covid- severity disease evaluate eihgty severe asthmatic biological agent omalizumab mepolizumab aged year mean standard deviation female male ratio  .% include study participant  .% contract covid- course covid- mild .% moderate patient .% patient severe course covid- mechanical ventilation intensive care follow require patient .% treat inpatient participant survive covid- recovery death occur case high rate covid- find patient severe asthma biologic compare report previous report patient covid- mild moderate disease course
66,introduction asthma common chronic disease worldwide disease respiratory tract site entry sars cov- virus important interplay asthma covid- disease area cover report asthma prevalence hospitalize cohort covid- non allergic severe asthma increase risk worsen clinical outcome covid- infection explore epidemiology asthma risk factor severity covid- infection consider role covid- play lead exacerbation asthma impact asthma endotype outcome discuss lastly address safety common asthma therapeutic literature search perform relevant term section review pubmed google scholar medline expert opinion asthma diagnosis risk factor severe covid- especially severe disease nonallergic phenotype covid- appear provoke asthma exacerbation asthma therapeutic continue patient exposure covid- clearly topic remain unknown identify key question interest future researchers.[figure text
67,background fourth wave covid- osaka prefecture japan cause medical crisis aim identify risk factor covid- severity compare patient wave fourth wave method perform observational retrospective study covid- case national hospital organization kinki chuo chest medical center result identify  patient median age year interquartile range  .% mild disease  .% moderate disease  .% severe disease overall mortality rate base multivariate logistic regression analysis cardiovascular disease fever dyspnea inflammatory biomarker independent risk factor moderate severe disease  mg dl increase c reactive protein  iu l increase lactate dehydrogenase  ng ml increase ferritin risk moderate severe disease increase .% .% .% respectively overall disease severity fourth wave high wave significant difference mortality shortage bed  severe patient .% fourth wave transfer advanced hospital conclusion cardiovascular disease fever dyspnea inflammatory biomarker risk factor moderate severe covid- cohort fourth wave covid- severity worsen increase number patient transfer bed severe case result medical crisis osaka
68,background potential protective role eosinophil covid- pandemic arouse great interest give potential virus clearance function infection resistance asthma patient coronavirus unknown eosinophil count serve predictor severity covid- method total  patient confirmed covid- admit leishenshan hospital wuhan china enrol study include  patient general ward  patient intensive care unit icu medical datum analyze association eosinophil icu admission death result  patient covid- low eosinophil count ratio observe severe case adjust confounder affect outcome find eosinophil count predictor icu admission  icu patient  survive  die low eosinophil level indicator death severe covid- patient cutoff value x area curve ci p sensitivity specificity respectively conclusion research reveal low eosinophil level predictor death icu patient cause icu admission
69,purpose review june coronavirus disease  covid- exceed  million report case responsible  million death globally asthma affect approximately  million people worldwide important cause morbidity mortality presently appear asthma associate increase risk contract covid- risk severe covid- covid- relate death severe asthma patient biologic question remain purpose review discuss evidence relationship asthma biologic covid- recent finding available evidence suggest severe asthmatic treatment biologic high risk severe acute respiratory syndrome coronavirus  infection compare general population appear high risk severe disease covid- relate death summary review suggest treatment biologic severe asthma safe maintain covid- pandemic study need address question role biological therapy different asthma phenotype
70,introduction give ongoing coronavirus disease  covid- pandemic consequent global healthcare crisis urgent need well understand risk factor symptom deterioration mortality patient covid- systematic review aim meet need determine predictive value chronic disease covid- severity mortality method search pubmed embase web science cumulative index nursing allied health complete identify study publish december december seventeen observational study  country involve patient include assess risk bias include study perform cumulative meta analysis result find covid- patient hypertension common condition associate high severity intensive care unit icu admission acute respiratory distress syndrome mortality chronic obstructive pulmonary disease strong predictor covid- severity admission icu mortality asthma associate reduce risk covid- mortality patient obesity high risk experience severe symptom covid- mortality patient cerebrovascular disease chronic liver disease chronic renal disease cancer likely severe covid- case great probability mortality conclusion covid- patient chronic disease likely experience severe symptom icu admission face high risk mortality aggressive strategy combat covid- pandemic target patient chronic disease priority
71,background importance clinicolaboratory characteristic covid- report finding alborz province accord late national guideline diagnosis treatment covid- outpatient inpatient trial version  march iran emphasize rrt pcr result clinical feature comorbiditie laboratory finding patient accord severity disease method study  patient include primarily  fulfil inclusion criterion cross sectional center study involve  symptomatic adult hospitalize diagnosis covid- march  april perform analyze frequency rrt pcr result distribution comorbiditie initial clinicolaboratory datum severe non severe case compare compatibility method categorize severity disease result accord finding  patient rrt pcr positive .%  rrt pcr negative indicate significant difference severity group relate date symptom onset admission base national guideline vital sign symptom mean oxygen saturation frequency nausea show significant difference group p significant difference observe comorbiditie curb- group vital sign comorbiditie mean oxygen saturation diabetes hypertension htn hyperlipidemia chronic heart disease chd asthma show significant difference group p significant difference see symptom conclusion study rrt pcr result hospitalize patient covid- relate severity category initial clinical characteristic decrease oxygen saturation appear common abnormality severe non severe category national guideline index comprehensive categorize patient severity group curb- compatibility non severe group national guideline curb- category
72,summary allergic rhinitis ar common disease affect general population worldwide coronavirus  covid- pandemic era observational study analyse effect asthma chronic obstructive pulmonary disease risk develop covid- conduct datum ar limited paper review risk develop sars cov- infection carry ar patient outcome covid- disease covid- influence allergic nasal symptom psychological status ar patient adult paediatric population ar patient protect covid  infection datum influence ar severity covid- disease conclusive ar patient increase risk poor covid- prognosis clinical manifestation ar distinguish covid- symptom treat ar adequately strongly recommend especially pandemic
73,summary currently world engage coronavirus disease  covid- cause acute respiratory syndrome coronavirus  sars cov- infection center disease control prevention cdc propose moderate severe asthma risk factor covid- susceptibility severity current evidence identify asthma  comorbiditie associate covid- fatality raise question patient different type asthma vulnerable sars cov- infection like respiratory infection increased number eosinophil elevated angiotensin convert enzyme  ace expression asthma suppose mechanism associate decrease covid- susceptibility asthmatic study perform evaluate mention factor asthmatic patient compare healthy individual address mechanism investigate ace eosinophil protect asthmatic patient sars cov- infection
74,description reinfection sars cov- recently report study focus exclusively reinfected case consider epidemiological context event objective perform complete analysis sequential infection community transmission event sars cov- reinfection include infection event precede exposure subsequent transmission analysis support host genetic viral genome sequencing phylogenomic viral population analysis refine epidemiological datum obtain interview involved subject reinfection involve -year old woman asthma case covid- episode april  severe second episode -/ month later sars cov- seroconversion august require hospital admission extended genomic analysis allow demonstrate strain involve case reinfection circulate epidemiological context case transmit subsequently case family context reinfection support phylogenetic analysis include  strain madrid reveal strain involve reinfection circulate time case suffer second episode august september absent time range correspond case episode importance present complete analysis epidemiological scenario reinfection sars cov- severe episode include case precede reinfection reinfected case se subsequent transmission seven case
75,objective role overcrowded multigenerational household risk factor covid- remain unmeasured objective study examine quantify association overcrowded multigenerational household covid- new york city nyc study design cohort study method conduct bayesian ecological time series analysis zip code tabulation area zcta level nyc assess zcta high proportion overcrowded define proportion estimate number housing unit occupant room multigenerational household define estimate percentage residence occupy grandparent grandchild  year age independently associate high suspect covid- case rate nyc department health syndromic surveillance datum march  main measure adjust incidence rate ratio irr suspect covid- case population final model control zcta level sociodemographic factor median income poverty status white race essential worker prevalence clinical condition relate covid- severity obesity hypertension coronary heart disease diabetes asthma smoking status chronic obstructive pulmonary disease spatial clustering result suspect covid- case present emergency department  zcta nyc adjust covid- case rate increase irr ci zcta quartile versus percent overcrowdedness increase irr ci quartile versus percent live multigenerational housing interaction exposure significant betainteraction ci conclusion overcrowdedness multigenerational housing independent risk factor suspected covid- early phase surge covid case social distancing measure increase house bind population inadvertently temporarily increase sars cov- transmission risk covid- disease population
76,background beginning coronavirus disease  covid- pandemic increase urgency identify pathophysiological characteristic lead severe clinical course patient infect severe acute respiratory syndrome coronavirus  sars cov- human leukocyte antigen allele hla suggest potential genetic host factor affect individual immune response sars cov- seek evaluate hypothesis conduct multicenter study hla sequencing method analyze association covid- severity hla  individual germany n spain n switzerland n united states n enrol march  august study include patient old  year diagnose covid- represent spectrum disease finally test result meta analyse datum prior genome wide association study gwas finding describe potential association hla c severe clinical course covid- carrier hla c twice risk intubation infect sars cov- risk ratio ci odd ratio ci adjust p value finding base datum country corroborate independent result gwas finding biologically plausible hla c few predict binding site relevant sars cov- peptide compare hla allele interpretation hla c carrier state associate severe clinical course sars cov- finding suggest hla class allele relevant role immune defense sars cov- funding fund roche sequencing solutions inc.
77,background pre exist comorbiditie link sars cov- infection evidence sparse importance pattern multimorbidity condition severity infection indicate hospitalisation mortality aim use multimorbidity index develop specifically covid- investigate association multimorbidity risk severe sars cov- infection method datum uk biobank link laboratory confirm test result sars cov- infection mortality datum public health england march  july review current literature covid- derive multimorbidity index include angina asthma atrial fibrillation cancer chronic kidney disease chronic obstructive pulmonary disease diabetes mellitus heart failure hypertension myocardial infarction peripheral vascular disease stroke adjust logistic regression model assess association multimorbidity risk severe sars cov- infection hospitalisation death potential effect modifier association assess age sex ethnicity deprivation smoking status body mass index air pollution -hydroxyvitamin d cardiorespiratory fitness high sensitivity c reactive protein result participant median age  range year white .%  severe sars cov- infection prevalence multimorbidity double severe sars cov- infection compare cluster multimorbiditie common severe sars cov- infection common cluster severe sars cov- infection stroke hypertension stroke hypertension diabetes hypertension chronic kidney disease hypertension multimorbidity independently associate great risk severe sars cov- infection adjust odd ratio confidence interval compare multimorbidity risk remain consistent potential effect modifier great risk old age high risk severe infection strongly evidence ckd diabetes ci conclusion multimorbidity index help identify individual high risk severe covid- outcome provide guidance tailor effective treatment
78,introduction allergic disease play role predispose factor coronavirus disease  covid- aim study investigate allergic comorbidity association covid- patient method demographic datum clinical manifestation laboratory report radiologic finding underlie comorbidity patient study allergic disease identify standard ga()len questionnaire severity covid- assess visual analog scale vas intensive care unit icu report result  covid- patient admit hospital  .% present different allergic disease reverse association observe have allergic comorbidity severity covid- infection p relative risk confidence interval ci respective frequency asthma allergic rhinitis ar chronic rhinosinusitis crs atopic dermatitis chronic urticaria food drug allergy .% .% significantly ar reversely associate severity covid- p relative risk ci additionally patient present hypoxemia .% chest ct scan involvement interestingly patient allergic disease significantly low hypoxemia chest ct involvement compare non allergic patient p respectively conclusion result study establish allergic disease determine predispose factor severe acute respiratory syndrome sars coronavirus  sars cov- infection significantly ar patient develop mild clinical manifestation covid- admit icu compare non ar patient
79,background demonstration severe acute respiratory syndrome coronavirus type  sars cov- enter cell angiotensin convert enzyme  receptor raise concern hereditary angioedema hae disease characterize bradykinin mediate angioedema attack coronavirus disease  covid- trigger angioedema attack increase frequency and/or severity attack cause severe symptom covid- objective objective evaluate severity covid- patient hae course hae attack angioedema activity quality life score covid- pandemic method patient diagnose hae  month include study -day angioedema activity score angioedema quality life ae qol questionnaire complete onset pandemic march  june sars cov- infection month recover covid- result  patient hae .% diagnose covid- median interquartile range age  patient diagnose covid- year year  patient woman covid-  patient angioedema attack patient severe hae experience significant increase angioedema activity covid- compare basal activity score remain patient similar low attack frequency basal level  patient relative increase attack convalescence period statistically significant difference pre covid- covid- post covid- period function mood fear and/or shame nutrition total score ae qol questionnaire fear dimension relatively affected p conclusion sample size small analysis datum support symptom covid- severe hae significant difference ae qol questionnaire score frequency severity angioedema attack course covid- patient hae
80,datum pertain risk factor analysis coronavirus disease  covid- confound lack datum ethnically diverse population addition lack datum young adult study conduct assess risk factor predict covid- severity mortality hospitalize young adult retrospective observational study conduct center china india covid- patient aged year regression analysis predict adverse outcome perform parameter include age sex country origin hospitalization duration comorbiditie lymphocyte count national early warning score  news score admission total  patient east asians  south asians include predictive model intensive care unit icu admission variable news category ii high diabetes mellitus liver dysfunction low lymphocyte count area curve auc value sensitivity specificity predictive model mortality news category iii cancer decrease lymphocyte count auc value sensitivity specificity combine predictive model bronchial asthma low lymphocyte count contrast auc value sensitivity specificity news score presentation news supplement comorbidity profile lymphocyte count help identify hospitalize young adult risk adverse covid- outcome
81,introduction assess risk factor consequence infection severe acute respiratory syndrome coronavirus  sars cov- pregnancy essential guide clinical care previous study sars cov- infection pregnancy hospitalize patient exaggerated risk estimate severe outcome case sars cov- infection pregnant population include objective study identify risk factor outcome sars cov- infection pregnancy independent severity infection universally test population identify risk factor outcome severe infection require hospital admission material method prospective population base cohort study denmark datum danish national patient register danish microbiology database prospectively register datum medical record include pregnancy march  october  compare woman positive sars cov- test pregnancy non infected pregnant woman case sars cov- infection pregnancy identify prospectively register linkage ensure case identify case pregnant infection main outcome measure pregnancy delivery maternal neonatal outcome severe infection define hospital admission coronavirus disease  covid- symptom result  pregnancy  woman sars cov- infection pregnancy correspond incidence  pregnancy  .% require hospital admission covid- risk factor infection asthma odd ratio ci foreign bear ci risk factor hospital admission covid- include obesity ci smoking ci infection gestational age ga  week ga week ci ga week ci have asthma ci find difference obstetrical neonatal outcome conclusion   woman sars cov- infection pregnancy require admission hospital covid- risk factor admission comprise obesity smoking asthma infection ga  week severe adverse outcome sars cov- infection pregnancy rare
82,background objective ecological study suggest association exposure particulate matter mum pm coronavirus disease  covid- severity finding validate individual level study aim determine association long term pm exposure hospitalization individual patient infect severe acute respiratory syndrome coronavirus  sars cov- method estimate pm exposure residential zip code covid- patient diagnose university cincinnati healthcare system  march   september logistic regression determine odd ratio ci covid- hospitalization associate pm adjust socioeconomic characteristic comorbiditie result covid- patient include study .% hospitalize geometric mean sd pm mug m adjusted analysis  mug m increase annual average pm associate high hospitalization ci likewise  mug m increase pm estimate year  associated high hospitalization ci conclusion long term pm exposure associate increase hospitalization covid- stringent covid- prevention measure need area high pm exposure reduce disease morbidity healthcare burden
83,aim exposure poor air quality establish factor exacerbation respiratory system disease rsd air pollutant cause development rsd remain unclear study aim examine relationship covid- transport restriction hospital admission rsd dublin city county study design retrospective population base cohort method admission datum collect health service executive hospital patient enquiry daily count hospital admission dublin city county address primary diagnosis rsd perform daily air nitrogen dioxide datum obtain environmental protection agency epa result period transport restriction reduction annual mean  mug m  mug m p decrease hospital admission rsd observe  patient episode include study mean age admission year .% female n mean standard deviation length stay day conclusion study routinely gather datum suggest decrease ambient related covid- transport restriction significantly associate low asthma chronic obstructive pulmonary disease admission
84,recent appearance sars cov- responsible ongoing coronavirus disease  covid- pandemic bring light importance understand highly pathogenic agent prevent future pandemic virus single strand positive sense rna family coronaviridae epidemic cause virus sars cov- mers cov. pandemic crucial focus highlight understand risk factor contribute disease severity predict covid- outcome imperative understand virology sars cov- immunological response elicit clinical manifestation progression covid- review provide clinical datum base analysis multiple risk factor sex race hla genotype blood group vitamin d deficiency obesity smoking asthma contribute inflammatory overactivation cytokine storm frequently see covid- patient focus il- pathway draw comparison virulence pathophysiology sars mers establish parallel immune response discuss potential therapeutic approach limit disease progression patient high risk profile cover late information approve upcoming covid- vaccine paper provide perspective emerge variant associate opportunistic infection black mold fungus add mortality part world india compilation exist covid- study datum provide excellent reference tool research clinical public health community
85,dna methylation dnam pattern time  cpgs coronavirus relate gene assess understand vary difference susceptibility symptom outcome sars cov- infection child young adult explain epigenetic alteration host cell transcriptional apparatus coronaviruse dnam datum isle wight birth cohort iowbc birth  year age include linear mixed model repeat measurement stratify sex examine temporal pattern cluster analysis perform identify cpgs follow similar pattern cpg autosome sex chromosome analyze separately association identify cpgs expression gene evaluate pathway enrichment analysis gene conduct fdr dnam   cpgs autosome show statistically significant time effect fdr  cpgs classify cluster represent unique temporal pattern dnam  cpgs sex chromosome dnam seven cpgs male cpgs female show time effect fdr sex specific non specific association dnam gene expression find   cpgs respectively gene map  cpgs represent  biological process suggest observe variability dnam advance age partially explain differ susceptibility disease severity mortality coronavirus infection different age group
86,urgent need identify cellular molecular mechanism responsible severe covid- result death initially perform untargeted target lipidomic focus biochemical analysis  plasma sample find elevate metabolite associate secreted phospholipase spla activity mitochondrial dysfunction patient severe covid- deceased covid- patient high level circulate catalytically active spla group iia spla iia median value high patient mild disease high median value survivor severe covid- elevated spla iia level parallel index covid- disease severity e.g. kidney dysfunction hypoxia multiple organ dysfunction decision tree generate machine learning identify spla iia level central node stratification patient die covid- random forest analysis absolute shrinkage selection operator base lasso base regression analysis additionally identify spla iia blood urea nitrogen bun key variable  clinical index predict covid- mortality combine pla bun index perform significantly well independent cohort n confirm high plasma spla iia level deceased patient compare level plasma patient severe mild covid- pla bun index base decision tree satisfactorily stratify patient mild severe fatal covid- clinically test inhibitor available study identify spla iia therapeutic target reduce covid- mortality
87,background cigarette smoke cs chronic obstructive pulmonary disease copd affect severe acute respiratory syndrome coronavirus  sars cov infection severity controversial investigate effect copd cs expression sars cov- entry receptor ace vivo copd patient control cs expose mouse effect cs sars cov- infection human bronchial epithelial cell vitro method quantify pulmonary ace protein level immunostaine elisa ace and/or tmprss mrna level rt qpcr independent human cohort pulmonary ace protein level immunostaine elisa cbl/ wt mouse expose air cs  month effect cs exposure sars cov- infection evaluate vitro infection calu- cell differentiate human bronchial epithelial cell hbecs respectively result ace protein mrna level decrease peripheral airway copd patient versus control similar central airway mouse expose cs decrease ace protein level bronchial alveolar epithelium versus air expose mouse cs treatment decrease viral replication calu- cell determine immunofluorescence stain replicative double strand rna dsrna western blot viral n protein acute cs exposure decrease vitro sars cov- replication hbecs determine plaque assay rt qpcr conclusion ace level decrease bronchial alveolar epithelial cell copd patient versus control cs expose versus air expose mouse cs pre exposure potently inhibit sars cov- replication vitro finding urge investigate controversial effect cs copd sars cov- infection
88,background global health agency list asthma vulnerability severe case coronavirus disease  covid- evidence support scarce method nationwide cohort study conduct validate korean national health insurance claim datum patient diagnose covid- january  april asthma comorbidity determine diagnosis code assign physician prescription asthma relate medication clinical course covid- classify  severity grade accord requirement oxygen supply mechanical ventilation evaluate association asthma overall hospital mortality covid- result asthma morbidity significant risk factor severe covid- grade  require oxygen supply adjusted odd ratio aor confidence interval ci .- p grade  require mechanical ventilation lead death aor ci p multinomial logistic regression adjust co risk factor asthma significantly associate mortality covid- aor ci p reveal short time hospital mortality covid- p patient recent asthma exacerbation show severe covid- grade  ci p high mortality ci p univariable analysis statistical significance find multivariable analysis conclusion asthma morbidity associate severity mortality covid- patient asthma pay attention avoid worsen covid-
89,persistent ill health acute covid refer long covid post acute covid- syndrome post covid- condition emerge major concern undertake international consensus exercise identify research priority aim understand long term effect acute covid- focus people pre existing airway disease occurrence new onset airway disease associated symptom  international expert invite submit minimum research idea phase internal review process final list  research topic score  expert patient pre existing post covid- airways disease contribute exercise weight select criterion highest rank research idea focus investigation relationship prognostic score hospital admission morbidity  month  month hospital discharge patient pre existing airway disease high priority assign comparison prevalence severity post covid- fatigue sarcopenia anxiety depression risk future cardiovascular complication patient pre existing airway disease approach enable development set priority inform future research study funding decision prioritisation process adapt non respiratory aspect long covid
90,objective failure achieve high level medication adherence obstructive lung disease major cause uncontrolled disease purpose study reveal clinician opinion level patient adherence change adherence covid- pandemic method questionnaire contain multiple choice question treatment adherence patient obstructive lung disease voluntarily apply doctor work tertiary hospital chest disease result eighty doctor mean age year standard deviation year  .% woman answer questionnaire clinician participate study report frequently ask patient adhere treatment clinician think -% patient asthma patient chronic obstructive pulmonary disease decrease medication adherence appear year treatment clinician think main reason patient obstructive lung disease adhere patient reluctance treat regularly impact covid- pandemic patient drug adherence .% clinician observe adherence increase start pandemic conclusion adherence medication desire level patient obstructive lung disease face health threat covid- pandemic patient realize severity illness begin treatment regularly
91,background curcumin derivative spice turmeric adopt eastern medicine century adjunct treat medical condition e.g. anorexia arthritis establish anti inflammatory property study show use curcumin mouse model lead reduction inflammatory marker key inflammatory pathway enzyme result study western medicine develop determine recognize benefit utilize patient inflammatory lung disease asthma study seek well understand curcumin adjunctive therapy improve asthma control patient moderate severe asthma finding hope allow affordable treatment method study utilize randomized placebo control double blind pilot superiority phase  trial outpatient pulmonary clinic southern california usa subject receive curcumin  mg matching placebo mouth twice daily study period  week subject randomize placebo intervention curcumin subject  clinic visit screen visit baseline visit monthly clinic visit week week follow clinic visit phone week change asthma control test score number day miss school work fev predict fev fvc ratio fvc predict blood eosinophil count blood total ige feno level compare group time discussion therapeutic effect curcumin study limited basis asthmatic show mixed result far study hope establish benefit curcumin potential issue arise study design address paper onset covid- pandemic result safety concern delay initiation study study contribute exist literature curcumin role reduce lung inflammation present asthmatic patient suffer covid- trial registration study protocol approve institutional review board loma linda university health nct ind  registered april th 
92,background primary week result ongoing phase double blind ad study nct demonstrate positive benefit risk profile upadacitinib topical corticosteroid tcs patient moderate severe atopic dermatitis objective evaluate efficacy safety upadacitinib tcs  week method patient aged   year chronic moderate severe atopic dermatitis /=% body surface area affect eczema area severity index easi /= validate investigator global assessment atopic dermatitis viga ad /= worst pruritus numerical rating scale wp nrs score randomize daily upadacitinib  mg tcs upadacitinib  mg tcs placebo pbo tcs rerandomize week  upadacitinib tcs safety efficacy include proportion patient experience improvement easi easi- viga ad clear clear improvement /= grade viga ad wp nrs improvement /= assess week miss datum primarily handle nonresponse imputation incorporate multiple imputation miss value coronavirus disease  covid- result  patient  randomize upadacitinib  mg tcs  upadacitinib  mg tcs  pbo tcs end point efficacy upadacitinib  mg tcs upadacitinib  mg tcs week  maintain week week proportion patient treat upadacitinib  mg tcs upadacitinib  mg tcs experience easi- .% respectively .% .% respectively experience viga ad .% .% respectively experience wp nrs improvement upadacitinib tcs tolerate  week new important safety risk current label observe death report major adverse cardiovascular event venous thromboembolic event infrequent patient year conclusion result  week demonstrate long term maintenance efficacy favorable safety profile upadacitinib tcs patient moderate severe ad
93,little know association novel coronavirus disease  covid- type- diabetes child -year old female patient history type- diabetes admit life threaten diabetic ketoacidosis dka recover dka  hour insulin infusion rehydration day diagnose covid- dka relapse require restart insulin develop leukopenia neutropenia high ferritin recovery discharge self quarantine severity dka child covid- multifactorial clinical suspicion covid heighten patient present unexplainedly severe dka
94,background current study asthma history coronavirus disease  covid- outcome limited lack consideration disease status objective conduct population base study assess asthma disease status chronic obstructive pulmonary disease copd relation covid- severity method patient diagnose covid- n large diverse integrate health care system identify asthma copd history medication use covariate extract electronic medical record asthma patient categorize clinical visit asthma  few month prior covid- diagnosis label active inactive asthma respectively primary outcome include covid relate hospitalization intensive respiratory support irs intensive care unit admission  day mortality  day covid- diagnosis logistic cox regression relate covid- outcome asthma copd history result cohort female hispanic mean age year patient active asthma increase odd hospitalization irs intensive care unit admission odd ratio p compare patient asthma copd increase risk observe patient inactive asthma chronic obstructive pulmonary disease associate increase risk hospitalization irs mortality odd ratio hazard ratio p active asthma patient asthma medication great low odd covid- outcome medication conclusion patient asthma require clinical care  few month prior covid- individual copd history increase risk severe covid- outcome proper medication treatment asthma lower risk
95,evidence real impact severe acute respiratory syndrome coronavirus  sars cov- infection preterm birth unclear available series report composite pregnancy outcome and/or stratify patient accord disease severity purpose research determine real impact asymptomatic mild sars cov- infection preterm birth maternal respiratory failure case control study involve woman admit sant anna hospital turin delivery  september   january cumulative incidence coronavirus disease- compare preterm birth case group n term delivery control group n woman spontaneous medically indicate preterm birth placental vascular malperfusion pregnancy relate hypertension complication include current past sars cov- infection determine nasopharyngeal swab testing detection igm igg antibody blood sample significant difference cumulative incidence coronavirus disease- case .% control group .% p= observe case group burden high prevalence know risk factor body mass index asthma chronic hypertension severe coronavirus disease- logistic regression analysis show asymptomatic mild sars cov- infection independent predictor spontaneous medically indicate preterm birth pregnancy relate hypertension complication confidence interval pregnant patient comorbiditie need reassure asymptomatic mild sars cov- infection increase risk preterm delivery preterm birth severe coronavirus disease- share common risk factor i.e. body mass index asthma chronic hypertension explain high rate indicate preterm birth maternal condition report literature
96,background covid- newly emerge infectious disease spread globally unpredictable unique pattern extent world health organization announce covid- pandemic couple month study aim describe clinical demographic feature covid- patient influence risk factor severity disease method research retrospective study base saudi arabia ministry health covid- datum analysis rely datum covid- patient record riyadh st march  th july statistical analysis perform investigate effect demographic characteristic clinical presentation comorbiditie infection severity result total number  covid- patient identify base demographic datum follow  case case male  case case saudi patient diagnose mild sign symptom  case  patient case demonstrate moderate sign symptom  case severe  critical febrile illness fever cough sore throat shortness breath common symptom patient covid- study comorbiditie covid- patient diabetes mellitus hypertension prevalent result bivariate logistic regression analysis reveal old age diabetes mellitus asthma smoking fever associate severe critically ill case conclusion finding study old age fever comorbiditie involve diabetes mellitus asthma smoking significantly associate infection severity
97,background chronic obstructive pulmonary disease copd associate increase risk severe covid- mechanism unclear patient severe covid- report increase level immune mediator method ninety protein quantify  plasma sample  asthmatic  copd patient  healthy control age year recruit colombia covid- pandemic protein level compare disease group healthy control significant protein compare gene signature sars cov- infection report covid- drug gene set library experimentally test protein biomarker severe covid- result plasma protein show difference patient control asthmatic patient increase level il- copd patient broader systemic inflammatory dysregulation drive hgf opg chemokine cxcl cxcl cxcl cxcl cxcl mcp- mcp- ccl ccl ccl protein involve chemokine signal pathway relate response viral infection find regulate sars cov- experimental infection calu- cell report covid- related gene set database increase hpg cxcl cxcl il- mcp- tnf en rage experimentally detect patient severe covid- conclusion copd patient alter level plasma protein report increase patient severe covid- study suggest copd patient systemic dysregulation chemokine network include hgf cxcl susceptible severe covid- il- level increase asthmatic patient especially female influence response covid- finding study depict novel panel inflammatory plasma protein copd patient potentially associate increase susceptibility severe covid- useful biomarker signature future experimental validation
98,covid- global emergency  million case  death worldwide sars cov- rna virus belong family coronaviridae high infectivity manifestation disease range asymptomatic mild symptom severe pneumonia ards ct scan lung show consolidation ground glass opacities person comorbiditie consider high rate acquire infection asthma allergy identify major risk factor covid- number asthmatic patient have covid- high consider occurrence covid- copd patient relate smoking ace- expression patient considerably high relation covid- tuberculosis reflect term stigma associate diagnosis treatment disease community eventually increase chance people reluctance seek medical help cancer patient usually susceptible infection lung cancer different additionally lung cancer strong association smoke increase risk risk get infection severity high autoimmune disorder fungal infection currently definite treatment covid- currently modality hydroxychloroquine antiviral drug
99,background february million texans diagnose covid- young adult risk sars cov- exposure work academic social setting study investigate demographic clinical risk factor severe disease readmission young adult year old diagnose hospital encounter houston texas usa method finding retrospective registry base chart review conduct investigate demographic clinical risk factor severe covid- patient age positive sars cov- test large metropolitan healthcare system houston texas usa cohort young adult patient diagnose covid- infection hospital encounter include  pregnant woman score  charlson comorbidity index  obese kg m  day diagnostic encounter  patient diagnose pneumonia  receive severe disease diagnosis  return hospital discharge home multivariable logistic regression analysis increase age adjust odd ratio aor confidence interval ci p male gender aor ci p hispanic ethnicity aor ci p obesity ci p asthma history aor ci p congestive heart failure aor ci p cerebrovascular disease aor ci p diabetes aor ci p predictive severe disease diagnosis  day non hispanic black race aor ci p obesity aor ci p asthma history aor ci p myocardial infarction history aor ci p household exposure aor ci p predictive -day readmission conclusion investigation demonstrate significant risk severe disease readmission young adult population especially marginalize community people comorbiditie include obesity asthma cardiovascular disease diabete health authority emphasize covid- awareness prevention young adult continue investigate risk factor severe disease readmission long term sequalae
100,underlying disease associate severe course adult laboratory abnormality widely report sufficient datum clinical course coronavirus disease  covid- child pre existing comorbid condition laboratory finding aim describe independent risk factor estimate severity covid- child child  month  year old hospitalize period march -december result covid- include study patient categorize mild group moderate severe critically group severity base criterion demographic characteristic comorbiditie laboratory variable group compare total  child confirm covid- infection include study common associated disease obesity asthma bronchiale observe disease progress severely patient underlie disease especially obesity asthma bronchiale patient obesity odd ratio confidence interval ci p patient asthma bronchiale ci p group  patient presence lymphopenia hypoalbuminemia elevation serum level c reactive protein procalcitonin uric acid detect result statistically significant p value p p p p p respectively strong predictor moderate severe covid- infection child uric acid odd ratio ci p lymphocyte odd ratio ci p child susceptible covid- pre existing comorbid condition predispose severe disease addition lymphopenia high uric acid indicator covid- infection progress severely
101,concern person underlie respiratory disease increase susceptibility covid- and/or increase severity mortality infect information patient wave epidemic lack japan survey chest physician nationwide collect anonymous datum concern  patient covid- patient prevalence asthma chronic obstructive pulmonary disease copd interstitial lung disease ild .% .% .% respectively covid- patient  comorbiditie exacerbation comorbidity occur .% .% .% respectively mortality .% overall .% .% .% respectively prevalence asthma covid- patient high general population mortality covid- patient asthma high mortality covid- patient underlie respiratory disease covid- patient have copd ild relatively high mortality especially ild
102,objective investigate symptom laboratory result child hospitalise diagnosis covid- aim reveal characteristic symptomatic case study design descriptive cross sectional study place duration study department pediatrics kastamonu training research hospital kastamonu turkey march december methodology seventy child hospitalise diagnosis covid- include study divide group symptomatic asymptomatic demographic datum laboratory result clinic patient group compare result mean age participant year n= girl patient symptomatic group comorbiditie allergic asthma cerebral palsy type- diabetes mellitus anorexia nervosa common symptom fever .% n= noteworthy nlr high nlr symptomatic significantly patient high nlr group symptomatic compare low nlr group p=. hand symptomatic child significantly high level c reactive protein iqr mg l vs. iqr mg l p=. procalcitonin iqr ng ml vs. iqr ng ml p symptom child cerebral palsy die pneumonia study conclusion c reactive protein procalcitonin nlr level find significantly high symptomatic child nlr suggest potential marker associate disease severity covid- patient need support study key word covid- child neutrophil lymphocyte ratio c reactive protein procalcitonin
103,purpose review increase knowledge pathogenesis sars cov- infection complex interaction host viral factor allow clinician stratify severity covid- infection epidemiological datum help model viral carriage infectivity review present comprehensive summary pathophysiology covid- mechanism action sars cov- virus correlation clinical biochemical characteristic disease recent finding ace tmprss receptor emerge key player mechanism infection sars cov- distribution body show impact organ specific manifestation covid- immune evasive subsequently immunoregulative property sars cov- show implicate disease proliferation progression information glean virological property sars cov- consistent reflect clinical behavior covid- infection study specific clinical phenotype severity class covid- assist development target therapeutic halt progression disease mild moderate severe understanding pathophysiology mechanism action sars cov- continue grow hope well effective treatment option continue emerge
104,apparent association risk complication severe acute respiratory syndrome coronavirus  sars cov- infection patient history exist chronic respiratory disease pandemic coronavirus disease  covid- sars cov- pose severe risk cardiopulmonary management chronic respiratory disease amplify risk morbidity mortality afflict population pandemic era present review outline importance pulmonary rehabilitation pr person chronic respiratory disease chronic obstructive pulmonary disease copd asthma covid- era context population pre existing pulmonary diagnosis contract sars cov- follow initial medical management acute recovery exercise base pulmonary rehabilitation pr play crucial role long term management recovery energy conservation technique play pragmatic role pr mild moderate severity case counter post covid- fatigue urgent need effectively address post covid- anxiety depression affect pr delivery system
105,introduction covid- pandemic challenge health care world severity disease high mortality rate consequence management patient chronic disease area cover review summarize date publish datum impact covid- management outcome patient chronic noninfectious respiratory illness include obstructive sleep apnea asthma chronic obstructive pulmonary disease bronchiectasis interstitial pulmonary vascular disease lung cancer expert opinion chronic respiratory disease asthma cystic fibrosis associate severe covid- poor outcome mechanism involve identify therapeutic management patient chronic respiratory disease covid- similar patient post recovery course bad population follow development pulmonary fibrosis bronchiectasis pulmonary hypertension pandemic highly impact usual medical activity limit access diagnosis procedure necessity develop new method monitoring disease adapt therapeutic strategy long term consequence change unknown
106,abstract early period covid- pandemic substantial decrease pediatric emergency department ped visitation intent study report ped utilization covid- pandemic urban pediatric referral center locate close epicenter northeastern us.a retrospective analysis medical record patient visit ped robert wood johnson university hospital rwjuh perform datum include daily census admission rate emergency severity index icd- diagnosis code period february july  week march th visit decrease compare average previous  year census nadir last  week  week postnadir average daily census recover level low prior year norm remain level subsequent month great decrease see low acuity visit visit behavioral health fracture decrease approximately respectively recover prior year norm june july visit asthma exacerbation decrease remain record low remainder study period substantial persistent decrease ped visitation experience covid- pandemic visit behavioral health fracture recover prior year norm visit asthma exacerbation remain record low research need ascertain cause change include patient perception ped
107,continue rise sars cov infection globally emergence wave different country understand characteristic susceptibility infection clinical severity outcome remain vital retrospective study datum extract patient de identify mount sinai health system covid- database assess risk mortality base presence comorbiditie organ specific sequela cov positive patient prevalence cardiovascular metabolic comorbiditie high sars cov+ individual diabetes obesity coronary artery disease hypertension atrial fibrillation heart failure increase overall mortality risk asthma ethnicity modify risk mortality associate comorbiditie regard secondary complication setting infection individual acute kidney injury acute myocardial injury show increase mortality risk cerebral infarct acute venous thromboembolic event associate increase risk mortality biomarker cardiovascular injury coagulation inflammation compare deceased survive individual find cardiac coagulation biomarker elevate fall normal range deceased patient inflammatory marker evaluate increase deceased patient summary identify comorbiditie sequelae peripheral blood biomarker associate elevated clinical severity poor outcome covid- patient overall finding detail granularity previously report factor impact susceptibility clinical severity mortality course covid- disease
108,central feature sars cov- pandemic individual severely ill die mild disease course asymptomatic report development improve multimeric alphabeta t cell stain reagent platform maxi ferritin spheromer display  peptide mhc complex spheromer stain specific t cell efficiently peptide mhc tetramer capture broad portion sequence repertoire give peptide mhc analyze response unexposed individual find t cell recognize peptide conserve coronaviruse abundant tend memory phenotype compare unique sars cov- significantly cd(+ t cell conserve specificity abundant covid- patient mild disease versus severe illness suggest protective role
109,epithelial characteristic underlie differential susceptibility chronic asthma sars cov- covid- viral infection currently unclear revisit transcriptomic datum patient th low versus th high asthma mild moderate severe asthmatic characterize change expression human coronavirus influenza viral entry gene relative sex airway location disease endotype find sexual dimorphism expression sars cov related gene ace tmprss tmprss slca ace receptor downregulation occur specifically female th high asthma protease broadly assist coronavirus influenza viral entry tmprss tmprss highly upregulated sex overall change sars cov relate gene expression specific th high molecular endotype asthma different asthma severity airway location downregulation ace covid- sars anpep hcov e viral receptor wascorrelate loss club ciliated cell th high asthma increase dpp mers cov stgal stgal influenza associate increase goblet basal activate cell overall study elucidate sex airway location disease endotype change epithelial heterogeneity potential factor underlie asthmatic susceptibility lack thereof sars cov-
111,antibodies b cell plasma cell population responsible production key component human immune system response sars cov- cause coronavirus disease  covid- pandemic review finding address nature antibody response sars cov- role protect infection modulate covid- disease severity year learn replicate independent study human immune response pathogen contribute development effective vaccine important question remain duration effectiveness antibody response difference immunity derive infection compare vaccination cellular basis serological finding extent viral variant escape current immunity
112,background transmissible variant sars cov- variant concern lineage b emerge uk aim estimate risk critical care admission mortality patient critically ill overall mortality associate lineage b compare non b compare clinical outcome group method observational cohort study link large primary care qresearch national critical care intensive care national audit research centre case mix programme national covid- testing public health england database sars cov- positive sample s gene molecular diagnostic assay failure sgtf proxy presence lineage b extract cohort datum primary care cohort comprise patient primary care positive community covid- test report nov jan know sgtf status critical care cohort comprise patient admit critical care positive community covid- test report nov jan know sgtf status explore association sars cov- infection lineage b admission critical care unit ccu -day mortality -day mortality follow ccu admission royston parmar model adjust age sex geographical region sociodemographic factor deprivation index ethnicity household housing category smoking status primary care cohort ethnicity body mass index deprivation index dependency admission acute hospital ccu cohort comorbiditie asthma chronic obstructive pulmonary disease type   diabetes hypertension primary care cohort cardiovascular disease respiratory disease metastatic disease immunocompromised condition ccu cohort report information type duration organ support b non b group finding primary care cohort include  patient sars cov- infection  lineage b  .% admit ccu  .% die  day critical care cohort include  patient admit ccu  .% lineage b  .% die end critical care primary care cohort estimate adjusted hazard ratio hrs ci .- ccu admission -day mortality patient lineage b compare non b group adjusted hr mortality critical care estimate critical care cohort patient lineage b compare non b infection interpretation patient lineage b increase risk ccu admission -day mortality compare patient non b sars cov- patient receive critical care mortality appear independent virus strain finding emphasise importance measure control exposure infection covid- funding wellcome trust national institute health research oxford biomedical research centre medical sciences division university oxford
113,methacholine challenge test consider gold standard bronchoprovocation test diagnose asthma test perform pulmonary function lab doctor office methacholine mch act induce airway tightening bronchoconstriction importantly mch hydrolyze cholinesterase enzyme che recently american thoracic society raise concern pulmonary function testing covid- pandemic recently report correlation cholinesterase covid- pneumonia severity mortality show cholinesterase level reduce acute phase severe covid- pneumonia work describe microfabrication potentiometric sensor copper substrate chemically polymerize graphene nanocomposite transducing layer track kinetic mch enzymatic degradation real blood sample vitro estimation characteristic parameter mch metabolism michaelis menten constant km reaction velocity vmax find mum mum min respectively propose sensor design companion diagnostic device answer question patient eligibility perform methacholine challenge test ii individualize personalize medical dosing methacholine iii provide portable inexpensive device allow automate readout need operator intervention iv recommend therapeutic intervention include intensive care early stage reflect disease state covid- pneumonia hope methacholine electrochemical sensor help assay che activity timely manner predict severity prognosis covid- improve treatment outcome decrease mortality
114,purpose scarce datum sars cov- infection patient inborn error immunity iei unresolved question aim describe clinical outcome sars cov- infection brazilian iei patient identify factor influence infection method cross sectional multicenter study include patient age affect iei sars cov- infection variable study sex age type iei comorbiditie number type treatment use iei clinical manifestation severity sars cov- infection result  patient include .% female age month  yo median age yo patient predominantly antibody deficiency n infection asymptomatic n mild n child multisystem inflammatory syndrome mis c observe sex relate susceptibility weak correlation age severity infection number comorbiditie high severe case particularly bronchiectasis cardiopathy severe case hereditary angioedema patient patient age   year die antibody deficiency conclusion outcome mild patient case fatality ratio high general population type iei determine factor severity complement deficiency link mild covid- severity sars cov- infection related old age high number comorbiditie type comorbiditie bronchiectasis cardiopathy
116,background study role eosinophil coronavirus disease  covid- scarce available finding suggest possible association disease severity study analyze relationship eosinophil covid- focus disease severity patient underlie chronic respiratory disease method perform retrospective analysis  subject attend public hospital madrid spain pcr confirm sars cov- infection january  april patient eosinophil count .x()/l consider eosinopenia individual chronic respiratory disease n= classify accord particular underlying condition i.e. asthma chronic pulmonary obstructive disease obstructive sleep apnea result  patient enrol  exclude lack information time admission  subject assess  patient present eosinophil count perform admission reveal eosinopenia  case eosinopenia admission associate high risk intensive care unit icu respiratory intensive care unit ricu admission ci:.- p. conclusion eosinopenia admission confer high risk severe disease require icu ricu care associate increase mortality patient chronic respiratory disease develop covid- age main risk factor progression severe disease death
117,background manage severe asthma severe acute respiratory syndrome coronavirus  sars cov- pandemic challenge particularly safety concern use systemic corticosteroid biologic objective seek determine association biologic systemic corticosteroid use pcr positivity sars cov- coronavirus disease  covid- outcome asthmatic patient method computerized database clalit health services large health care provider israel identify asthmatic adult patient undergo pcr testing sars cov- march december cohort approach assess association biologic use steroid treatment covid- severity -day mortality result overall test asthmatic patient positive pcr testing result sars cov- biologic systemic corticosteroid associate increase risk sars cov- infection multivariate analysis reveal biologic associate significantly increase risk moderate severe covid- composite end point moderate severe covid- cause mortality  day chronic systemic corticosteroid use associate significantly increase risk test outcome recent previous  day systemic corticosteroid use use significantly associate increase risk moderate severe covid- composite moderate severe covid- cause mortality conclusion biologic approve asthma systemic corticosteroid associate increase risk sars cov- infection contrast systemic corticosteroid independent risk factor bad covid- severity cause mortality finding underscore risk recent current exposure systemic corticosteroid asthmatic patient infect sars cov-
118,understanding protective versus pathological immune response sars cov- virus cause coronavirus disease  covid- limit inadequate profiling patient extreme disease severity spectrum perform multi omic single cell immune profiling  covid- patient range disease severity outpatient mild disease fatal case transcriptomic epigenomic proteomic analysis reveal widespread dysfunction peripheral innate immunity severe fatal covid- include prominent hyperactivation signature neutrophil nk cell identify chromatin accessibility change nf kappab bind site cytokine gene loci potential mechanism striking lack pro inflammatory cytokine production observe monocyte severe fatal covid- demonstrate emergency myelopoiesis prominent feature fatal covid- collectively result reveal disease severity associate immune phenotype covid- identify pathogenesis associate pathway potential target therapeutic intervention
119,introduction organ tropism sars cov- respiratory tract potentially aggravate asthma susceptibility patient asthma develop exacerbation infect sars cov- unknown aim investigate symptom present patient asthma infect sars cov- method result patient  year age test positive sars cov- rt pcr include n patient asthma n .%  female symptom therapy phenotype record seventeen patient mild asthma  moderate severe patient asthma asymptomatic  developed symptom require hospital admission  hospitalise patient admit asthma exacerbation pneumonia symptom patient wheeze pneumonia comparison wheeze patient non t asthma rest patient statistically significant p conclusion sars cov- infection significant cause asthma exacerbation patient present wheeze especially case pneumonia severity asthma associate symptom disease
120,background acute asthma exacerbation common cause emergency department ed visit hospitalization child outbreak coronavirus disease  covid- education system closure total lockdown israel march notice decrease pediatric ed visit increase hospitalization asthma exacerbation objective examine pattern ed visit asthma exacerbation covid- outbreak comparison previous year method retrospective study compare asthma relate ed visit hospitalization child age year tertiary center southern israel time period select  prelockdown //  b lockdown //  c postlockdown // compare parallel time period datum demographic number ed visit clinical severity parameter collect analyze result child visit ed asthma exacerbation  child   child lockdown period  reveal significantly few ed visit day compare parallel calendar period  vs. p significantly high hospitalization rate .% vs. .% p long length stay vs. day p observe lockdown conclusion lockdown associate few ed visit asthma exacerbation probably reduce exposure viral infection environmental allergen decrease availability primary physician family reluctance arrive ed ed visit lockdown characterize high hospitalization rate long los
121,objective establish international literature respiratory virus trigger asthma exacerbation virus affect patient manner extent pandemic sars cov- virus bring interest study association novel virus patient mild moderate severe asthma term susceptibility severity treatment data source study selection perform extensive search current literature database pubmed scopus google scholar original article decide include type article case study publish end february  focus effect covid- respiratory system main treatment recommendation date patient bronchial asthma result clear evidence asthmatic high risk experience exacerbation infect high mortality rate general population knowledge molecular pathway asthma phenotype past decade grow underline need predict unique response patient infection novel coronavirus clear certain sub population asthmatic high risk conclusion despite lack evidence high susceptibility and/or mortality relation covid- asthmatic patient treat inhaled bronchodilator corticosteroid biologic maintain controller therapy make alteration
122,background man reportedly suffer severe disease high mortality global sars cov- covid- pandemic analyse sex difference low epidemic area low overall mortality covid- population base set patient treat specialized healthcare method enter hospitalize laboratory confirm covid- case specialized healthcare hospital capital province finland population base quality registry describe demographic severity case fatality sex covid- wave february june result altogether  patient male identify patient hospitalize specialist healthcare n male ci .- age man asthma thyroid insufficiency coronary artery disease compare woman mean time symptom onset diagnosis day long man p=. man require intensive care unit icu vs. long length stay icu male sex associate significantly high case fatality vs. excess male death occur week onset man fatal outcome delay covid- testing hospital admission positive test delay patient severe fatal outcome differ markedly sex multivariable analysis male sex associate independently case fatality ci conclusion male sex associate high disease severity case fatality late presentation male fatal case represent different treatment seek behaviour disease progression sex
123,importance information underlying condition severe covid- illness child limited objective examine risk severe covid- illness child associate underlie medical condition medical complexity design setting participant cross sectional study include patient age  year young international statistical classification diseases tenth revision clinical modification code u. covid- b. coronavirus emergency department inpatient encounter march  january datum collect premier healthcare database special covid- release include datum  hospital multivariable generalized linear model control patient hospital characteristic estimate adjusted risk severe covid- illness associate underlie medical condition medical complexity exposure underlie medical condition medical complexity ie presence complex noncomplex chronic disease main outcomes measures hospitalization severe illness hospitalize ie combine outcome intensive care unit admission invasive mechanical ventilation death result  patient covid- aged  year young median interquartile range age  year  .% female patient  .% underlying medical condition common diagnose condition asthma .% neurodevelopmental disorder .% anxiety fear relate disorder .% depressive disorder .% obesity strong risk factor hospitalization type  diabetes adjust risk ratio arr ci obesity arr ci .- strong risk factor severe covid- illness type  diabetes arr ci cardiac circulatory congenital anomaly arr ci prematurity risk factor severe covid- illness child young  year arr ci chronic complex chronic disease risk factor hospitalization arrs ci ci .- respectively severe covid- illness arrs ci ci .- respectively conclusion relevance cross sectional study find high risk severe covid- illness child medical complexity certain underlying condition type  diabetes cardiac circulatory congenital anomaly obesity health care practitioner consider potential need close observation cautious clinical management child condition covid-
124,objective aim investigate theimpact asthma co morbidity susceptibility clinical course covid- asthma patient patient method material method electronic database pubmed google scholar search keyword search conclusion conclusion despite previous concern increase risk covid- asthmatic study show increase covid- incidence asthmatic compare general population large number study investigate role concomitant asthma susceptibility severity covid- conflicting result indicate numerous factor affect process need large scale study adjust result concomitant factor assess true impact asthma susceptibility severity covid- base recommendation gina  management asthma patient covid- potential protective effect asthma therapy high risk exacerbation discontinue basic therapy consider appropriate continue take asthma patient therapy asthma pandemic
125,objective aim study identify epidemiological clinical laboratory feature coronavirus disease  covid- child method retrospective study conduct pediatric infectious disease specialist  different hospital turkey case record form pediatric case diagnose covid- march june  include case characteristic include age sex date disease onset diagnosis family contact information record clinical datum include duration severity symptom collect laboratory parameter like biochemical test complete blood count chest x ray chest compute tomography ct determine result confirm pediatric covid- case total male case constitute n female constitute n median age confirm case year total case  young  year age .%  year age .%  year age .%  year age .%  year age .%  case old  year age common symptom patient visit fever n median  day iqr day fever median degree c degree c second common symptom cough n .% common symptom sore throat n .% myalgia n .% dyspnea n .% diarrhea n .% stomachache n .% nasal discharge n .% patient classify accord disease severity  .% patient asymptomatic  .% patient mild disease  .% moderate disease  .% case severe disease .% case underlying disease total case patient severe disease underlying condition p need hospitalization differ patient underlying condition p need intensive care high patient underlying condition p seven .% case have underlying condition asthma lung disease asthma conclusion good knowledge large pediatric datum confirm covid- case child age appear susceptible covid- significant difference symptomatology laboratory finding mean age distribution
126,introduction objective severe asthma management coronavirus disease  covid- pandemic challenge continue month herd immunity mirage lot learn covid- affect underlie disease severe asthma exception method narrative review paper available february  pubmed google scholar relate severe asthma covid- main research topic sars cov- infection immunology respiratory pathology interrelationship severe asthma endotype covid- disease mechanism severe asthma epidemiology covid- biologic severe asthma context covid- result covid- disease mechanism start upper respiratory cell infection immunological facet activate contribute disease severity cell mediate immunity antibody production infrequent covid- course patient develop cytokine storm cause organ damage lead acute respiratory distress syndrome multiorgan failure severe asthma endotype type high protective role infection risk disease course conflict datum epidemiological relationship covid- severe asthma patient study report increase risk infection disease course way round biologic severe asthma increase risk infection severe covid- evidence need conclusion globally era covid- major respiratory society recommend continue biologic treatment preferably self home administration program
127,novel severe acute respiratory syndrome coronavirus  sars cov- cause coronavirus disease- covid- responsible approximately  million case million death globally december currently treatment modality management option recommend national institutes health nih prior patient hospitalization supplemental oxygen requirement pose unique challenge outpatient primary care physician task initial care patient early disease course pandemic family practice provide medical care approximately family locate surround brooklyn community telemedicine disposal clinic task treat patient present remotely covid- large clinical diagnosis give absence person testing co administer azithromycin consider supportive agent increase benefit hydroxychloroquine azithromycin perform reason show antiviral activity rna virus anti inflammatory property antiviral effect bronchial epithelial cell azithromycin show efficacy add treatment reduce asthma exacerbation pertinent pro inflammatory pulmonary condition covid- progression prevent treat bacterial co infection patient sars cov- order investigate association azithromycin covid- disease process clinical study retrospectively identify patient prescribe azithromycin mg day  mg day peak month covid- pandemic new york city march  patient prescribe azithromycin suspicion covid- infection interview telephone constellation symptom compliance prescribed antibiotic intend course symptom duration prior follow antibiotic course initiation complication illness present ultimately majority patient interview phone conclude course azithromycin help improve symptom infection covid- outcome complication patient treat azithromycin noteworthy report pulmonary complication deterioration pulmonary function treatment e.g. shortness breath wheeze dyspnea etc patient experience residual coughing nasal discharge post treatment believe study treatment setting experimental randomized control trial reveal benefit azithromycin term reduce infection severity length limit incidence complication patient covid-
128,background define socio demographic factor clinical presentation underlie disease associate covid- severity helpful management study aim clarify determinant clinical risk factor disease severity patient infect covid- method multi centre descriptive study patient diagnose covid- province tehran march  dec  conduct datum socio demographic characteristic clinical presentation comorbiditie health outcome patient examine characteristic study population describe assess association study variable disease severity chi squared test multiple logistic regression model apply result mean age study population year .% woman half patient present low level blood oxygen saturation icu admission rate .% overall mortality rate old age male sex comorbiditie include hypertension cancer chronic respiratory disease asthma chronic liver disease chronic kidney disease chronic neurological disorder hiv aids infection risk marker poor health outcome clinical presentation relate bad prognosis include fever difficulty breathing impaired consciousness cutaneous manifestation conclusion result alert physician pay attention determinant risk factor associate poor prognosis patient covid- addition finding aid decision maker emphasise vulnerable group public health strategy aim prevent spread disease mortality
129,inflammation characteristic marker numerous lung disorder immune cell macrophage dendritic cell eosinophil t b lymphocyte synthetize release cytokine involve inflammatory process gender difference incidence severity inflammatory lung ailment include asthma chronic obstructive pulmonary disease copd pulmonary fibrosis pf lung cancer lc infectious relate illness report effect sex hormone androgen estrogen testosterone tes beta estradiol e drive characteristic inflammatory pattern lung inflammatory disease investigate general androgen display anti inflammatory action estrogen produce pro inflammatory effect instance androgens regulate negatively inflammation asthma target type  innate lymphoid cell ilcs t helper th)- cell attenuate interleukin il)-a mediate response leukotriene lt biosynthesis pathway estrogen promote neutrophilic inflammation subject asthma copd activation estrogen receptor induce tumorigenesis chapter summarize recent advance functional role associated signal pathway inflammatory cellular response asthma copd pf lc newly occur covid- disease meticulously deliberate influence sex steroid development progress common severe lung disease
130,sex difference anatomy physiology respiratory system widely report intrinsic sex difference show modulate pathophysiology incidence morbidity mortality lung disease life span chapter describe epidemiology sex difference respiratory disease include neonatal lung disease respiratory distress syndrome bronchopulmonary dysplasia pediatric adult disease include asthma cystic fibrosis idiopathic pulmonary fibrosis chronic obstructive pulmonary disease lung cancer lymphangioleiomyomatosis obstructive sleep apnea pulmonary arterial hypertension respiratory viral infection respiratory syncytial virus influenza sars cov- discuss current state research mechanism underlie observe sex difference lung disease susceptibility severity importance consider sex gender variable research study design analysis
132,objective analysis describe clinical feature covid- early phase pandemic ghana method datum extract national covid- treatment center ghana  weeks(from march descriptive inferential statistic perform modify order logistic negative binomial regression analysis apply establish factor associate illness severity non communicable disease ncds count respectively analysis conduct confidence level p value /= stata result  patient average age preponderance male common symptom present cough .% headache .% sore throat .% patient history fever patient asymptomatic approximately underlying co morbid ncd hypertension .% diabetes .% asthma common odd moderate severe mos significantly high unknown exposure similar illness aor(%ci compare non exposure similar illness increased unit ncd count significantly increase odd covid- mos illness cor(%ci adjust age aor(%ci)=.(.- conclusion presence cardiovascular co morbidity dictate frequency report symptom severity covid- infection sample ghanaians physician aware presence co morbid ncd prepare manage effectively covid- patient funding declare
133,objective aim examine comorbiditie associate outcome illness severity death hospitalize patient coronavirus disease  covid- method datum provide national medical center korea disease control prevention agency datum include clinical epidemiological information patient hospitalize covid- discharge april  korea conduct comorbidity network multinomial logistic regression analysis identify risk factor associate covid- disease severity mortality outcome variable clinical severity score css categorize mild oxygen treatment need severe oxygen treatment need death result total patient include fully adjust model chronic kidney disease ckd odd ratio confidence interval ci chronic obstructive pulmonary disease copd ci significantly associate disease severity ckd ci heart failure hf ci malignancy ci dementia ci diabetes mellitus ci associate increase risk death asthma hypertension show statistically insignificant association increase risk death conclusion underlie disease contribute differently severity covid- efficiently allocate limited medical resource underlie comorbiditie closely monitor particularly ckd copd hf
134,background severe acute respiratory syndrome coronavirus  sars cov- cause coronavirus disease  covid- infect m patient result death worldwide major clinical feature severe covid- patient require ventilation acute respiratory distress syndrome ards possibly associate cytokine storm objective elucidate serum level tnf alpha soluble tnf receptor  stnfr patient severe mild covid- disease determinant disease severity method determine serum tnf alpha stnfr concentration  patient laboratory confirm covid- patient severe disease intensive care unit icu  non severe non icu patient  healthy control admission elisa subject recruit march  masih daneshvari hospital tehran iran result serum level stnfri significantly high icu patient p non icu patient p=. compare healthy subject serum stnfr significantly high icu patient non icu patient p serum tnf alpha level great icu non icu patient healthy subject group p stnfri concentration icu r=. p=. non icu r=. p=. patient positively correlate age serum stnfri level icu patient significantly high old healthy subject stnfri concentration icu patient negatively correlate esr conclusion study demonstrate high stnfri icu patient severe covid- disease biomarker disease severity mortality future study examine low level systemic stnfr admission indicate well disease outcome
135,context sars cov- population wide testing implement clinical feature antibody response infect document africa information provide analyze datum population wide testing critical understand infection dynamic devise control strategy describe clinical feature assess antibody response people screen sars cov- infection analyze datum cohort  people molecularly screen sars cov- infection routine activity record people sars cov- diagnosis age gender blood type white blood cell wbc symptom chronic disease status time sars cov- rt pcr conversion positive negative calculate age base distribution sars cov- infection analyze proportion spectrum covid- severity furthermore nested sub study screen  covid- patient  contact case anti sars cov- antibody male female account respectively people screen study population median mean age  year   people .% diagnose sars cov- infection male female represent respectively median mean age sars cov- infected subject   year respectively low rate infection observe elderly aged rate sars cov- infection young year old middle aged adult year old analysis sars cov- infection age distribution show middle aged adult account .% sars cov- positive person follow respectively young adult .% child .% elderly n sars cov- infected person asymptomatic n influenza like symptom n influenza like symptom associate anosmia ageusia n dyspnea n respiratory failure result death datum show sars cov- infected subject chronic disease hypertension diabetes asthma concurrent chronic disease represent respectively record chronic disease half sars cov- rt pcr positive patient cure  day follow initiation anti covid- treatment protocol .% covid- patient sars cov- rt pcr confirm negative contact case positive anti sars cov- antibody patient severe critical illness high leukocyte high neutrophil low lymphocyte count contrarily asymptomatic patient patient mild moderate illness neutrophilic leukopenia prevalent asymptomatic patient patient mild moderate disease  week diagnosis patient severe critical illness neutrophilic leukocytosis neutrophilia lymphocytopenia -% frequent participant blood type o. important note infection rate slightly high b blood type compare type o. african setting young middle aged adult likely drive community transmission covid- rate critical disease relatively low high rate anti sars cov- antibody observe sars cov- rt pcr negative contact case suggest subclinical infection overlook setting
136,coronavirus disease  covid- cause infection severe acute respiratory syndrome coronavirus  detect wuhan china late  continue spread worldwide persistent question remain relationship severity covid- comorbid disease chronic pulmonary condition systematic review meta analysis aim examine detail underlie chronic obstructive pulmonary disease copd asthma chronic respiratory disease crd associate increase risk severe covid- comprehensive literature search perform international search engine initial search  article identify eliminate duplicate record consideration eligibility criterion  study patient include final analysis copd present patient severe covid- patient non severe covid- random effect model ci z p crd present patient severe covid- patient non severe covid- random effect model ci z p asthma present patient severe covid- patient non severe covid- random effect model ci z p conclusion comorbid copd crd clearly associate high severity covid- association asthma severe covid- identify
137,chronic rhinosinusitis crs complex upper airway inflammatory disease broad spectrum clinical variant understanding disease pathophysiology evolve philosophy approach management crs endotyping gain favour phenotype base classification owe potential prognosticate disease severity deliver precision treatment endotyping especially useful challenge crs nasal polyposis case novel treatment option biological available late european position paper rhinosinusitis nasal polyps epos reflect change update rhinosinusitis classification new integrate care pathway coronavirus disease  covid- pandemic physician rhinologist balance responsibility manage patient upper airway adequately protect droplet aerosol transmission review summarise key update epos endotype base classification biomarker role biological crs lesson draw use severe asthma examine finally principle crs management covid- discuss
138,study aim explore social distancing self isolation measure aim protect vulnerable group covid- affect wellbeing physical activity level adult diagnose asthma seven participant take online focus group transcript analyse thematic analysis participant report health conscious label vulnerable relationship severity asthma alter report make positive change increase physical activity level finding suggest window opportunity engage people diagnose asthma promote beneficial lifestyle change self management
139,purpose review pediatric coronavirus disease  covid- respiratory disease distinct entity adult illness notable mild phenotype review summarize current knowledge clinical pattern cellular pathophysiology epidemiology covid- respiratory disease child specific attention factor account maturation relate difference disease severity recent finding past  month knowledge clinical presentation pathophysiology covid- pneumonia rapidly expand decreased disease severity covid- pneumonia child early observation difference efficiency viral cell entry timing immune recognition response child adult remain center ongoing research summary clinical spectrum covid- respiratory disease child define age relate difference protect child severe disease death remain incompletely understand
140,background coronavirus disease  covid- contagious disease symptom risk factor newly describe allergic disease include asthma define risk factor poor outcome covid- aim investigate role allergic disease allergic rhinitis severity covid- method case control study conduct sakarya educational research hospital toyota hospital yenikent state hospital march  august study include case group  randomly select patient diagnose allergic rhinitis advance have covid- control group  patient allergic rhinitis diagnose covid- evaluate participant status smoking symptom hospitalization length hospitalization number comorbiditie result statistically significant difference group percentage asymptomatic patient p presence smoking p hospitalization status p hospitalization length p group patient need care intensive care unit icu patient case group control group die covid- conclusion find allergic rhinitis affect severity covid- recommend literature augment study covid- prognosis patient allergic rhinitis
141,background insurgence covid- pandemic people die past month situation ongoing increase health social economic panic vulnerability country rely different preventive action control outcome covid- necessary boost knowledge effectiveness action policymaker country base appropriate action study generate evidence take impactful action combat covid- objective order generate community base scientific evidence study analyze outcome covid- response different control measure healthcare facility life expectancy prevalent disease method country datum collect different database perform comparative graphical analysis non linear correlation estimation r. result reduction covid- case strongly correlate earliness preventive initiation apathy take nationwide immediate precaution measure identify critical reason circumstance bad significant non linear relationship covid- case fatality number physician ncc p value /= nurse midwife ncc p value /= hospital bed ncc p value /= life expectancy sex ncc p value /= life expectancy female ncc p value /= life expectancy male ncc p value /= covid- death find reduce increase medical personnel hospital bed interestingly association comorbiditie severity covid- find exclude asthma cancer alzheimer smoking conclusion enhance healthcare facility early impose control measure valuable prevent covid- pandemic association covid- comorbiditie warrant investigation pathobiological level
142,background large airway epithelial barrier provide line defense respiratory virus include sars cov- cause covid- substantial inter individual variability individual disease course hypothesize partially mediate differential regulation gene interact sars cov- virus involve subsequent host response comprehensively investigate non genetic genetic factor influence covid relevant bronchial epithelial gene expression method analyze rna sequence datum bronchial epithelial brushing obtain uninfected individual relate ace gene expression host environmental factor spiromics cohort smoker chronic obstructive pulmonary disease copd replicate association asthma cohort sarp mast identify airway biology ace binding contribute increase susceptibility gene set enrichment analysis determine gene expression change indicative suppress airway immune response observe early sars cov- infection observe association host factor identify host genetic variant affect covid- susceptibility spiromics perform expression quantitative trait eqtl mapping investigate phenotypic association eqtl variant result find ace expression high relation active smoking obesity hypertension know risk factor covid- severity association interferon relate inflammation drive truncated non binding ace isoform discover expression pattern suppress airway immune response early sars cov- infection compare virus similar pattern associate obesity hypertension cardiovascular disease contribute covid susceptible airway environment eqtl mapping identify regulatory variant gene implicate covid- phewas evidence potential role respiratory infection conclusion datum provide evidence clinically relevant variation expression covid related gene associate host factor environmental exposure likely host genetic variation
143,background scarce publish datum differentiated thyroid cancer patient new coronavirus disease  covid- disease outcome mortality evaluate covid- infection outcome mortality thyroid cancer patient covid- infection design method include cohort patient thyroid cancer pcr confirm covid- disease  march   turkish ministry health database nationwide retrospective study compare mortality morbidity covid patient thyroid cancer univariate multivariate analysis assess independent factor mortality length hospital stay intensive care unit icu admission mechanical ventilation analyse effect radioiodine treatment severity death rate covid- disease result evaluate  covid- patient thyroid cancer median age  year interquartile range iqr  year male age gender match  covid- patient thyroid cancer patient thyroid cancer similar mortality ratio compare non cancer group patient thyroid cancer age presence diabetes mellitus asthma copd heart failure chronic kidney disease prior coronary artery disease ras blocker usage low lymphocyte count associate mortality radioactive iodine rai treatment cumulative radioactive iodine dosage negatively affect severity mortality covid- disease patient group conclusion study indicate history thyroid cancer increase risk mortality morbidity covid- disease rai therapy history dose radioactive iodine affect mortality outcome
144,objective previous study report correlation coronavirus disease- covid- asthma datum asthma constitute risk factor covid- prevalence asthma covid- case remain scant interrogate analyze association covid- asthma method study systematically search pubmed embase web science database study publish january  august include study report epidemiological clinical feature covid- prevalence asthma patient exclude review animal trial single case report small case series study evaluate coronavirus relate illness raw datum study pool meta analysis result analyze finding  study include asthma patient covid- pooled prevalence asthma covid- case ci .- overall .% p datum indicate asthma increase risk develop severe covid- odd ratio ci p i()=% addition significant difference incidence asthma age covid- infection ci p i()=% conclusion take datum suggest asthma significant risk factor development severe covid-
145,background december coronavirus disease  covid- emerge wuhan city spread rapidly china world aim describe clinical feature risk factor predictor hospitalization adult patient treat acute respiratory infection associate coronavirus sars cov- material method descriptive prospective study ambulatory hospitalize adult patient confirm covid- attend april  clinical feature chronic comorbiditie demographic datum record patient follow month outpatient result assess adult age   year man laboratory confirm covid- comorbiditie specially hypertension .% hypothyroidism .% asthma diabetes hospital admission require .% admit critical care unit .% connect mechanical ventilation common symptom include fatigue .% fever .% headache .% anosmia dysgeusia .% dry cough .% dyspnea .% diarrhea patient report persistence symptom month follow specially fatigue cough dyspnea multivariate analysis age fever cough dyspnea immunosuppression associate hospitalization icu admission age male sex moderate severe dyspnea associate requirement mechanical ventilation main predictor prolonged clinical course female sex presence comorbiditie history dyspnea cough myalgia abdominal pain conclusion clinical feature covid- highly unspecific prediction model severity help medical decision making primary care setting
146,purpose chest x ray cxr severity score bmi base obesity predictive risk factor covid- hospital admission relationship abdominal obesity cxr severity score fully explore method retrospective cohort study analyze association different adiposity index include waist circumference body mass index bmi cxr severity score  hospitalize patient covid- result patient abdominal obesity show significantly high cxr severity score high rate cxr severity score  compare abdominal obesity p /=  p p respectively waist circumference waist height ratio whtr correlate closely cxr severity score bmi r p /= vs p multivariate analysis indicate abdominal obesity risk ratio ci p bronchial asthma risk ratio ci p oxygen saturation admission risk ratio ci p independent factor associate high cxr severity score conclusion abdominal obesity phenotype associate high cxr severity score well bmi base obesity hospitalize patient covid- visit patient hospital setting waist circumference measure patient abdominal obesity monitor closely level evidence cross sectional descriptive study level v.
147,objective determine demographic clinical characteristic underlie comorbiditie outcome child coronavirus disease  covid- infection method retrospective study report  pediatric patient age year confirmed covid- march  july king abdulaziz university hospital jeddah saudi arabia result comorbid condition include cardiac neurological respiratory malignant disorder report  patient prominent present complaint fever cough patient .% mild disease .% moderate disease .% exhibit severe critical illness patient .% hospitalize  patient .% admit pediatric intensive care unit  .% patient die conclusion pediatric age group susceptible covid- gender difference covid- infection result critical illness mortality subset pediatric patient
148,objective aim study evaluate factor predict severe symptomatic laboratory confirm reverse transcription polymerase chain reaction rt pcr polymerase chain reaction severe acute respiratory syndrome coronavirus  sars cov- reinfection study design nationwide retrospective cohort study conduct mexico method datum  reinfection case  day episode onset analyze risk ratio rrs confidence interval cis evaluate predictor severe dyspnea require hospital admission secondary sars cov- infection result risk severe disease observed overall fatality rate patient primary disease likely develop severe symptom .% vs. .% p reinfection multiple analysis factor associate increase risk severe symptomatic sars cov- reinfection increase age rrper year ci comorbiditie obesity rr ci asthma rr ci type  diabetes mellitus rr ci previous severe laboratory confirm coronavirus disease  rr ci conclusion good knowledge study evaluate disease outcome large set laboratory positive case symptomatic sars cov- reinfection factor associate illness severity characterize result contribute current knowledge sars cov- pathogenicity identify population increase risk poor outcome reinfection
149,purpose review datum effect coronavirus disease  covid- host microbiome alteration subsequent effect susceptibility clinical course covid- especially atopic patient currently limited review study microbiome atopic patient respiratory infection discuss potential role probiotic therapeutic target covid- decrease susceptibility severity covid- recent finding respiratory tract virus infection affect gut airway microbiome structure host immune function diverse factor atopic disease affect airway gut microbiome structure expect negatively influence host health response respiratory virus infection atopic host depend preexisting microbiome immune response explain inconclusiveness effect covid- susceptibility morbidity mortality patient atopic disease beneficial probiotic therapeutic adjuvant covid- infection beneficial microbiome decrease viral load early phase respiratory virus infection improve morbidity mortality summary application probiotic potential adjuvant treatment respiratory virus infection improve host immune response disturbed microbiome structure atopic patient related study involve covid- warrant near future
150,extremely premature infant demonstrate increase survival advancement care population risk decrease lung function persist adolescence important clinician consider history treat assess patient contract sars cov- respiratory infection -year old premature infant  week gestation bpd present pediatric emergency department evaluation hypoxia increase work breathing setting sars cov- infection manage aggressively early noninvasive respiratory support remdesevir systemic steroid convalescent plasma utilization aggressive medical therapy early hospital course assist prevent intubation mechanical ventilation patient study examine severity sars cov- infection premature infant paucity datum vulnerable group age adolescence study need assess severity illness optimal management population
151,background covid- affect adult child variable presentation disease severity child present mild symptom fever cough shortness breath rapidly progress severe pneumonia require mechanical ventilation population include child young year old adolescent underlie comorbidity specifically immunosuppression prior cardio respiratory infection review discuss determinant severe disease paediatric patients- primarily asthma immune status obesity multisystem inflammatory syndrome child mis c asthma underlying lung pathology strong predictor ~% prevalence development severe covid- infection irrespective age compare asthma high mortality rate report immune compromise patient weaken immune system immunosuppressed individual time immunocompromised patient time vulnerable develop severe covid- disease similarly evidence suggest bmi great  kg m render individual susceptible develop covid related complication observation base negative impact obesity pulmonary function downplay immune system furthermore possible association covid- mis c report multiple study globe need study strengthen stance scarcity datum compare determinant discuss article author recommend researcher direct attention synthesize evolve evidence fill knowledge void paediatric population well enable paediatrician informed decision
152,face tremendous uncertainty current pandemic need clear consistent recommendation understanding evidence general family child allergic condition common concern parent child asthma risk person learn pose pandemic rostrum examine actual risk person learn child asthma novel coronavirus disease  covid- discrepancy perceive actual risk contribute factor discrepancy possible solution narrow divide overall evidence support child asthma increase risk covid- morbidity mortality compare child asthma asthma medication appear contribute incidence severity covid- disease high perceive risk person learn partially relate portray medium little guidance transition asthmatic child school properly counsel mediation risk difference regionally locally school reopening exemption implementation narrow divide perceive actual risk clear consistent ongoing communication necessary
153,background child affect covid- pandemic repercussion pediatric illness significant study examine indirect impact pandemic population critically ill child united states research question significantly few critically ill child admit picu second quarter significant change type disease admit study design method retrospective observational cohort study virtual pediatric systems database participant child admit picu  site united states quarter  q  q   pre covid-  covid- result average number admission similar pre covid- q covid- q decrease pre covid- q covid- q admission quarter large decrease respiratory condition include asthma subject pre covid- q .% patient vs  subject covid- q .% p bronchiolitis vs  p percentage trauma admission increase raw number trauma admission decrease admission diabetes mellitus poisoning ingestion increase multivariable model illness severity adjust odd icu mortality picu patient covid- q increase compare pre covid- q ci p interpretation pediatric critical illness admission decrease substantially second quarter significant change type disease see picu united states increase mortality child admit picu period
154,march april cyprus greece health authority enforce escalate level public health intervention control covid- pandemic quantify compliance  asthmatic schoolchildren cyprus  greece mean age year country intervention level wearable sensor continuously track personal location physical activity change fraction time spend home total step day assess mixed effect model adjust confounder observe significant mean increase fraction time spend home cyprus greece intervention level .% level .% level .% level respectively physical activity cyprus greece demonstrate significant mean decrease level level level total step day respectively significant independent effect weekend age find fraction time spend home similarly weekend age humidity gender independent effect physical activity suggest wearable technology provide objective continuous real time location activity datum make possible inform timely manner public health official compliance tier public health intervention pandemic
155,increasingly quantitative lung compute tomography qct)-derived metric provide novel insight chronic inflammatory lung disease include chronic obstructive pulmonary disease asthma interstitial lung disease metric relate parenchymal airway vascular anatomy measure associate lung function include regional parenchymal mechanic air trapping associate functional small airway disease dual energy derive measure perfuse blood volume offer ability characterize disease phenotype associate chronic inflammatory pulmonary disease emergence covid- widely vary degree severity rapid progression case potential lengthy post covid- morbidity new role apply establish qct base metric base utility qct tool lung disease previously validate supervised classical machine learning method emerge unsupervised machine learning deep learning approach able provide desperately need insight acute chronic phase inflammatory lung disease potential area qct imaging beneficial include improve accuracy diagnosis identification clinically distinct phenotype improvement disease prognosis stratification care early objective evaluation intervention response potential role qct evaluate increase population post covid- lung parenchymal change fibrosis work discuss basis lung qct method case example highlight potential application tool exploration characterization covid- offer scan protocol serve template image lung establish qct analysis good chance yield need new insight
156,purpose review coronavirus sars cov- outbreak china late  turn global pandemic numerous study report association environmental factor weather condition range air pollutant particulate matter nitrogen dioxide ozone etc wave covid- case review aim offer critical assessment role environmental exposure risk factor sars cov- infection covid- disease severity recent finding review provide critical assessment covid- risk factor identify gap knowledge e.g. indoor air pollution discuss methodological challenge association causation impact lockdown air quality addition draw attention ethnic socioeconomic factor drive viral transmission relate covid- complex role angiotensin convert enzyme  ace play covid- future promising avenue research discuss demonstrate causality stress need future epidemiologic study integrate personal air pollution exposure detailed clinical covid- datum range socioeconomic factor vitro vivo mechanistic study
157,background cystic fibrosis cf potentially mortal disease characterize chronic pulmonary disease persistent airway infection child disease susceptible respiratory infection limitation mucociliary transport anatomical disruption bronchial tree sars cov- cause covid- respiratory illness relate exacerbation chronic pulmonary pathology child cf asthma case report pediatric patient sars cov- infection cf share experience case report -month old male patient diagnose cf present hospital cough fever increase respiratory work patient receive supplemental oxygen antibiotic antiviral therapy positive result type b influenza rt pcr reverse transcription polymerase chain reaction sars cov- obtain persistence respiratory difficulty high flow therapy initiate good response episode hypoxemia bradycardia increase respiratory work secondary accumulate secretion orotracheal intubation invasive mechanical ventilation perform patient evolve clinical gasometric improvement  day hospital antibiotic management adequate clinical evolution patient discharge complete oral treatment home isolation conclusion present case chronic respiratory disease sars cov- infection severity criterion pediatric patient evolution favorable timely support management antibiotic therapy level hospital
158,background lockdown impose covid- pandemic result completely different style life possible effect attitude disease patient chronic lung disease asthma aim study investigate asthmatic child level asthma control maintenance therapy lockdown method asthmatic child attend clinic identify prescribe therapy march april  march april level asthma control gina score maintenance therapy lockdown march april compare march april separately analyze small group child severe asthma treat omalizumab lockdown result enrol  asthmatic child male compare  high proportion child modify maintenance therapy vs. .% p significant increase proportion child increase p child decrease therapy p level control result significantly high  march p april p  child treat omalizumab show good level control conclusion asthmatic child covid- pandemic lockdown significant impact asthma control attitude maintenance therapy
159,objective evidence pertain effect asthma coronavirus disease  outcome unclear improve understanding clinically important association asthma coronavirus disease method match cohort study perform datum mass general brigham health care system boston ma adult age /= year patient confirm coronavirus disease  chronic obstructive pulmonary disease cystic fibrosis interstitial lung disease march  july  analyze non asthma comparator match asthma patient base age  year sex date positive test  day primary outcome hospitalization mechanical ventilation death multivariable cox proportional hazard model account compete risk death appropriate patient follow outcome diagnosis coronavirus disease  july result  asthma patient  hospitalize  receive mechanical ventilation  die  match comparator  hospitalize  receive mechanical ventilation  die adjusted hazard ratio asthma patient confidence internal hospitalization confidence internal mechanical ventilation confidence internal death conclusion match cohort study large boston base healthcare system asthma associate comparable risk hospitalization mechanical ventilation low risk mortality
160,background impact asthma diagnosis asthma endotype outcome coronavirus disease  covid- infection remain unclear objective describe association asthma diagnosis endotype clinical outcome patient diagnose have covid- infection method retrospective multicenter cohort study outpatient inpatient present  hospital mount sinai health system new york metropolitan region march june covid- infection history asthma primary outcome evaluate hospital mortality secondary outcome include hospitalization intensive care unit admission mechanical ventilation hospital length stay outcome compare patient asthma multivariate cox regression model outcome stratify blood eosinophilia count evaluate result patient diagnose have covid- infection  hospitalize  diagnosis asthma adjust covid- disease severity comorbiditie concurrent therapy patient asthma low mortality adjust odd ratio p low rate hospitalization intensive care unit admission p p respectively blood eosinophil great equal  cell mul asthma low mortality conclusion patient asthma reduce risk poor outcome covid- infection eosinophilia asthma associate reduce mortality risk
161,severe acute respiratory syndrome coronavirus  sars cov- spread rapidly world late  cause critical illness death infected patient study aim examine laboratory factor especially inflammatory immunological mediator identify severity mortality associate biomarker ninety hospitalize patient confirm coronavirus disease  covid- classify base disease severity level biochemical hematological immunological inflammatory mediator assess association severity mortality evaluate hospitalize patient man .% average standard deviation age year mortality rate significantly high critical patient .% increase serum level blood sugar urea creatinine uric acid phosphorus total bilirubin serum glutamic oxaloacetic transaminase serum glutamic oxaloacetic transaminase lactic dehydrogenase c reactive protein ferritin procalcitonin significantly prevalent p=. p p p=. p=. p=. p p p p p p respectively covid- patient decrease red blood cell hemoglobin hematocrit significantly prevalent covid- patient healthy control subject p troponin interleukin- neutrophil lymphocyte ratio nlr procalcitonin d dimer show significant association mortality patient specificity sensitivity age sex underlie disease blood oxygen pressure complete blood count c reactive protein lactic dehydrogenase procalcitonin d dimer interleukin- evaluation help predict severity require management covid- patient investigation highly recommend large cohort study validation present finding
162,background patient asthma comparatively susceptible respiratory viral infection likely develop severe symptom people asthma coronavirus disease  covid- pandemic necessary adequately evaluate characteristic outcome population asthma population test diagnose have covid- objective perform study assess impact asthma covid- diagnosis present symptom disease severity cytokine profile method analysis prospectively collect cohort patient suspect have covid- present covid- testing tertiary medical center missouri march  september classify analyze patient accord pre existing asthma diagnosis subsequent covid- testing result result patient suspect have covid- n enrol study proportion patient test positive covid- .% group asthma asthma respectively frequency relevant symptom similar group asthma positive negative covid- test result population diagnose have covid- n asthma associate indicator covid- severity include hospitalization admission intensive care unit mechanical ventilation death covid- hospital mortality multivariate adjustment patient covid- asthma exhibit significantly low level plasma interleukin- patient asthma adjust p conclusion population asthma face challenge preliminary covid- evaluation owe overlap symptom covid- asthma asthma increase risk covid- severity infect
163,purpose review juncture covid- pandemic world currently early phase collect clinical datum report skin manifestation pathophysiology highly conjectural cutaneous manifestation associate covid- pediatric age group recent finding child infect sars cov- usually develop mild respiratory symptom cutaneous manifestation little prevalent adult skin feature infection coronavirus similar produce common virus report case heterogeneous clinical picture classification difficult date frequently report skin variant feature pediatric case purpuric pseudo chilblain necrotic acral ischemia hemorrhagic macule and/or cutaneous necrosis morbilliform maculopapular erythema multiforme urticarial vesicular kawasaki like miscellaneous highly variable frequency severity pathophysiological mechanism elusive likely result complex involvement mechanism like direct virus induce skin damage vasculitis like reaction and/or indirect injury consequence systemic inflammatory reaction review present discuss clinical case example different cutaneous response report child sars cov- infection differential diagnosis consideration preliminary conceptual approach probable associated pathologic mechanism
164,importance active pediatric covid- pneumonia mis c disease process require rapid diagnosis different treatment protocol objective distinguish active pediatric covid- pneumonia mis c present sign symptom patient characteristic laboratory value design patient diagnose hospitalize active covid- pneumonia mis c children alabama hospital birmingham april  september  identify retrospectively active covid- mis c case define diagnostic code verify accuracy current centers disease control case definition clinical note documentation covid- pneumonia mis c clinical note electronic medical record patient demographic present sign symptom prior exposure test sars cov- virus laboratory datum imaging treatment modality response treatment finding  patient identify  classify mild covid-  patient moderate covid-  patient severe covid-  mild mis c  severe mis c. group male predominance black hispanic patient overrepresente compare demographic alabama mis c patient healthy baseline covid- patient have underlie illness fever rash conjunctivitis gastrointestinal symptom predominant mis c population covid- patient present predominantly respiratory symptom group similar duration symptomatic prodrome exposure history sars cov- virus mis c patient long duration presentation exposure history covid- patient likely positive sar cov- pcr require respiratory support admission mis c patient low sodium level high level c reactive protein erythrocyte sedimentation rate d dimer procalcitonin covid- patient high lactate dehydrogenase level admission mis c patient coronary artery change echocardiography covid- patient conclusion relevance study directly compare covid- mis c pediatric population significant difference find symptom presentation demographic laboratory finding aide health care provider distinguish disease entity
166,child severe asthma treat biologic agent normally require weekly injection hospital march covid- need minimise hospital visit assess biologic give safely home multidisciplinary team identify child consider home administration virtually observe video link home spirometry perform feedback obtain carer young people  patient receive biologic  family agree homecare administration  administer parent patient  local nursing team video call omalizumab observe  occasion mepolizumab  occasion  month april july medication administer inaccurately occasion adverse event virtually observed home biologic administration severe asthmatic child support video call home spirometry feasible safe positively perceive child family
167,objective coordinated immune response host key successful combat body sars cov- infection decisive development progression covid- study aim investigate immunological phenotype patient associate duration illness patient severe covid- method single center study  patient severe critical covid- recruit retrospectively immunological parameter include count white blood cell neutrophil lymphocyte neutrophil lymphocyte ratio level circulate cytokine cytokine receptor screen association disease severity survival duration illness covid- result datum confirm previous result neutrophil lymphocyte ratio circulate level il- represent prominent biomarker prediction disease severity survival covid- study show time duration illness patient severe covid- positively associate serum level il- p=. soluble il ralpha p=. conclusion significant association duration illness circulate level il- soluble il ralpha patient severe covid- implicate neutrophil t cell involve evolution covid-
168,background limited evidence clinical characteristic sars cov- infection latin america present finding nationwide study argentina research question disease severity measure risk factor associate admission intensive care unit mortality study design method datum extract covid- database integrated argentina health information system encompass period march rd october nd standardized case report form include information contact history clinical sign symptom clinical diagnosis information collect initial site care follow conduct call regional healthcare authority confirm case covid- define have positive result sequencing real time reverse transcriptase polymerase chain reaction rt pcr assay nasal pharyngeal swab specimen result rt pcr testing positive case complete dataset available analysis case mean age year .% male frequent co existing condition include hypertension .% diabetes .% asthma obesity common symptom include fever .% cough .% headache .% sore throat death icu admission independently associate old age male coma dyspnea tachypnea seizure underlie co morbidity immunodeficiency chronic renal failure liver disease show strong effect interpretation case covid- diagnose argentina mild favorable outcome fatality rate relatively elevated risk factor adverse outcome include old age male sex coma seizure concurrent presence morbidity datum useful healthcare provider healthcare policy maker low middle income latin american country guide decision optimize care pandemic
169,article propose difference covid- morbidity associate transient receptor potential ankyrin  trpa and/or transient receptor potential vanilloid  trpv activation desensitization trpa trpv induce inflammation play key role physiology organ augment sensory vagal nerve discharge evoke pain symptom covid- include cough nasal obstruction vomiting diarrhea partly sudden severe loss smell taste trpa activate reactive oxygen specie regulate covid- trpa trpv channel activate pungent compound include nuclear factor erythroid derive nrf)-interacte food lead channel desensitization interaction nrf associate nutrient trpa trpv partly responsible severity covid- symptom regulation nrf trpa trpv unclear suggest limited clinical evidence covid- propose rapid desensitization trap trpv ingredient food reduce symptom severity provide new therapeutic strategy
170,background limited pediatric datum severe covid- disease study aim describe epidemiology identify risk factor severe covid- disease child method retrospective cohort study child positive sars cov- pcr march july  children hospital colorado risk factor severe disease analyze define hospital admission respiratory support critical care univariable multivariable analysis conduct result  patient identify sars cov-  .% female median age  year percent patient identify hispanic compare hospital visit  p  year adjust odd ratio aor p  year asthma gastrointestinal condition similar symptom presentation predictor respiratory support elevated c reactive protein associate need critical care median mg dl iqr .- versus mg dl iqr .- patient require critical versus critical care p conclusion extreme age comorbid condition elevated crp predictor severe disease child finding study inform pediatric provider public health official tailor clinical management pandemic planning resource allocation
171,covid- world public health emergency cause new coronavirus sarscov- drug repurpose treatment covid- patient include chloroquine cq cq bitter taste receptor agonist report relax airway suggest role prevent disease severity covid- patient asthma
172,background datum  influenza pandemic suggest asthma protect severe disease hospitalize patient asthma appear increase risk hospitalization mortality covid- objective study undertake atopy actually protect hospitalize covid- method retrospective chart review patient test positive sars cov-  month major adult pediatric tertiary referral center hospital chart evaluate history atopic disease need icu admission requirement supplemental oxygen and/or intubation hospital mortality result significant difference outcome patient n base atopic disease note icu admission versus atopic versus atopic disease respectively p supplemental oxygen use .% versus p intubation rate .% versus p mortality rate .% versus p patient atopic disease copd list diagnosis chart versus .% p  conclusion severity covid- hospitalize patient differ base atopic status adjust presence copd lead suggestion possible reduce severity patient atopy asthma
173,background evidence accumulate coronavirus disease  increase risk hospitalization mechanical ventilation pregnant patient preterm delivery impact maternal mortality morbidity differentially affect disease severity delivery trimester infection unknown objective study aim describe disease severity outcome severe acute respiratory syndrome coronavirus  infection pregnancy washington state include pregnancy complication outcome hospitalization case fatality study design pregnant patient polymerase chain reaction confirm severe acute respiratory syndrome coronavirus  infection march june identify multicenter retrospective cohort study  site washington state site capture annual state delivery case fatality rate pregnancy compare coronavirus disease  fatality rate similarly aged adult washington state rate ratio rate difference maternal neonatal outcome compare trimester infection disease severity time delivery result principal study finding follow  pregnant patient washington state severe acute respiratory syndrome coronavirus  infection   develop severe critical disease   hospitalize coronavirus disease   die coronavirus disease -associate hospitalization rate high similarly aged adult washington state .% vs .% rate ratio confidence interval pregnant patient hospitalize respiratory concern likely comorbidity underlying condition include asthma hypertension type  diabetes mellitus autoimmune disease class iii obesity  maternal death .% attribute coronavirus disease  maternal mortality rate  pregnancy confidence interval coronavirus disease  case fatality pregnancy significant confidence interval high pregnant patient similarly age individual washington state absolute difference mortality rate confidence interval preterm birth significantly high woman severe critical coronavirus disease  delivery woman recover coronavirus disease  .% severe critical coronavirus disease  vs .% mild coronavirus disease p conclusion coronavirus disease  hospitalization case fatality rate pregnant patient significantly high similarly aged adult washington state datum indicate pregnant patient risk severe critical disease mortality compare nonpregnant adult risk preterm birth
174,severe acute respiratory syndrome coronavirus- sars cov- infect child adult epidemiological clinical datum demonstrate child likely severe disease course die furthermore asthmatic child severe disease manifestation infect sars cov- compare adult review focus sars cov- childhood asthma interaction aim summarize current knowledge potential mechanism ameliorate disease symptomatology asthmatic child
175,background paucity information coronavirus disease  covid- outcome asthmatic objective identify risk factor associate admission subsequent mortality covid infected asthmatic method adult institution positive polymerase chain reaction covid- march  april retrospectively identify comorbiditie laboratory result mortality rate hospitalization record result total   .% asthma patient covid- see emergency department ed .% ed patient admit individual previously measure mean absolute eosinophil count aec /= cell mul likely admit odd ratio confidence interval ci p concomitant heart failure chf chronic kidney disease ckd chronic obstructive pulmonary disease copd risk factor admission hospitalize patient asthma peak hospital measure aec /= cell mul n likely die compare aec remain cell mul protective covid associated admission development eosinophilia aec /= cell mul hospitalization associate decrease mortality preadmission aec influence aec trend hospitalization have th asthma phenotype important predictor reduced covid- morbidity mortality explore prospective mechanistic study
176,background coronavirus disease  covid- emerge pandemic end cause large number people infected die objective determine allergic disease risk factor hospitalization covid- method conduct study include  pediatric patient covid- recovery international study asthma allergies childhood phase  questionnaire distribute detailed history environmental factor allergic evaluation include skin prick test specific immunoglobulin e test spirometry investigate prevalence allergic disease evaluate factor associate hospitalization covid- result total  patient hospitalize  patient follow closely outpatient clinic prevalence allergic rhinitis asthma atopic dermatitis episodic wheezing .% .% respectively study population have asthma allergic rhinitis atopic dermatitis passive tobacco exposure find relate hospitalization covid- have pet home find decrease risk hospitalization odd ratio confidence interval p spirometry test reveal high forced expiratory volume second force vital capacity ratio peak expiratory flow reversibility hospitalize patient nonhospitalize one p p respectively conclusion asthma allergic disease risk factor hospitalization child covid- have pet home protective effect pulmonary function testing important monitor lung damage covid-
177,rationale health outcome people coronavirus disease covid- range symptom severe illness death asthma common chronic lung disease consider likely increase severity covid- datum address hypothesis scarce recently objective review epidemiologic literature relate asthma potential role covid- severity method study identify pubmed medline database search term asthma sars cov- severe acute respiratory syndrome coronavirus covid- cross reference citation identify study available print online december main results asthma prevalence datum obtain study people covid- regional health statistic identify  study worldwide allow compare prevalence asthma patient covid- region disease severity mortality result analysis provide clear evidence increase risk covid- diagnosis hospitalization severity mortality asthma conclusion finding provide reassurance people asthma potential increase risk severe morbidity covid-
178,report determine change white blood cell count inflammatory biomarker relate disease outcome coronavirus disease  covid- utilize prognostic biomarker introduce factor diagnostic prognostic biomarker diagnostic test accuracy dta systematic review meta analysis recommend time aim determine accuracy white blood cell count inflammatory biomarker prognosis covid- patient outcome dta meta analysis august search web sciences scopus medline pubmed database achieve related paper summary point line include study calculate x table bivariate hierarchical model critical condition mortality consider outcome total  patient  study include study biomarker contain leukocytosis neutrophilia lymphopenia increase level c reactive protein procalcitonin pct ferritin meet inclusion criterion analysis area curve auchsroc indicate pct applicable prognostic biomarker critical condition mortality auchsroc=. condition pooled diagnostic odd ratio ci .- prognosis critical condition ci .- mortality biomarker insufficient accuracy condition auchsroc evaluate biomarker pct good accuracy prognosis critical condition mortality covid- consider single prognostic biomarker poor outcome pct accuracy prognosis mortality comparison critical condition
179,emergence highly pathogenic virus name severe acute respiratory syndrome coronavirus  sars cov- account severe pneumonia world  million world population infect sars cov- number death increase day study aim evaluate frequency sars cov- hospitalize patient acute respiratory infection ari outbreak sars cov- nasopharyngeal oropharyngeal swab collect  hospitalize patient severe pneumonia include  male  female collect sample different city khuzestan province  february to-  march rna extract sample subject real time polymerase chain reaction pcr test detection sars cov- simultaneously computerized tomography ct scan test presence ground glass opacity lung patient total number  specimen  .% case include  female  male positive sars cov-  .% case include  male  .% negative sars cov- real time pcr p=.).four sixteen .% case positive ground glass opacity lung ct scan .% trial prove positive sars cov- real time pcr p=. study .% patient positive sars cov- result positive case ct scan show high real time pcr screen sars cov- real time pcr method line choice
180,coronavirus disease  covid- critical pandemic st century severe  influenza pandemic severe acute respiratory syndrome coronavirus  sars cov- infect host bind angiotensin convert enzyme  ace role ace pathophysiology coronavirus disease  covid- topic debate clinical experimental evidence indicate multifaceted relationship ace activity disease severity review mechanism peptidergic substrate product ace ace contribute physiological pathophysiological process hypothesise regulation ace sars cov- cellular entry disrupt homeostasis well understanding endocrinology disease particular neuroendocrinology ace covid- contribute timely design new therapeutic strategy include regulation ace steroid hormone ameliorate severity covid-
181,objective basic clinical study show magnesium sulphate ameliorate lung injury control asthma attack anti inflammatory bronchodilatory effect intravenous inhale magnesium sulphate clinical impact acute severe asthma inhibition airway smooth muscle contraction magnesium sulphate dilate constricted pulmonary artery reduce pulmonary artery resistance affect systemic artery administer intravenously large number patient covid- admit hospital suffer pulmonary involvement covid- cause hypoxia involvement respiratory airway parenchyma circulatory impairment induce ventilation perfusion mismatch condition result hypoxemia low arterial blood oxygen pressure saturation present degree dyspnoea shortness breath inhale magnesium sulphate smooth muscle relaxant natural calcium antagonist cause bronchodilator consequently vasodilator effect direct effect alveolar arteriole ventilate area respiratory tract aim investigate inhale magnesium sulphate adjuvant therapy standard treatment reduce ventilation perfusion mismatch respiratory tract subsequently improve arterial oxygen saturation hospitalize patient covid- trial design multi centre open label randomised control trial rct parallel arm design (: ratio participant patient aged year hospitalize masih daneshvari hospital shahid dr. labbafinejad hospital tehran shahid sadoughi hospital yazd include meet inclusion criterion study inclusion criterion define confirm diagnosis sars cov- infection base polymerase chain reaction pcr nasopharyngeal secretion clinical manifestation chest compute tomography chest ct scan present moderate severe covid- lung involvement confirm chest ct scan arterial oxygen saturation length hospital stay hour patient underlie cardiovascular disease include congestive heart failure bradyarrhythmia heart block myocardial injury exclude study intervention comparator participant randomly divide arm patient intervention arm give standard treatment covid- accord national guideline magnesium sulphate cc injectable vial  cc injectable vial dilute  cc distil water nebulize mask hour day patient control comparator arm receive standard treatment covid- main outcomes improvement respiratory function symptom include arterial blood oxygen saturation dyspnoea accord nyha functional classification cough day randomization randomisation block randomisation allocate eligible patient study arm ratio computer software apply randomly select block blinding masking study open label rct blind number randomised sample size trial perform  patient randomly divide arm control intervention trial status protocol version january recruitment participant start july anticipate complete february trial registration trial register iranian registry clinical trials irct july available  registration number irctn protocol protocol attach additional file accessible trials website additional file interest expedite dissemination material familiar formatting eliminate letter serve summary key element protocol
182,objective emerge observational evidence aim perform meta analysis summarize overall effect chronic use inhale corticosteroid clinical outcome patient coronavirus disease  covid- method systematic literature search electronic database perform identify observational study investigate preadmission use inhale corticosteroid risk fatal severe course illness patient covid- report adjust measure association adjust odd ratio relative risk corresponding confidence interval study pool produce pooled odd ratio confidence interval result meta analysis reveal significant difference risk development fatal course covid- preadmission use inhale corticosteroid patient covid- relative non use inhale corticosteroid pool odd confidence interval .- similarly meta analysis observe significant difference risk development severe course covid- preadmission use inhale corticosteroid patient covid- relative non use inhale corticosteroid pool odd confidence interval .-.).conclusion finding assure safety continue use inhale corticosteroid covid- pandemic
184,coronavirus disease  covid- rapidly expand worldwide short period relationship chronic comorbiditie unclear aim determine effect chronic comorbiditie clinical outcome patient covid- analysis patient suspicion viral respiratory disease sars cov- positive sars cov- negative january   national administrative healthcare open datum mexico sars cov- infection confirm reverse transcriptase polymerase chain reaction general characteristic chronic comorbiditie explore clinical outcome interest hospital admission pneumonia intensive care unit admission endotracheal intubation mortality prevalence chronic comorbiditie multivariate logistic regression analysis show effect age male sex bronchial asthma diabetes mellitus chronic kidney disease clinical outcome similar sars cov- positive negative patient adverse clinical outcome associate time symptom onset medical contact chronic obstructive pulmonary disease hypertension obesity sars cov- positive patient cardiovascular disease sars cov- negative patient p value comparison chronic comorbiditie commonly find patient suspicion viral respiratory disease knowledge impact comorbiditie adverse clinical outcome well define covid- patient high risk different impact specific type chronic comorbidity clinical outcome patient sars cov- infection require research finding need confirmation datum source
185,purpose review december novel respiratory illness cause severe acute respiratory syndrome coronavirus  sars cov- describe name coronavirus disease  covid- knowledge base surround covid- sars cov- grow rapidly significant gap knowledge remain inaccurate information continue circulate review discuss interaction asthma covid- provide comprehensive understanding base currently available publish datum recent finding non sars human coronaviruse hcovs significant cause asthma exacerbation sars cov- appear exacerbate asthma datum far strongly suggest patient asthma increased risk infection sars cov- severe disease infect covid- datum extremely limited inhale corticosteroid biologic medication remain datum suggest therapeutic positively negatively impact severity outcome covid- summary datum rapidly evolve covid- asthma time asthma appear positively negatively affect outcome covid- imperative practitioner abreast change literature await vaccine control pandemic
186,objective study investigate quantify severity covid- infection high resolution compute tomography ct chest determine relationship clinical parameter study aim ct change clinical recovery progression disease cross sectional study perform july  august chest hrct clinical feature include laboratory confirm covid-  patient attend depertment radiology imaging bangabandhu sheikh mujib medical university bsmmu dhaka bangladesh study include clinical symptom comorbiditie patient hrct chest characteristic ct severity score collection require datum careful medical chest review clinical datum laboratory confirm patient compile tabulate study group  patient patient th th dacade mean age year study  patient male female average sex ratio male female prevalance clinical presentation study sample population distribute fever cough .% shortness breath sore throat common clinical manifestation patient .% symptom like headache chest tightne anosmia diarrhoea major comorbid condition diabet mellitus hypertension bronchial asthma chronic kidney disease ckd patient comorbid disease especially multiple high symptomatic presentation  patient patient co morbidity .% ptaient co existing disease accord hrct imaging severity score lung pathological change evaluate typical covid finding intermediate atypical normal chest ct finding patient symptomatic presentation find high .% ct severity index sympotomatic presentation less .% ct severity index ct severity index see patient .% patient .% patient .% patient positive ct finding prominent symptomatic co morbid patient hrct chest covid- patient major diagnostic prognostic importance clinical symptom patient directly correlate ct severity score ct imaging find useful predict clinical recovery patient progression disease
187,objective evaluate efficacy safety ivermectin patient mild moderately severe covid- trial design phase single center randomized open label control trial parallel group design (: ratio participant severe acute respiratory syndrome departments shahid mohammadi hospital bandar abbas iran screen patient age  year weight kg following criterion inclusion criterion patient mild covid- symptom outpatient diagnose mild pneumonia compute tomography ct and/or chest x ray cx r imaging require hospitalization sign informed consent inclusion criterion patient moderate covid- symptom inpatient confirm infection pcr diagnose moderate pneumonia ct and/or cxr imaging require hospitalization hospitalize  hour sign informed consent exclusion criterion severe critical pneumonia covid- underlie disease include aids asthma loiasis severe liver kidney disease use anticoagulant e.g. warfarin ace inhibitor e.g. captopril history drug allergy ivermectin pregnancy breastfeeding intervention comparator intervention group outpatient inpatient group receive standard treatment regimen mild moderate covid- base iranian ministry health medical education protocol oral ivermectin msd company france single dose mg kg control group outpatient group receive hydroxychloroquine sulfate amin pharmaceutical company iran dose  mg twice day day  mg twice day seven subsequent day inpatient group receive mg lopinavir ritonavir heterd company india twice day seven day plus dose  mcg interferon beta cinnagen iran day supportive routine care outpatient inpatient group main outcome primary outcome composite include improvement clinical symptom need hospitalization outpatient group length hospital stay discharge need icu admission discharge need mechanical ventilation inpatient group seven day randomization secondary outcome incidence adverse drug reaction seven day randomization randomization patient outpatient mild inpatient moderate group randomize treatment control group base follow method simple randomization method table random number select number patient allocate treatment group odd patient allocate control group ratio blinding masking open label study blind number randomized sample size total number  patient outpatient  patient randomize group patient intervention group  patient control group trial status protocol version november recruitment begin november anticipate complete february trial registration clinical trial register iranian registry clinical trials irct registration number irctn registration date november protocol protocol attach additional file accessible trials website additional file interest expedite dissemination material familiar formatting eliminate letter serve summary key element protocol
188,angiotensin convert enzyme  ace serine protease tmprss implicate cell entry severe acute respiratory syndrome coronavirus  sars cov- virus responsible coronavirus disease  covid- expression ace tmprss lung epithelium implication risk sars cov- infection severity covid- use human genetic variant proxy angiotensin convert enzyme ace inhibitor drug effect cardiovascular risk factor investigate exposure affect lung ace tmprss gene expression circulate ace level observe consistent evidence association genetically predict serum ace level outcome weak evidence association genetically predict serum ace level ace gene expression lung eqtl consortium p finding replicate evidence positive association genetic liability type  diabetes mellitus lung ace gene expression gene tissue expression gtex study p  x circulate plasma ace level interval study p lung ace expression lung eqtl consortium study p association genetically proxie liability cardiometabolic trait outcome study provide consistent evidence support effect serum ace level proxy ace inhibitor cardiometabolic risk factor lung ace tmprss expression plasma ace level
190,background covid- consider critical health pandemic st century extremely high transmission rate people susceptible viral infection covid- patient have chronic type- asthma prevail major risk aggravate disease morbidity objective present review mainly focus correlate influence covid- type- asthmatic patient delineate treatment measure drug manage mild moderate severe symptom covid- asthmatic patient prevent exacerbation method depth research carry different article till september  renowned database like pubmed frontier medline related website like cdc mohfw information analyse write simplified manner result progressive result conflicting severe case covid- show increase level cytokine augment inflammation bronchial tract worsen asthma attack contradict certain finding reveal decrease severity covid- elevation t cell type- asthmatic patient prominent reduction t cell see covid- positive patient help counteract balance immune response ameliorate disease progression conclusion asthmatic patient remain cautious covid- pandemic maintain precaution stay safe limited research datum future strategy include well understanding asthmatic exacerbation relation covid-
191,introduction coronavirus infectious disease  covid- currently important public health crisis affect global human population continue spread widely world lack specific treatment vaccine virus scenario covid- yemen obscure lack adequate datum develop electronic questionnaire distribute online yemeni people aim study understand covid- epidemiological situation yemen well currently limited publish datum limited availability covid- testing methodology -question web base survey distribute social medium outlet target people yemen datum aggregation analysis visualization perform tableau microsoft excel result individual report symptom concern covid- infection .% report chronic medical condition diabetes hypertension asthma immune deficiency associate increase severity disease obesity cardiovascular disease kidney disease liver disease  individual .% confirmatory covid- pcr test presence high fever dyspnea chest pain dysphagia symptom tend correlate bad clinical outcome conclusion study provide important information early overspread covid- yemeni community june july show online questionnaire help collect datum pandemic resource limit country testing availability limited
192,introduction obesity diabetes hypertension age point factor influence progression covid- evidence condition inconclusive objective identify clinical characteristic relate covid- severity determine age act modifier relationship cardio metabolic comorbiditie cmc covid- progression method datum -year old confirm case n analyze hospitalization development pneumonia intubation requirement intensive care unit admission death dependent variable poisson regression model estimation interaction age different cmc independent variable result have cmcs comorbiditie directly relate covid- progression chronic obstructive pulmonary disease relate increase risk die risk covid- severity low age advanced asthma smoking risk factor progression covid- conclusion mexican population risk covid- progression associate comorbiditie high young adult
193,diagnosis severe acute respiratory syndrome coronavirus  sars cov- case base count real time reverse transcription plymerase chain reaction rt pcr positive people viral load real time rt pcr suggest biomarker sars cov- infection association viral load severity disease resolve nasopharyngeal sample  patient test rt pcr sars cov- diagnosis relative quantitation comparative threshold cycle deltadeltact formula orfab viral rnase p housekeeping gene absolute viral load calculate reference positive control prevalent clinical sign cough .% myalgia .% fever hypertension .% neurological disease .% asthma hypothyroidism .% frequent comorbiditie fever exclusive symptom combine associate high viral load  c t range .- log rna copy test week onset symptom mild patient  year old detect peak viral load child  year old high viral load  day postinfection sharp decline case   year old show low moderate viral load  day postinfection range patient  year old high viral load second week onset symptom range .- indicate long presence virus finding suggest viral load nasopharyngeal swab help monitor sars cov- infection mild coronavirus disease  case
194,large country variation covid- death rate partly explain diet country low covid- death rate common feature eat large quantity fermented vegetable cabbage continent spice fermented vegetable spice agonist antioxidant transcription factor nuclear factor erythroid derive  nrf spice transient receptor potential ankyrin  vanillin  trpa v agonist mechanism explain covid- symptom severity appear synergy nrf trpa v food explain role diet covid- mechanism covid- appear oxygen specie ros)-mediate process synergy trp channel modulate nrf pathway spicy food likely desensitize trp channel act synergy exogenous antioxidant activate nrf pathway
195,background prognosis patient covid- infection uncertain derive validate new risk model predict progression disease severity hospitalization admission intensive care unit icu mortality patient covid- infection gal covid- score method retrospective cohort study patient covid- infection confirm reverse transcription polymerase chain reaction rt pcr galicia spain datum extract electronic health record patient include age sex comorbiditie accord international classification primary care code icpc- logistic regression model estimate probability disease severity calibration discrimination evaluate assess model performance result incidence infection  patient total  patient .% require hospitalization  .% admit icu  .% die variable include model predict severity include age gender chronic comorbiditie cardiovascular disease diabetes obesity hypertension chronic obstructive pulmonary disease asthma liver disease chronic kidney disease haematological cancer model demonstrate fair good fit predict hospitalization auc area receiver operating characteristic roc curve confidence interval ci admission icu auc ci death auc ci conclusion gal covid- score provide risk estimate predict severity covid- patient ability predict disease severity help clinician prioritize high risk patient facilitate decision making health authority
196,background worldwide outbreak coronavirus disease covid- bring disaster people world researcher carry clinical epidemiological study patient covid- previously risk factor patient different level severity unclear method  patient laboratory confirm covid-  hospital china include retrospective study related clinical information therapy imaging datum extract electronic medical record compare patient severe non severe status explore risk factor associate different severity covid- patient logistic regression method result base guideline cite  patient classify non severe  severe age range year median age  iqr .- elderly patient old  year old non severe group likely suffer fever asthma accompany high level d dimer red blood cell distribution width low density lipoprotein furthermore find liver kidney function male patient bad female patient severe non severe group different age level severe female fast esr low inflammatory marker major laboratory marker non severe case baseline albumin lymphocyte percentage high white blood cell neutrophil count low addition severe patient likely accompany increase cystatin c mean hemoglobin level decrease oxygen saturation advanced age indicator count white blood cell glucose prove common risk factor prevent covid- patient aggravate conclusion potential risk factor find study show great significance prevent covid- patient aggravate turn critical case treatment focus gender age factor group different severity covid- pay attention specific clinical symptom characteristic improve efficacy personalized intervention treat covid- effectively
197,severity coronavirus disease covid- associate comorbiditie study demonstrate potential risk respiratory failure mortality covid- patient pre existing asthma select  adult covid- patient korean health insurance review assessment covid- database nationwide retrospective cohort study  patient asthma assess severity evaluate clinical outcome covid- compare patient asthma  adult covid- patient  asthma  asthma compare asthma significant risk factor respiratory failure mortality covid- patient odd ratio p p adjust age sex charlson comorbidity score history acute exacerbation p significant risk factor death covid- patient asthma asthma risk factor poor prognosis covid- asthma patient experience acute exacerbation previous year covid- show high covid relate mortality especially case old age male sex
198,background impact asthma coronavirus disease  covid- remain largely unknown objective investigate asthma prevalence patient covid- compare outcome patient asthma method systematic review meta analysis search pubmed embase web science study report asthma prevalence general patient covid- compare outcome patient asthma exclude duplicate publication review editorial comment single case report small case series case determine pool estimate effect random effect model result basis  study patient find great variability prevalence comorbid asthma patient covid- different country region range .% .% significant difference asthma prevalence find hospitalize nonhospitalized risk ratio rr ci .- severe nonsevere rr ci .- intensive care unit non intensive care unit rr ci .- dead survive rr ci .- intubate mechanically ventilate nonintubate mechanically ventilated rr ci patient covid- patient asthma low risk death compare patient asthma rr ci asthma associate high risk intubation mechanical ventilation rr ci conclusion great variability asthma prevalence patient covid- different country region asthma associate high covid- severity bad prognosis patient asthma find low risk death compare patient asthma
199,sars cov specific antibody particularly prevent viral spike receptor bind domain rbd interaction host angiotensin convert enzyme  ace receptor neutralize virus unknown feature serological response affect clinical outcome covid- patient analyze  longitudinal plasma sample  hospitalize covid- patient  sars cov infected outpatient asymptomatic individual cohort  patient die illness high ratio igg antibody target s rbd domain spike compare nucleocapsid antigen see outpatient mild illness versus severely ill patient plasma antibody increase correlate decrease viral rnaemia antibody response acute illness insufficient predict inpatient outcome pseudovirus neutralization assay scalable elisa measure antibody block rbd ace interaction correlate patient igg titer rbd outpatient asymptomatic individual sars cov- antibody include igg progressively decrease observation month post infection
200,background effect chronic inhale systemic corticosteroid use covid- susceptibility severity unclear patient chronic pulmonary disease rely corticosteroid control disease important understand risk use pandemic aim study use inhaled systemic corticosteroid affect likelihood develop covid- infection method national jewish health electronic medical record research database identify cohort subject test suspect covid- march  june testing result medication use comorbiditie obtain medical record follow comparison different propensity score weighting method overlap propensity score weighting analyze association medication use covid- diagnosis result cohort consist  patient test positive majority patient history chronic pulmonary disease significant association inhale corticosteroid use testing positive covid- interestingly systemic corticosteroid use associate low odd ratio ci test positive covid- similar result note analysis restrict chronic pulmonary disease asthma chronic obstructive pulmonary disease copd conclusion study support recommendation patient chronic pulmonary disease include asthma copd require treatment inhaled systemic corticosteroid continue use covid- pandemic
201,aim study nct investigate relationship platelet activation myocardial injury mortality patient affect coronavirus disease  covid- patient respiratory failure severe acute respiratory syndrome coronavirus  sars cov- infection enrol case patient clinical presentation negative sars cov- infection include control blood sample collect different time point inclusion t   day t   day t platelet aggregation light transmittance aggregometry circulate level soluble cd ligand scdl p selectin measure platelet biomarker differ case control scdl high covid- patient p covid- patient p selectin scdl level decrease t t high case require admission intensive care unit p p respectively patient myocardial injury die high value biomarker platelet activation p myocardial injury independent predictor mortality covid- patient admit hospital respiratory failure heighten platelet activation associate severity illness myocardial injury mortality.clinicaltrials.gov number nct
202,objective describe clinical manifestation severity child adolescent affect covid- treat sabara hospital infantil method cross sectional retrospective observational study case covid- confirm rt qpcr patient see hospital emergency room aid room icu analyze severity case classify accord chinese consensus result  child include predominance boy verify median age year total  child hospitalize  icu total comorbiditie predominance asthma fever cough nasal discharge frequent symptom respiratory symptom report child gastrointestinal symptom child asymptomatic  upper airway symptom  mild pneumonia  severe pneumonia hospitalized child young non hospitalize child month vs.  month hospitalize patient high frequency irritability dyspnea drowsiness respiratory distress low oxygen saturation hepatomegaly observe chest radiography perform  child abnormal exam child require mechanical ventilation death conclusion child adolescent affect covid- mild upper airway symptom clinical manifestation covid- severe young child exhibit gastrointestinal respiratory symptom frequently
203,background scant datum currently available potential link comorbid chronic lung disease cld risk severity coronavirus disease  covid- infection method describe clinical characteristic outcome patient covid- infection include patient comorbid respiratory disease primarily hospitalize pulmonology department strasbourg university hospital france retrospective single center study include confirm case covid- march  april compare symptom biological radiological finding outcome patient cld result  patient enrol median age  year  patient male overall patient n= preexisting cld include chronic obstructive pulmonary disease copd n= asthma n= patient transfer intensive care unit icu patient die unit cld predictive icu hospitalization significantly high total mortality observe vs. .% p patient conclusion result suggest lack representation cld covid- represent patient cohort pulmonology department cld risk factor icu management tendency high global mortality observe covid- patient cld study warrant determine risk covid- patient comorbid cld
204,introduction coronavirus disease covid- infection cause novel severe acute respiratory syndrome coronavirus- sars cov- primarily affect lung tobacco relate illness include asthma chronic obstructive pulmonary disease copd coronary artery disease know reduce lung capacity impair immune system body greatly influence ability fight novel coronavirus purpose state art literature review summarize evidence association tobacco use severity covid- manifestation method article describe association tobacco use severity covid- manifestation search pubmed medline google review cover relevant study subject publish january  september result tobacco use form smoking chewing significantly associate severe covid- outcome pre exist comorbiditie tobacco user cardiovascular disease diabetes respiratory disease hypertension find aggravate disease manifestation make treatment covid- patient challenging rapid clinical deterioration conclusion current review indicate nicotine exposure link cardiopulmonary vulnerability covid- tobacco use potential risk factor get viral infection severe manifestation current pandemic provide teachable moment break cycle nicotine addiction accelerate national tobacco control program achieve tobacco free world
205,background conflicting result literature frequency allergic disease covid- patient effect have allergic disease covid- disease severity little study purpose study try determine frequency allergic disease covid- patient effect have allergic disease covid- disease severity design method retrospective cross sectional study conduct patient diagnose covid- state hospital istanbul turkey patient contact phone approve participate study question sociodemographic characteristic body mass index smoking history atopic status rate atopic disease mild severe covid- patient risk estimate mild disease atopic non atopic covid- patient calculate result study population consist  adult covid- mean age year standard deviation year  male study population  .% subject atopic symptom wheeze rhinitis eczema subject atopic status .% subject wheeze .% rhinitis .% eczema  month atopic status associate time high odd mild disease atopic atopic find associate covid- severity p conclusion information atopic disease common covid- patient guide clinical risk classification
206,introduction novel coronavirus disease  covid- rapidly spread globe pre exist comorbiditie find dramatic effect disease course seek analyze effect asthma disease progression outcome covid- patient method conduct multi center retrospective study positively confirm covid- patient primary outcome interest hospital mortality secondary outcome intensive care unit icu admission intubation mechanical ventilation length hospital stay result total  covid- adult patient asthma  non asthma cohort mean age year include study frequency asthma hospitalize cohort univariate analysis reveal asthma patient likely obese versus .% p high frequency intubation .% versus .% p require long duration hospitalization versus p adjustment multivariable analysis show asthmatic patient associate high risk icu admission ci p endotracheal intubation ci p complication ci p asthmatic patient associate high odd prolonged hospital length stay ci p icu stay ci p kaplan meier curve show significant difference overall survival group p conclusion despite increase prevalence hospitalization eld asthmatic covid- patient adjustment variable associate increase severity bad outcome
207,severe acute respiratory syndrome coronavirus  sars cov- transmit human mainly contact droplet transmission entry cell mediate efficient binding spike s viral protein angiotensin convert enzyme- ace receptor acute respiratory distress syndrome ards cause sars cov- fulfill criterion berlin definition considerable proportion patient covid- dissociation relatively preserve lung mechanic severity hypoxaemia extent pneumococcal relate morbidity mortality largely unknown respiratory comorbiditie increase risk severe disease mortality sars cov- include chronic obstructive pulmonary disease asthma bronchiectasis fibrotic interstitial lung disease regardless aetiology pneumococcal seasonal influenza vaccination useful prevent substantial burden mortality high risk population general quarantine social distancing reduce infiltration virus community date therapeutic agent study currently examine hydroxychloroquine chloroquine ritonavir lopinavir remdesivir colchicine interleukin- inhibitor usage clinical practice base randomised clinical trial result view extreme caution remdesivir promising option rigorous effort way development safe successful vaccine sars cov-
209,pandemic coronavirus disease  covid- cause severe acute respiratory syndrome coronavirus  sars cov- cause unprecedented global social economic impact high number death risk factor identify progression covid- severe critical stage include old age male gender underlie comorbiditie hypertension diabetes obesity chronic lung disease heart liver kidney disease tumor clinically apparent immunodeficiency local immunodeficiency early type interferon secretion capacity pregnancy possible complication include acute kidney injury coagulation disorder thoromboembolism development lymphopenia eosinopenia laboratory indicator covid- laboratory parameter monitor disease progression include lactate dehydrogenase procalcitonin high sensitivity c reactive protein proinflammatory cytokine interleukin il)- il beta krebs von den lungen- kl- ferritin development cytokine storm extensive chest compute tomography imaging pattern indicator severe disease addition socioeconomic status diet lifestyle geographical difference ethnicity expose viral load day initiation treatment quality health care report influence individual outcome review highlight scientific evidence risk factor severity covid-
210,pandemic covid- emerge health crisis globally india extensively affect active case report till date present study focus demographic clinical laboratory profile patient tertiary level non covid respiratory care hospital retrospective observational study seventy seven sick patient fulfil covid suspect criterion admit isolation area rt pcr test designated laboratory  confirm covid- patient detailed demographic clinical laboratory profile covid- patient study mean age year male predominance majority case symptomatic common symptom cough follow breathlessness fever nineteen .% patient co morbidity  .% chronic lung disease comorbiditie nearly half patient require supplementary oxygen presentation patient invasive mechanical ventilation  patient require non invasive ventilation shift covid hospital conclude covid- patient chronic respiratory disease manifest high prevalence symptom high severity disease symptomatology covid- closely mimic acute exacerbation chronic lung disease cautious screening testing especially pulmonary department
211,severe acute respiratory syndrome coronavirus  infection cause coronavirus disease  covid- manifest range severity mild illness life threaten pneumonia multi organ failure severe covid- characterize inflammatory signature include high level inflammatory cytokine alveolar inflammatory infiltrate vascular microthrombi patient severe covid- produce unique serologic signature include increased likelihood igg afucosylated fc glycan fc modification severe acute respiratory syndrome coronavirus  iggs enhance interaction activate fcgamma receptor fcgammariiia incorporate immune complex fc afucosylation enhance production inflammatory cytokine monocyte include interleukin- tumor necrosis factor result disease severity covid- correlate presence proinflammatory igg fc structure include afucosylated igg.
215,background association severity coronavirus disease  covid- presence certain chronic condition suggest unlike influenza virus disease burden covid- patient asthma evident objective understand impact covid- patient asthma method big data analytic artificial intelligence savana manager clinical platform analyse clinical datum patient asthma january  result  patient asthma  .% suffer covid- compare asthmatic individual covid- patient asthma covid- significantly old versus  year predominantly female versus smoke frequently high prevalence hypertension dyslipidaemia diabetes obesity allergy relate factor rhinitis eczema common asthmatic patient covid- p addition high prevalence comorbiditie observe patient covid- require hospital admission use inhale corticosteroid ics low patient require hospitalisation covid- compare non hospitalise patient versus .% ci patient treat biologic n= .% show increase severity comorbiditie ear nose throat level covid relate hospitalisation patient relatively low conclusion patient asthma covid- old increase risk comorbidity relate factor ics biologic generally safe associate protective effect severe covid- infection
217,aim pre exist cardiovascular disease cvds propose identify patient high risk adverse coronavirus disease  covid- outcome existing evidence conflicting unclear pre existing cvd independently important predictor severe covid- method result nationwide danish cohort hospital screen covid- patient age /= investigate pre exist cvds predict -day risk composite outcome severe covid- ii cause mortality estimate -day risk cox regression model include age sex cvd comorbidity chronic obstructive pulmonary disease asthma diabetes chronic kidney disease illustrate cvd comorbiditie importance evaluate predict risk death severe infection sex age total  covid- hospital screen patient observe  august .% cvd .% severe infection  day .% die predict risk outcome age  man single cvd comorbiditie differ clinically meaningful amount compare man comorbiditie risk composite outcome severe infection woman heart failure .% ci atrial fibrillation .% ci show modest increase compare woman comorbiditie .% ci conclusion result show modest effect cvds increase risk poor covid- outcome important allow public health authority clinician provide tailored guidance cardiovascular patient heretofore group high risk disease status
218,coronaviruse rna virus cause disease upper low respiratory tract human animal lately new coronavirus cause pneumonia case detect wuhan china december soon virus identify severe acute respiratory syndrome world health organization name disease coronavirus disease- covid- country case begin appear second week march study aim investigate demographic characteristic risk factor patient diagnosis covid- total  patient female  male include study patient include study randomly select registration system information evaluate retrospectively mean age patient age range= risk factor catch disease evaluate determine risk factor  patient  patient close contact covid- patient social environment  patient travel history outside city  day common symptom patient cough fever dyspnea weakness sore throat diarrhea headache sputum common comorbid condition patient detect hypertension diabetes mellitus dm congestive heart failure allergic asthma chronic obstructive pulmonary disease rheumatoid arthritis coronary artery disease solid organ tumour depression epilepsy mean age  patient monitor intensive care unit  y mean age  patient follow service difference statistically significant p= group compare term comorbid disease presence dm high n= intensive care patient difference statistically significant p= addition majority patient patient hospitalize intensive care unit male p= smoking evaluate risk factor illness   patient intensive care unit smoking history patient die covid- smoking history finding suggest smoking increase severity covid- disease result knowledge disease increase rapidly share study risk factor transmission route clinical feature covid- infection affect world
219,introduction underlie disease critical role vulnerability population great morbidity mortality suffer covid- aim current study evaluate prevalence underlie disease die people covid- method current study conduct accord prisma guideline international database include pubmed scopus web science cochrane google scholar search relevant study  june relevant article report underlying disease die case covid- include analysis result screen exclude duplicate irrelevant study  article include analysis prevalent comorbiditie hypertension diabetes cardiovascular disease liver disease lung disease malignancy cerebrovascular disease copd asthma report underlying disease high low prevalence relate hypertension asthma estimate respectively conclusion summary underlie disease critical role poor outcome severity disease high mortality rate covid- case patient hypertension cardiovascular disease diabetes carefully monitor aware health protocol
220,background aim coronavirus disease  covid- pandemic global health emergency accord finding male patient covid- infection increase risk severe complication female cause issue unknown probably multifactorial sexual hormone affect immune system estrogen strengthen immune system testosterone suppress report high prevalence androgenic alopecia hospitalize patient covid- high risk respiratory disease increase use allergy asthma medication patient polycystic ovary syndrome pcos hyperandrogenism condition compare non pcos woman review aim evaluate androgens role covid- method  relate article   keyword androgen hormonal factor hair loss combination covid- medical research database result evidence transmembrane protease serine  tmprss expression lung tissue androgen regulate gene express mainly adult prostate interpret increase susceptibility male gender severe covid- complication angiotensin convert enzyme  ace- act functional receptor severe acute respiratory syndrome coronavirus  sars cov- male hormone effective ace- passageway simplify sars cov- entry host cell conclusion study severity symptom patient covid- hyperandrogenism condition compare control group recommend
221,severe acute respiratory syndrome coronavirus  sars cov- responsible covid- pneumonia pandemic precipitate huge pressure world social economic system disease severity vary individual sars cov- infection associate e.g. flu like symptom dyspnoea severe interstitial pneumonia acute respiratory distress syndrome multiorgan dysfunction generalized coagulopathy nitric oxide small signal molecule impact pleiotropic function human physiology involve significant effect covid- infection neurotransmitter involve neural olfactory process central nervous system infected patient report anosmia symptom additionally know vasodilator important coagulation mediator anti microbial effector inhibitor sars cov replication exhale strongly related type- inflammatory response find asthma suggest protective sars cov- infection report indicate use inhale effective therapy pandemic ventilation perfusion ratio covid- patient improve require mechanical ventilation aim mini review summarize relevant action beneficial treatment covid-
222,infection severe acute respiratory syndrome sars coronavirus- sars cov- causative agent new disease covid- risk severe covid- increase certain underlie comorbiditie include asthma cancer cardiovascular disease hypertension diabetes obesity notably exposure hormonally active chemical call endocrine disrupt chemical edcs promote cardio metabolic disease endocrine relate cancer immune system dysregulation link high risk severe covid- bisphenol bpa common edc exert effect receptor widely distribute human tissue include nuclear oestrogen receptor eralpha erbeta membrane bind oestrogen receptor g protein couple receptor gpr human nuclear receptor oestrogen relate receptor gamma paper focus potential role bpa promote comorbiditie associate severe covid- potential bpa induce effect key sars cov- infection mediator angiotensin convert enzyme  ace transmembrane serine protease  tmprss interestingly gpr appear exhibit great co localisation tmprss key tissue like lung prostate suggest bpa exposure impact local expression sars cov- infection mediator overall potential role bpa risk severity covid- merit investigation
223,purpose review matrix metalloproteinase mmps family  zinc dependent protease different biological pathological activity implicate disease nonselective mmp inhibitor know induce effect target individual mmps offer safe therapeutic potential disease provide concise overview mmp- give association pulmonary disease include asthma chronic obstructive pulmonary disease copd idiopathic pulmonary fibrosis progressive pulmonary fibrosis ppf occur coronavirus disease recent finding asthma copd ppf increase mmp- level associate inflammation and/or structural change lung negatively correlate functional parameter increased pulmonary mmp- level mmp- gene expression relate disease severity asthma copd target mmp- show potential animal model pulmonary disease human datum scarce summary potential role mmp- asthma copd ppf pathophysiological aspect await elucidation target mmp- provide insight mmp- related mechanism translate clinical outcome warrant research
224,covid- pandemic great threat physical mental health lead psychological stress connect economic crisis threat unemployment fear lose family member emerge datum show general public vulnerable pandemic relate stress experience frequently prevalent anxiety study involve  subject .% female conduct online covid- pandemic follow scale insomnia severity index isi beck depression inventory bdi revised university california los angeles r ucla loneliness scale daily life fatigue scale dlf woman high mean score depression loneliness daily life fatigue male start exercise people professionally active pandemic case increase alcohol consumption student difference alcohol consumption pattern find gender people live high score loneliness daily life fatigue compare live respondent start take new drug covid- home confinement high outcome questionnaire home confinement high score depression insomnia loneliness everyday fatigue observe
226,purpose come attention specific vascular change vcs appear frequently chest compute tomography ct patient coronavirus disease  covid- study aim investigate specific vcs chest ct correlate clinical severity disease method ct image  patient undergo low dose noncontrast chest ct covid-  march   april  evaluate retrospectively patient divide group base presence vcs ct image vcs chest ct patient covid- define follow descriptor decrease lumen caliber vascular wall irregularity angulation course vessel vascular disruption and/or interruption relationship vcs disease symptom fever cough shortness breath comorbid condition diabetes hypertension asthma smoking habit disease specific laboratory change white blood cell lymphocyte count neutrophil lymphocyte ratio c reactive protein crp d dimer lactate dehydrogenase ldh ferritin procalcitonin lung parenchymal infiltration pattern ground glass opacity crazy paving pattern consolidation distribution peripheral central mixed upper lobe low lobe right middle lobe ct investigate comparison variable patient vcs chest ct result vcs observe   patient typical parenchymal involvement covid- significant difference term age sex find irregularity wall vascular structure distal branch decrease lumen caliber vessel relate ground glass opacity  patient concentric luminal narrowing annular form  patient angulation traction springiness vascular structure active lesion  patient interruption vascular course  patient vcs significantly correlate fever .% shortness breath change significantly remarkable common disease involve upper low lobe case substantial increase crp mean .+/- mg dl ldh value compare vcs conclusion result study suggest specific vcs observe chest ct predict disease severity case covid- pneumonia change relate respiratory distress disease
227,background aim angiotensin convert enzyme ace type  receptor sarscov- cell entry lung cell ace- modulate ace inhibitor aceis angiotensin ii receptor blocker arb concern patient treat aceis arb high risk covid- infection severity study seek analyse association severe form covid- mortality hypertension previous treatment acei arb method prospective follow  consecutive patient hospitalise covid- pneumonia confirm pcr highly probable clinical biological radiological finding include covhyp study mortality severe covid- criterion death intensive care unit hospitalisation day compare patient receive aceis arb follow hospital discharge .% month result age year female follow mean days  patient severity criterion death  intensive care unit hospital stay day hypertension .% vs .% p antihypertensive treatment associate severe covid- mortality association acei arb treatment covid- severity criterion find univariate analysis odds ratio ci p=. confirm adjust age gender hypertension adjust p=. diabetes hypothyroidism associate severe covid- history asthma conclusion study suggest previous treatment acei arb associate hospital mortality -month mortality severity criterion patient hospitalise covid- protective effect acei arb severe pneumonia relate covid- demonstrate
228,coronavirus disease  covid- cause highly transmissible severe acute respiratory syndrome coronavirus  sars cov- affect global population despite socioeconomic status amazed surveillance agency incidence mortality recovery rate covid- affect age group suggest progress severe disease cause mortality confirm case depend individual characteristic affected population big unanswered question individual develop severe stage disease current datum indicate critically ill elderly comorbiditie hypertension diabetes asthma note population severe disease observe young individual -year old report underlying medical condition certainly factor contribute disease severity include intrinsic host factor genetic variant expression level tissue protein consider aspect review aim discuss expression level tissue protease different profile immune response influence susceptibility covid- disease severity outcome
229,mozambique locate east coast africa country affect covid- case report  march  case increase gradually country worldwide environmental population characteristic analyze worldwide understand possible association covid- article seek highlight evolution possible contribution risk factor covid- severity accord available datum mozambique available datum highlight covid- severity magnify mainly hypertension obesity cancer asthma hiv sida malnutrition condition buffer age youthful population covid- epidemic evolution particularly cabo delgado need increase laboratory diagnosis capacity monitor compliance preventive measure particular attention give cabo delgado include isolation province overcome local transmission spread sars cov-
230,coronavirus disease covid- cause severe acute respiratory syndrome coronavirus- sars cov- present respiratory symptom life threaten severe case start pandemic allergy asthma chronic obstructive pulmonary disease copd consider risk factor covid- tend exacerbate respiratory viral infection recent literature show airway allergic disease high risk factor increase severity covid- decrease angiotensin convert enzyme  ace gene expression nose bronchial cell allergic airway disease conventional asthma treatment include inhale corticosteroid ics allergen immunotherapy ait biologic continue reduce risk asthmatic coronavirus infection enhance antiviral defence alleviate inflammation
231,background coronavirus disease  covid- pandemic demonstrate significantly bad outcome minority black hispanic individual understand reason covid related disparity patient asthma important public health implication objective determine factor contribute health disparity asthma covid- pandemic method anonymous survey send social medium adult patient asthma separate survey send physician provide asthma care patient survey address demographic information include socioeconomic status asthma control attitude health behavior covid- result total  patient .% minority individual  physician complete survey minority patient likely affect covid- eg unemployed live community high covid- case bad asthma control increase emergency visit asthma low asthma control test score likely live urban area low household income initial difference attitude health behavior disappear control baseline demographic feature institutional racism demonstrate finding minority individual likely primary care physician trouble afford asthma medication covid- likely lose health insurance covid- physician find challenging care black individual asthma covid- conclusion difference socioeconomic status effect institutional racism health behavior source information attitude play role disparity see patient asthma covid-
232,background early description patient admit hospital covid- pandemic show low prevalence asthma chronic obstructive pulmonary disease copd expect acute respiratory disease like covid- lead speculation inhale corticosteroid ics protect infection severe acute respiratory syndrome coronavirus  development sequela assess association ics covid relate death people copd asthma link electronic health record ehrs england uk method observational study analyse patient level datum people copd asthma primary care ehrs link death datum office national statistics opensafely platform index date start follow cohort march follow last copd cohort individual eligible aged  year old copd current smoker prescribe ics long act beta agonist plus long act muscarinic antagonist laba lama combination therapy  month index date asthma cohort individual eligible aged  year old diagnose asthma  year index date prescribe ics short act beta agonist saba  month index date compare outcome covid relate death people prescribe ics prescribed alternative respiratory medication ics versus laba lama copd cohort low dose medium dose high dose ics versus sabas asthma cohort cox regression model estimate hazard ratio hrs ci association exposure category outcome population adjust age sex prespecifie covariate calculate e value quantify effect unmeasured confound result finding identify  people copd  people asthma give relevant respiratory medication  month index date people copd prescribe ics increase risk covid relate death compare prescribe laba lama combination adjust hr ci compare prescribed saba people asthma prescribe high dose ics increase risk death give low medium dose sensitivity analysis show apparent harmful association observe explain relatively small health difference people prescribe ics prescribe ics record database e value low ci interpretation result support major role regular ics use protect covid relate death people asthma copd observe increased risk covid relate death plausibly explain unmeasured confound disease severity funding uk medical research council
233,objective describe prevalence nature risk factor main clinical sequela coronavirus disease  covid- survivor discharge hospital  month method longitudinal study base telephone follow survey covid- patient hospitalize discharge renmin hospital wuhan university wuhan china  march demographic clinical characteristic self report clinical sequela survivor describe analyse cohort volunteer free covid- live urban area wuhan outbreak select comparison group result  survivor .% female median interquartile range age year time discharge hospital follow day clinical sequela common include general symptom n .% respiratory symptom n cardiovascular relate symptom n psychosocial symptom n .% alopecia n .% find physical decline fatigue p /= bpm hospitalization associate rest heart rate increase convalescence duration virus shed covid- onset hospital length stay long survivor physical decline fatigue postactivity polypnoea conclusion clinical sequela early covid- convalescence common sequelae relate gender age clinical characteristic hospitalization
234,background coronavirus disease  covid- spread worldwide rapidly effect asthma asthma medication asthma severity clinical outcome covid- establish method study include  de identify patient confirm covid- severe acute respiratory syndrome coronavirus  rna pcr test conduct link medical claim datum provide health insurance review assessment service asthma asthma severity step suggest global initiative asthma define diagnostic code history asthma medication usage result  covid- patient  .% underlying asthma total medical cost associate covid- patient underlie asthma significantly high patient mortality rate covid- patient underlying asthma .% significantly high patient .% p asthma independent risk factor clinical outcome covid- adjustment asthma medication use asthma severity affect clinical outcome covid- use oral short act beta agonist independent factor increase total medical cost burden patient step  asthma show significant prolonged duration admission compare step  asthma univariate multivariate analysis conclusion asthma lead poor outcome covid- underlie asthma use asthma medication asthma severity independent factor poor clinical outcome covid- generally
235,purpose systematic review meta analysis explore literature collate datum compare mortality coronavirus disease  covid- patient asthma database pubmed scopus embase google scholar medrxiv.org search study compare clinical outcome asthmatic patient nonasthmatic patient diagnose covid- mortality datum summarize mantel haenszel ci random effect model retrospective study meet inclusion criterion meta analysis datum  asthmatic patient nonasthmatic patient indicate presence asthma significant effect mortality ci p result stable sensitivity analysis descriptive analysis clinical outcome indicate difference duration hospitalization risk intensive care unit icu transfer asthmatic nonasthmatic patient conclude preliminary datum indicate asthma comorbidity increase mortality covid- datum influence asthma risk hospitalization duration hospitalization requirement icu admission disease severity limited draw strong conclusion study large sample size require establish strong evidence
236,gender specific difference prevalence incidence comorbiditie prognosis severity risk factor drug relate aspect outcome medical condition document present literature review extent research field develop year reveal gap gender sensitive awareness clinical portrayal translation gender specific treatment regimen guideline gender orient preventive strategy health policy subsequently lens gender describe domain detail select medical condition asthma obesity overweight chronic kidney disease coronavirus disease key gender difference apparent adolescence focus developmental stage finally propose model base influential issue investigate gender specific medical profile relate health condition single disease dynamic gender disparity developmental stage integrative approach take account additional risk factor ethnicity socio demographic variable minority lifestyle habit etc increase awareness gender specific medicine daily practice tailored guideline adolescent reduce inequity facilitate prediction future trend properly address characteristic need certain subpopulation gender
237,background coronavirus disease  covid- cause novel coronavirus sars cov- associate severe respiratory disease extensive publication chest compute tomography ct finding covid- pneumonia ground glass opacity ggo mix ggo consolidation common finding interstitial thickening manifest reticular opacity typically superimpose ground glass opacity give crazy paving pattern case report report case -year old man background asthma chronic obstructive pulmonary disease copd overlap syndrome acos present progressive cough shortness breath  day close contact confirm covid- case reverse transcription polymerase chain reaction analysis nasopharyngeal swab positive sars cov- initial chest radiograph negative lung consolidation ground glass opacity admission worsen shortness breath desaturation prompt chest ct examination perform day  illness chest ct reveal atypical finding predominant focal subpleural interstitial thickening right low lobe provide supportive treatment steroid antibiotic recover subsequently test negative  consecutive swab discharge  day conclusion interstitial thickening reticular pattern ct describe covid- pneumonia largely association ground glass opacity consolidation case demonstrate atypical predominance interstitial thickening chest ct covid- pneumonia day  illness expect time great severity disease
238,result severe acute respiratory syndrome coronavirus  sars cov- infection clinical complication arise characterize hyperinflammatory cytokine profile term cytokine storm protein complex nuclear factor kappa light chain enhancer activate b cell nf kappab intricately involve regulate inflammation immune response follow viral infection reduction cytokine production observe follow decrease nf kappab activity approve asthma drug montelukast find modulate activity nf kappab result corresponding decrease proinflammatory mediator hypothesize repurpose montelukast suppress nf kappab activation result attenuation proinflammatory mediator decrease cytokine production lead reduction symptom severity improve clinical outcome patient coronavirus  covid-
239,purpose tmprss host co receptor cell entry sars cov- prior report suggest use androgen deprivation therapy downregulate tmprss protect man prostate cancer infection material method cohort study prospective registry patient test sars cov- march  june  complete followup disease recovery death main exposure examine use androgen deprivation therapy outcome measure rate sars cov- positivity disease severity function androgen deprivation therapy use result study cohort consist man prostate cancer total test population .% positive sars cov- prostate cancer  .% sars cov- positive  .% androgen deprivation therapy androgen deprivation therapy positive compare .% androgen deprivation therapy man androgen deprivation therapy slightly old vs year p=. likely smoke .% vs .% p=. likely report take steroid .% vs .% p factor know increase risk infection disease severity equally distribute asthma diabetes mellitus hypertension coronary artery disease heart failure immune suppressive disease multivariable analysis indicate difference infection risk prostate cancer androgen deprivation therapy ci p=. conclusion androgen deprivation therapy appear protective sars cov- infection
240,prove safe effective therapy child develop life threaten complication severe acute respiratory syndrome coronavirus  sars cov- convalescent plasma cp demonstrate potential benefit adult sars cov- theoretical risk present report cp child life threaten coronavirus disease  covid- provide datum pediatric patient acute respiratory distress syndrome measure donor antibody level recipient antibody response prior follow cp infusion infusion cp associate antibody dependent enhancement ade suppress endogenous antibody response find cp safe possibly efficacious randomized pediatric trial need
242,introduction life threaten respiratory disease coronavirus  covid- spread globe december prognostic factor forward predict risk death outcome current study evaluate survival rate hypertensive non hypertensive infected patient method patient include study admit  february  march  fars southwest iran province hospital datum collect electronic base registry contain demographic information medical symptom sign underlie disease ct scan result final outcome result  positive case  .% know hypertension ant group significantly old non hypertensive patient year v year p accord kaplan meier survival curve log rank test see hypertensive patient deteriorate rapidly non hypertensive group p hiv cardiovascular kidney disease diagnose factor increase risk death hypertensive patient conclusion current study survival rate covid- patient show hypertensive patent danger disease severity relate age probability complication like diabetes smoking asthma kidney cardiovascular disease infection hiv condition complicate need consideration prevent noxious outcome
244,background inconclusive controversial evidence association allergic disease risk adverse clinical outcome coronavirus disease  covid- objective seek determine association allergic disorder likelihood positive severe acute respiratory syndrome coronavirus  sars cov- test result clinical outcome covid- admission intensive care unit administration invasive ventilation death method propensity score match nationwide cohort study perform south korea datum obtain health insurance review assessment service korea adult patient age year test sars cov- south korea january analyze association sars cov- test positivity allergic disease entire cohort n difference clinical outcome covid- evaluate patient allergic disease sars cov- positivity n result entire cohort patient undergo sars cov- testing evaluate ascertain asthma allergic rhinitis associate increased likelihood sars cov- test positivity propensity score matching find asthma allergic rhinitis associate bad clinical outcome covid- patient sars cov- test positivity patient nonallergic asthma great risk sars cov- test positivity bad clinical outcome covid- patient allergic asthma conclusion korean nationwide cohort allergic rhinitis asthma especially nonallergic asthma confer great risk susceptibility sars cov- infection severe clinical outcome covid-
245,medical personnel contact patient infect sars cov- especially high risk adverse psychological effect aim study assess mental health factor healthcare worker quantify severity anxiety depression sleep disorder current sars cov- pandemic take account coexist disease study involve  healthcare professional include  healthcare worker emergency ward infectious ward intensive care unit control group consist  healthcare worker work ward individual study group work regression adjust age gender occurrence hypertension diabetes mellitus dyslipidemia asthma autoimmune disease cigarette smoking show elevated risk anxiety generalized anxiety disorder gad- scale p depression patient health questionnaire phq- scale p sleep disorder insomnia severity index isi scale p study show healthcare worker expose sars cov infect patient emergency ward infectious ward intensive care unit high risk show symptom anxiety depression sleep disorder healthcare worker work ward
246,objective comprehensive review focus currently available evidence maternal fetal neonatal mortality case associate coronavirus disease  covid- infection july method systematically search pubmed scopus google scholar web science database identify report case maternal fetal neonatal mortality associate covid- infection reference relevant study hand search result  study screen  study report  maternal  perinatal mortality case fetal demise  neonatal death finally eligible inclusion review maternal death see woman previous co morbidity common obesity diabetes asthma advanced maternal age acute respiratory distress syndrome ards severity pneumonia consider lead cause maternal mortality case die thromboembolism postpartum period fetal neonatal mortality suggest result severity maternal infection prematurity respectively interestingly evidence vertical transmission positive covid- test result expire neonate conclusion current available evidence suggest maternal mortality happen woman previous co morbidity neonatal mortality result prematurity infection report need magnitude maternal perinatal mortality determine precisely
248,study objective study objective examine effect coronavirus disease treatment adherence self report sleep duration patient obstructive sleep apnea osa treat positive airway pressure therapy method retrospective review medical record patient see sleep circadian clinic brigham health immediate period  month national lockdown announce march patient osa include positive airway pressure adherence datum available  month month lockdown patient sleep disorder patient osa adherence datum exclude result mean age patient year participant man mean body mass index kg m severe osa note compare .% moderate osa .% mild osa increased number patient report insomnia lockdown vs p sex stratification show worsen insomnia woman significant difference positive airway pressure adherence measure hour use self report sleep duration use sleep medication conclusion post- coronavirus disease lockdown negative impact sleep evidence increase reporting insomnia particularly woman impact positive airway pressure adherence self report sleep duration
249,large difference covid- death rate exist country region country low death rate country eastern asia central europe balkans common feature eat large quantity ferment food bias exist examine ecological study ferment vegetable cabbage associate low death rate european country sars cov- bind receptor angiotensin convert enzyme  ace result sars cov- bind ace downregulation enhance angiotensin ii receptor type  r axis associate oxidative stress lead insulin resistance lung endothelial damage severe outcome covid- nuclear factor erythroid derive  nrf potent antioxidant human block particular r axis cabbage contain precursor sulforaphane active natural activator nrf fermented vegetable contain lactobacillus potent nrf activator example kimchi korea westernized food slum paradox propose fermented cabbage proof concept dietary manipulation enhance nrf associate antioxidant effect helpful mitigate covid- severity
250,background avoid surge demand healthcare system covid- pandemic reduce transmission individual chronic condition risk severe illness covid- aim understand perception context attitude individual chronic condition covid- pandemic clarify potential risk infection method cross sectional survey nest compare e cohort adult chronic condition france assess participant perception risk severe illness covid- context i.e. work household contact external people attitude situation involve frequent occasional contact symptomatic asymptomatic people datum collect march  april lockdown france analysis weight represent demographic characteristic french patient chronic condition subgroup participant high risk accord recommendation french high council public health examine result  recruit participant patient feel risk severe illness quarter .% risk infection work outside home household member work outside home regular visit external contact participant refuse contact symptomatic people mask contact asymptomatic people patient consider high risk accord recommendation french high council public health feel risk lead incautious attitude conclusion individual chronic condition distort perception risk severe illness covid- addition expose covid- context attitude
252,coronavirus disease respiratory tract infection evolve pandemic expect affect patient underlying respiratory disease great number great severity patient underlying disorder true interesting question challenge doctor patient respiratory disease remission prevent exacerbation proper recommendation propose wide range respiratory disorder include chronic obstructive pulmonary disease copd asthma interstitial lung disease continuation treatment period way maintain stability
255,backgroundinitial report severe acute respiratory coronavirus  sars cov- pandemic describe child susceptible coronavirus disease  covid- adult subsequently severe novel pediatric disorder term multisystem inflammatory syndrome child mis c emerge report unique hematologic immunologic parameter distinguish covid- mis c provide insight pathophysiology methodswe prospectively enrol hospitalize patient evidence sars cov- infection classify have mis c covid- patient covid- classify have minimal severe disease cytokine profile viral cycle threshold cts blood smear soluble cb- value analyze clinical datum resultstwenty patient enrol severe covid-  minimal covid-  mis c cytokine ifn gamma il- il- il- tnf alpha contribute analysis tnf alpha il- discriminate patient mis c severe covid- presence burr cell blood smear cts differentiate patient severe covid- mis c.conclusionpediatric patient sars cov- risk critical illness severe covid- mis c. cytokine profiling examination peripheral blood smear distinguish patient mis c severe covid-.fundingfinancial support project provide chop frontiers program immune dysregulation team national institute allergy infectious diseases national cancer institute leukemia lymphoma society cookies kids cancer alex lemonade stand foundation childhood cancer children oncology group stand  cancer team connor kate amato foundations burroughs wellcome fund cams clinical immunology society american academy allergy asthma immunology institute translational medicine therapeutics
256,recent year number epidemiological study demonstrate exposure air pollution associate adverse outcome acute low respiratory infection chronic obstructive pulmonary disease asthma cardiovascular disease lung cancer disease air pollutant sulfur oxide nitrogen oxide carbon monoxide dioxide particulate matter pm ozone volatile organic compound vocs commonly find high level big city and/or vicinity different chemical industry association air concentration pollutant human respiratory virus interact adversely affect respiratory system report present review aim assess potential relationship concentration air pollutant airborne transmission sars cov- severity covid- patient infect coronavirus result study suggest chronic exposure certain air pollutant lead severe lethal form covid- delay complicate recovery patient disease
258,background coronavirus disease  covid- global pandemic -% severe case  death worldwide objective study aim address risk factor associate severity covid- patient mortality severe patient method  hospitalize laboratory confirm covid- patient include study electronic medical record include patient demographic clinical manifestation comorbiditie laboratory test result radiological material collect analyze accord severity outcome patient divide group nonsurvived n survive severe n nonsevere n group clinical laboratory radiological datum compare group principal component analysis pca apply reduce dimensionality visualize patient low dimensional space correlation clinical radiological laboratory parameter investigate univariate multivariate logistic regression method determine risk factor associate mortality severe patient longitudinal change laboratory finding survive severe case nonsurvived case hospital stay collect result  patient median age  year range  .% patient male final follow date study  .% patient discharge hospital  .% patient die eld age underlie comorbiditie increase laboratory variable leukocyte count neutrophil count neutrophil lymphocyte ratio nlr c reactive protein crp procalcitonin pct d dimer alanine aminotransferase alt aspartate aminotransferase ast blood urea nitrogen bun admission find survive severe case compare nonsevere case accord multivariate logistic regression analysis eld age high number affected lobe elevated crp level admission increase prevalence chest tightness dyspnea smoking history independent risk factor death severe patient trajectory pca observe nonsevere nonsurvived severe survive patient strong correlation age patient affected lobe number laboratory variable identify dynamic change laboratory finding survive severe case nonsurvived case hospital stay show continue increase leukocyte neutrophil count sustain lymphopenia eosinopenia progress decrease platelet count high level nlr crp pct ast bun serum creatinine associate hospital death conclusion survive severe nonsurvived covid- patient distinct clinical laboratory characteristic separate principle component analysis eld age increase number affected lobe high level serum crp chest tightness dyspnea smoking history risk factor mortality severe covid- patient longitudinal change laboratory finding helpful predict disease progression clinical outcome severe patient
259,global pandemic cause newly describe severe acute respiratory syndrome coronavirus  sars cov- cause worldwide suffering death unimaginable magnitude coronavirus disease  covid- virus transmit aerosol droplet cause severe acute respiratory syndrome sars cov- use receptor bind domain spike protein s attach host angiotensin convert enzyme  receptor lung airway cell bind require help host protein transmembrane protease serine s member factor likely contribute efficient transmission sars cov- receptor bind domain sars cov- high receptor bind capacity compare previous pandemic coronaviruse addition asymptomatic person infect sars cov- high viral load nasal secretion silently efficiently spread disease pcr base test emerge criterion standard diagnosis infection caution exercise interpret antibody base test validate false sense security immune sars cov- discuss development symptom allergic rhinitis serve clue new onset covid- mixed report asthma risk factor severe covid- possibly difference asthma endotype rapid spread covid- focus effort scientist repurpose exist food drug administration approve drug inhibit viral entry endocytosis genome assembly translation replication numerous clinical trial launch identify effective treatment covid- initial datum placebo control study suggest fast time recovery patient remdesivir evaluate additional control study discuss review till effective vaccine treatment emerge important understand scientific rationale pandemic mitigation strategy wear facemask social distancing implement
260,limited information describe characteristic clinical outcome patient infect coronavirus disease  covid- especially underserved urban area minority population united states retrospective single center study patient admit covid- infection datum collection  march  april demographic clinical laboratory treatment datum present descriptive statistic frequency chi test multivariate logistic regression determine association risk factor clinical outcome total  inpatient include mean age  /-standard deviation total female african american comorbiditie include hypertension diabetes mellitus copd asthma old age associate high risk inpatient death odd ratio confidence interval ci p inpatient mortality occur need mechanical ventilation ci p require continuous renal replacement therapy hemodialysis crrt hd ci p need vasopressor ci p biomarker disease severity baseline crp level  mg l associate mortality ci p majority hospitalize patient hypertension diabetes old age independent risk factor inpatient mortality requirement mechanical ventilation vasopressor use crrt hd associate significantly inpatient mortality high baseline crp significantly associate inpatient death
261,nowadays coronavirus disease  covid- increase mortality world mercilessly learn day new symptom mutate quickly disease tie desperate death rate disease increase patient pre existing medical condition especially cardiovascular one eliminate angiotensin convert enzyme ace)- receptor lung ace angiotensin receptor blocker arb stimulate ace expression bad prognosis intravenous infusion acei arb experimental animal increase number ace receptor reason covid- infect cell patient treat hypertension congress cardiology recommend discontinue anti hypertensive drug brief report evaluate covid- view cardiovascular disease take account current report suggest possible solution virus control
262,background coronavirus disease covid- identify wuhan december  pandemic month discovery impact covid- rapid spread severity determinant severity fully delineate objective identify factor associate hospitalization disease severity racially ethnically diverse cohort covid- patient method analyze datum covid- patient diagnose university cincinnati health system march  severe covid- define admission intensive care unit death logistic regression model adjust covariate identify factor associate hospitalization severe covid- result  covid- patient include study .% non hispanic white .% non hispanic black .% hispanic .% race ethnicity .% patient hospitalize .% severe disease adjusted analysis sociodemographic factor associate hospitalization and/or disease severity include old age non hispanic black hispanic race ethnicity compare non hispanic white smoking follow comorbiditie diabetes hypercholesterolemia asthma copd chronic kidney disease cardiovascular disease osteoarthritis vitamin d deficiency associate hospitalization and/or disease severity hematological disorder anemia coagulation disorder thrombocytopenia associate hospitalization disease severity conclusion study confirm race ethnicity predictor severe covid- find clinical risk factor hospitalization severe covid- previously identify vitamin d deficiency hypercholesterolemia osteoarthritis anemia
263,background viral infection know exacerbate asthma adult previous study find patient asthma severe acute respiratory syndrome coronavirus  sars cov- pneumonia case relationship sars cov- infection severe asthma exacerbation know objective assess frequency asthma exacerbation patient asthma hospitalize sars cov- pneumonia compare symptom laboratory radiological finding patient asthma sars cov- pneumonia method include  patient march  april hospitalize chest diseases department strasbourg university hospital  asthma assess patient asthma status  period define month onset covid- symptom p prehospitalization p hospitalization p severe asthma exacerbation define accord global initiative asthma guideline p p. p define severe asthma deterioration onset breathlessness wheezing require systemic corticosteroid inhale beta agonist result find significant difference patient asthma term severity length stay maximal oxygen flow need noninvasive ventilation requirement intensive care unit transfer .% patient asthma global initiative asthma step  asthma patient severe exacerbation p  patient p  patient treat systemic corticosteroid inhale beta agonist p. conclusion result demonstrate patient asthma appear risk severe sars cov- pneumonia sars cov- pneumonia induce severe asthma exacerbation
267,background unclear asthma affect susceptibility severity coronavirus disease  covid- child pediatric asthma service worldwide respond pandemic objective describe impact covid- pandemic pediatric asthma service disease burden patient method online survey send member pediatric asthma real life think tank world allergy organization pediatric asthma committee include question service provision disease burden clinical course confirm case covid- infection child asthma result ninety respondent care estimate population child asthma complete survey covid- significantly impact pediatric asthma service cease physical appointment stop accept new patient limited patient visit consultation halve median  interquartile range patient week virtual clinic helpline launch center well expect disease control report -% patient control negatively affect adherence appear increase  confirm case covid- report population estimate incidence apparently different report general pediatric cohort conclusion child asthma appear disproportionately affect covid- outcome improve possibly increase adherence and/or reduce exposure clinical service rapidly respond pandemic limit replace physical appointment virtual encounter
268,rationale asthma constitute risk factor coronavirus disease- covid- unclear aim assess asthma common chronic disease child associate high covid- risk severity pediatric population method perform systematic literature search stage pubmed embase cinahl systematic review severe acute respiratory syndrome coronavirus  sars cov- covid- pediatric population primary article second search pubmed study covid- sars cov- asthma wheeze evaluate result study include pediatric population repeat second search biorxiv.org medrxiv.org find pre print information pediatric asthma result search systematic review find pediatric population  primary study include datum pediatric asthma comorbidity covid- second search find  result pubmed report asthma adult include datum child search  pre print include datum asthma child find report centers disease control prevention state ~.% child datum chronic condition chronic lung disease include asthma tertiary hospital new york report asthma ~.% child hospitalize covid- conclusion scarcely datum childhood asthma pediatric respiratory disease constitute risk factor sars cov- infection covid- severity study need count number case pediatric age range
269,background objective initial anecdotal report coronavirus disease  covid- china grow number study report smell and/or taste dysfunction std objective aim study investigate frequency severity std covid- patient evaluate association demographic characteristic hospital admission symptom comorbiditie blood biomarker method perform multicenter cross sectional study patient positive sars cov- n= control n=  spanish hospital datum std collect prospectively person survey severity std categorize visual analog scale analyze time onset recovery rate time recovery hospital admission pneumonia comorbiditie smoking symptom result std common covid positive patient control covid positive hospitalize patient old low frequency std recover early outpatient analysis stratify severity std show half covid- patient present severe loss smell .% taste sense impair multivariate analysis old age years hospitalize increase c reactive protein associate well sense smell and/or taste covid positive patient report improvement smell .% taste .% time survey  week infection conclusion std common symptom covid- present mainly young nonhospitalized patient study need evaluate follow chemosensory impairment
270,background centers disease control prevention advise patient moderate severe asthma belong high risk group susceptible severe coronavirus disease  covid- association asthma covid- establish objective primary objective determine prevalence asthma patient covid- major health system assess clinical characteristic comorbiditie asthmatic nonasthmatic patient covid- determine risk hospitalization associate asthma and/or inhale corticosteroid use method medical record patient covid- search computer algorithm march  april chart review validate diagnosis asthma medication prescribe asthma patient pcr confirm covid- demographic clinical feature characterize regression model assess association asthma corticosteroid use risk covid related hospitalization result  patient identify covid-  classify have asthma asthma associate increase risk hospitalization relative risk ci adjust age sex comorbiditie ongoing use inhale corticosteroid increase risk hospitalization similar adjust model relative risk ci conclusion despite substantial prevalence asthma covid- cohort asthma associate increase risk hospitalization similarly use inhale corticosteroid systemic corticosteroid associate covid related hospitalization
271,covid- pandemic surprise entire population world face unprecedented pandemic spanish flu similar disastrous consequence result drastic measure lockdown adopt worldwide healthcare service overwhelm extraordinary influx patient require high intensity care mortality associate severe comorbiditie include chronic disease patient frailty victim sars cov- infection allergy asthma prevalent chronic disorder child adolescent need careful attention necessary adaptation regular treatment plan fortunately present young people suffer covid- incidence severity age include infancy affect pandemic base background italian society pediatric allergy immunology feel necessary provide consensus statement expert panel consensus document offer rationale help guide decision making management child adolescent allergic immunologic disease
272,background  million people carry diagnosis asthma datum suggest high risk infection adverse outcome severe acute respiratory syndrome coronavirus asthma remarkably heterogeneous currently unclear patient intrinsic factor relate coronavirus disease objective seek identify characterize subset patient asthma increase risk severe acute respiratory syndrome coronavirus  infection method participant  large asthma cohort stratify clinically relevant parameter identify factor relate angiotensin convert enzyme- ace expression bronchial epithelium ace correlate gene signature interrogate publicly available database identify upstream signal event novel therapeutic target result stratify type  inflammatory biomarker identify subject demonstrate low peripheral blood eosinophil accompany increase expression severe acute respiratory syndrome coronavirus  receptor ace bronchial epithelium gene highly correlate ace overlap type   ifn signature normally induce viral infection t cell recruitment activation bronchoalveolar lavage cell ace high subject reciprocally increase patient demonstrate characteristic correspond risk factor severe coronavirus disease include male sex history hypertension low peripheral blood elevate bronchoalveolar lavage lymphocyte conclusion ace expression link upregulation viral response gene subset type -low patient asthma characteristic resemble know risk factor severe coronavirus disease therapy target ifn family t cell activate factor benefit subset patient
273,background pandemic coronavirus disease  covid- cause severe acute respiratory syndrome coronavirus  sars cov- infection widespread impact recently aim investigate clinical characteristic covid- child different severity allergic status method datum extract electronic medical record include demographic clinical manifestation comorbiditie laboratory immunological result radiological image  hospitalize covid- child summarize analyze result median age  year range  day  year boy male female ratio study  patient child infect family member fever dry cough .% common symptom gastrointestinal manifestation account .% include diarrhea abdominal discomfort vomiting .% abnormal chest compute tomography ct scan image typical sign pneumonia ground glass opacity local patchy shadowing admission laboratory result normal range small ratio lymphopenia .% eosinopenia .% observe majority .% infected child severe  .% asymptomatic infection compare child pneumonia manifest asymptomatic acute upper respiratory infection child pneumonia associate high percentage comorbidity history symptom fever cough increase level serum procalcitonin alkaline phosphatase serum interleukin il)- il- il- il- tnf alpha difference treatment duration hospitalization time positive negative nucleic acid testing outcome child mild pneumonia pneumonia hospitalize covid- child recover death intussusception sepsis  allergic child covid- allergic rhinitis .% major disease follow drug allergy atopic dermatitis food allergy asthma demographic clinical feature significantly different allergic nonallergic group allergic patient show increase acute phase reactant procalcitonin d dimer aspartate aminotransferase level compare patient immunological profile include circulate t b nk lymphocyte subset total immunoglobulin complement level serum cytokine difference allergic pneumonia group eosinophil count serum total immunoglobulin e ige level show significant correlation immunological measure immunoglobulin complement lymphocyte subset number serum cytokine level conclusion pediatric covid- patient tend mild clinical course patient pneumonia high proportion fever cough increase inflammatory biomarker pneumonia difference allergic nonallergic covid- child disease incidence clinical feature laboratory immunological finding allergy risk factor develop severity sars cov- infection hardly influence disease course covid- child
275,objective aim randomised gcp control trial clarify combination therapy antibiotic azithromycin hydroxychloroquine anti inflammation immune modulation antiviral efficacy pre emptive treatment supra infection shorten hospitalisation duration patient covid- measure day alive hospital primary outcome reduce risk non- invasive ventilation treatment intensive care unit death trial design multi centre randomised placebo control -arm ratio parallel group double blind study participant  participant recruit trial site hospital study place denmark aalborg bispebjerg gentofte herlev hillerod hvidovre odense slagelse hospital inclusion criteria patient admit danish emergency department respiratory medicine department internal medicine department age>/=  year hospitalize  lo min equivalent fio measure know intolerance allergy azithromycin hydroxychloroquine hypersensitivity quinine derivative neurogenic hearing loss psoriasis retinopathy maculopathy visual field change breastfeeding severe liver disease amoebiasis inr spontaneously severe gastrointestinal neurological hematological disorder investigator assess egfr  ms myasthenia gravis treatment digoxin glucose phosphate dehydrogenase deficiency porphyria hypoglycaemia blood glucose time hospitalization  year vs. year site recruitment patient follow chronic lung disease copd asthma bronchiectasis interstitial lung disease yes vs. blind masking participant study personnel blind i.e. know group participant allocate number randomised sample size study require  patient randomise  group trial status protocol version april recruitment ongoing patient recruit april final patient expect recruit october trial registration clinicaltrials.gov identifier nct register march protocol protocol attach additional file accessible trials website additional file interest expedite dissemination material familiar formatting eliminate letter serve summary key element protocol study protocol report accordance standard protocol items recommendation clinical interventional trials spirit guideline additional file
276,introduction little know covid- patient asthma data covid- patient severe asthma patient asthma treat monoclonal antibody case study present case severe eosinophilic asthmatic benralizumab treatment anti il r monoclonal antibody initiate  year ago prior benralizumab treatment viral infection result prolonged course oral corticosteroid ocs initiation benralizumab patient good asthma control mid march patient develop high fever result sars cov pcr nasopharyngeal swab positive patient symptom subside day ocs need asthma control questionnaire -item scale worsen moderately week infection return normal level asthma control test measure long term asthma control show decline conclusion course covid- mild particular patient severe eosinophilic asthma far evidence suggest severe course covid- patient asthma worth note prior initiation benralizumab patient multiple exacerbation year trigger viral infection /year require ocs whilst anecdotal case study provide evidence support current recommendation continue monoclonal antibody patient severe asthma covid- pandemic
277,respiratory virus common trigger asthma exacerbation virus affect patient equally strong evidence support patient asthma high risk seriously ill coronavirus disease  co vid- recent report usa uk suggest asthma common child adult mild severe covid- previously report asia europe previous severe acute respiratory syndrome sars outbreak patient asthma especially child appear susceptible coronavirus low rate asthma exacerbation different expression viral receptor t inflammation responsible different outcome future study focus asthma allergic disorder need provide great understanding impact underlie asthma allergic inflammation covid- susceptibility disease severity moment crucial asthmatic patient maintain controller medication inhale corticosteroid biologic make dose adjustment stop medication new datum emerge daily rapidly update understanding novel coronavirus
279,background morbidity mortality covid- cause novel coronavirus sars cov- accelerate worldwide novel clinical presentation covid- report range human cell tissue target sars cov- potential receptor associated regulating factor largely unknown aim study analyze expression known potential sars cov- receptor related molecule extensive collection primary human cell tissue healthy subject different age patient risk factor know comorbiditie covid- method perform rna sequencing explore available rna seq database study gene expression co expression ace cd bsg cd dpp direct indirect molecular partner primary human bronchial epithelial cell bronchial skin biopsy bronchoalveolar lavage fluid blood peripheral blood mononuclear cell pbmcs monocyte neutrophil dcs nk cell ilc ilc ilc cd(+ cd(+ t cell b cell plasmablast analyze material healthy child adult adult relation disease covid- risk factor status result ace tmprss coexpresse epithelial site lung skin cd bsg cyclophilin ppia andppib cd dpp relate molecule express epithelium immune cell observe distinct age relate expression profile gene pbmc t cell healthy child adult asthma copd hypertension smoking obesity male gender status generally lead high expression ace- cd relate gene bronchial biopsy bal blood additionally cd relate gene correlate positively age bmi interestingly observe high expression cd relate gene lesional skin patient atopic dermatitis conclusion datum suggest different receptor repertoire potentially involve sars cov- infection epithelial barrier immune cell alter expression receptor relate age gender obesity smoking disease status contribute covid- morbidity severity pattern
280,widely believe infection sars cov- virus trigger disproportionate immune response cause devastating systemic injury particularly individual obesity chronic multi organ inflammatory disease immune cell accumulate visceral adipose tissue paracrine adipocyte release wide range biologically active cytokine include il beta il il il result local pulmonary systemic inflammation intense cytokine storm postulate mechanism extreme immune response see severe covid- strike dangerous combination obesity covid- result great risk icu admission high mortality furthermore patient bame background appear increase mortality sars cov- infection high prevalence central obesity metabolic complication absence effective vaccine therapeutic potential immune modulate drug priority development new drug expensive time consume pragmatic solution seek repurpose exist drug particularly suppress heightened cytokine activity see obesity major risk factor poor prognosis covid- montelukast cysteinyl leukotriene receptor antagonist license treat asthma allergic rhinitis show diminish pulmonary response antigen tissue eosinophilia il- expression inflammatory cell show decrease elevated level il beta il human viral upper respiratory tract infection compare placebo treat patient addition silico study demonstrate high bind affinity montelukast molecule terminal site virus main protease enzyme need virus rna synthesis replication montelukast cheap safe widely available appear potential ideal candidate drug clinical trial particularly early stage disease irreparable tissue damage occur hypothesis direct anti viral effect suppression heighten cytokine release response sars cov- montelukast reduce severity immune mediate multiorgan damage result covid- particularly patient central obesity metabolic syndrome
281,objective estimate proportion total number general adult population high risk severe covid- brazil method include participant nationally representative household base health survey pns conduct brazil estimate proportion number adult  year risk severe covid- sex educational level race ethnicity state base presence follow risk factor age  year medical diagnosis cardiovascular disease diabetes hypertension chronic respiratory disease cancer stroke chronic kidney disease moderate severe asthma smoking status obesity results adult risk severe covid- brazil vary million million nationwide educate adult present high prevalence risk factor compare university graduate find difference sex race ethnicity sao paulo rio de janeiro minas gerais rio grande sul vulnerable state absolute relative term adult risk conclusion proportion total number adult risk severe covid- high brazil wide variation state adult subgroup finding consider design implement prevention measure brazil argue result support broad social isolation measure particularly testing capacity sars cov- limited
283,coronavirus disease  covid- global pandemic infectious disease cause severe acute respiratory syndrome coronavirus- sars cov- abnormal overactivated innate immunity cytokine storm propose potential pathological mechanism rapid covid- progression theoretically asthmatic patient increase susceptibility severity sars cov- infection deficient antiviral immune response tendency exacerbation elicit common respiratory virus exist study show expect prevalence asthmatic individual covid- patient certain aspect type  immune response include type  cytokine il- il- etc accumulation eosinophils provide potential protective effect covid- furthermore conventional therapeutic asthma include inhale corticosteroid allergen immunotherapy ait anti ige monoclonal antibody reduce risk asthmatic suffer infection virus alleviate inflammation enhance antiviral defense interaction covid- asthma deserve attention clarification
284,objective characterize symptom disease severity pregnant woman coronavirus disease  covid- infection laboratory finding imaging clinical outcome method pregnant woman covid- infection identify affiliate hospital new york city march  april case series study woman diagnose covid- infection base universal testing admission testing covid related symptom disease classify asymptomatic mild moderate severe base dyspnea tachypnea hypoxia clinical demographic risk factor moderate severe disease analyze calculate odd ratio ors ci laboratory finding associated symptom compare mild asymptomatic moderate severe disease clinical course associated complication woman hospitalize moderate severe disease describe result  pregnant woman covid- infection  mild asymptomatic disease  moderate severe disease  hospitalize woman moderate severe disease  receive respiratory support supplemental oxygen require intubation woman moderate severe disease high likelihood have underlie medical comorbidity vs ci asthma common moderate severe disease vs ci woman moderate severe disease significantly likely leukopenia elevated aspartate transaminase ferritin woman moderate severe disease significantly high risk cough chest pain pressure woman receive icu step level care include  day long woman undergo preterm delivery clinical status deteriorate conclusion pregnant woman contract covid- infection develop moderate severe disease include small proportion prolonged critical illness receive icu step level care
286,world health organization european centre disease prevention control suggest individual age  year underlying cardiovascular disease cancer chronic obstructive pulmonary disease asthma diabete increase risk severe covid- prevalence prognostic factor unknown country aim describe burden prevalence prognostic factor severe covid- national county level sweden calculate burden prevalence prognostic factor severe covid- base record swedish national health care population register  year st january individual include study population .% prognostic factor severe covid- individual .% factor individual prevalence underlie medical condition range .% chronic obstructive pulmonary disease individual .% cardiovascular disease individual county specific prevalence prognostic factor range .% stockholm individual .% kalmar individual individual sweden increase risk severe covid- compare critical care capacity local national level result aid authority optimally plan healthcare resource current pandemic finding apply underlie assumption disease burden model effort support covid- planning
287,limited datum available clinical presentation outcome coronavirus disease covid- patient united states hospitalize normal caseload nonsurge condition retrospectively study  consecutive adult patient hospitalize covid-  hospital san francisco bay area california usa march -april death rate hospitalize covid- patient .% median length hospitalization day  total intensive care unit patient  .% die median length intensive care unit stay  day  patient  .% underlying cardiovascular disease  .% underlying pulmonary disease study death rate low report region united states experience high volume covid- patient
288,background chest radiography validate prognostic utility evaluate patient coronavirus disease  covid- purpose analyze prognostic value chest radiograph severity scoring system young nonelderly patient covid- initial presentation emergency department ed outcome interest include hospitalization intubation prolonged stay sepsis death material methods retrospective study patient age   year present ed urban multicenter health system march  march covid- confirmation real time reverse transcriptase polymerase chain reaction identify patient ed chest radiograph divide zone examine opacity cardiothoracic radiologist score collate total concordant lung zone severity score clinical laboratory variable collect multivariable logistic regression evaluate relationship clinical parameter chest radiograph score patient outcome result study include  patient  man median age  year interquartile range year adjustment demographic comorbiditie independent predictor hospital admission n chest radiograph severity score  odd ratio confidence interval ci p obesity odd ratio ci morbid obesity patient admit chest radiograph score  independent predictor intubation n odd ratio ci p hospital site significant difference find primary outcome race ethnicity history tobacco use asthma diabetes mellitus type ii conclusion patient age year coronavirus disease  present emergency department chest radiograph severity score predictive risk hospital admission intubation c rsna  online supplemental material available article
289,zoonotic disease spread globally million human being possibly domestic wild animal eradication coronavirus disease  covid- appear practically impossible press need improve understanding immunology disease contain pandemic develop vaccine medicine prevention treatment patient review aim improve understanding immune response immunopathological change patient link deteriorate clinical condition cytokine storm acute respiratory distress syndrome autopsy finding change acute phase reactant serum biochemistry covid- similar viral infection asymptomatic disease present significant currently unknown fraction affect individual majority patient -week self limit viral respiratory disease typically occur end development neutralize antiviral t cell antibody immunity igm- iga- igg type virus specific antibody level important measurement predict population immunity disease cross reactivity coronaviruse take place high viral load infection repeat exposure virus especially healthcare worker important factor severity disease note aspect severe patient unique covid- rarely observe respiratory viral infection severe lymphopenia eosinopenia extensive pneumonia lung tissue damage cytokine storm lead acute respiratory distress syndrome multiorgan failure lymphopenia cause defect antiviral immune regulatory immunity time cytokine storm start extensive activation cytokine secrete cell innate adaptive immune mechanism contribute poor prognosis elevated level acute phase reactant lymphopenia early predictor high disease severity prevention development severe disease cytokine storm acute respiratory distress syndrome novel approach prevent development main route future research area learn live amidst virus understand immunology disease assist contain pandemic develop vaccine medicine prevent treat individual patient
290,novel coronavirus disease  rapidly increase pandemic scale appear wuhan china december troubled day scientific community ask rapid reply prevent combat emergency generally accept achieve well understanding interaction virus host immune response pathogenesis infection crucial identify valid therapeutic tool control virus entry replication spread impair lethal effect basis recent research progress severe acute respiratory syndrome coronavirus  result previous coronaviruse contribution underscore main unsolved problem focus pathogenetic aspect host immunity virus basis touch important aspect immune response asymptomatic subject immune evasion severe acute respiratory syndrome coronavirus  severe patient difference disease severity age sex
291,background december coronavirus disease  covid- outbreak occur wuhan datum clinical characteristic outcome patient severe covid- limited objective seek evaluate severity admission complication treatment outcome patient covid- method patient covid- admit tongji hospital january february retrospectively enrol follow march potential risk factor severe covid- analyze multivariable binary logistic model cox proportional hazard regression model survival analysis severe patient result identify  .%  patient severe case admission old age underlie hypertension high cytokine level il r il- il- tnf alpha high lactate dehydrogenase level significantly associate severe covid- admission prevalence asthma patient covid- .% markedly low adult population wuhan estimate mortality nonsevere patient .% severe case average  day follow period survival analysis reveal male sex old age leukocytosis high lactate dehydrogenase level cardiac injury hyperglycemia high dose corticosteroid use associate death patient severe covid- conclusion patient old age hypertension high lactate dehydrogenase level need careful observation early intervention prevent potential development severe covid- severe male patient heart injury hyperglycemia high dose corticosteroid use high risk death
293,event global infectious pandemic drastic measure need limit require adjustment ambulatory allergy service rationale prioritize service shut patient care exist consensus base ad hoc expert panel allergy immunology specialist united states canada develop service patient prioritization schematic temporarily triage allergy immunology service recommendation feedback develop iteratively adapt modify delphi methodology achieve consensus ongoing pandemic social distancing encourage allergy immunology care postpone delay handle virtual care exception patient primary immunodeficiency patient venom immunotherapy patient asthma certain severity limited need face face visit condition suggestion intend help provide logical approach quickly adjust service mitigate risk medical staff patient importantly individual community circumstance unique require contextual consideration decision enact measure rest judgment clinician individual health care system pandemic unanticipated enforce social distancing quarantining highly unusual expert panel consensus document offer prioritization rational help guide decision making situation arise allergist immunologist force reduce service make decision
294,background coronavirus disease  covid- cause severe acute respiratory syndrome coronavirus  sars cov- infection widely spread aim investigate clinical characteristic allergy status patient infect sars cov- method electronic medical record include demographic clinical manifestation comorbiditie laboratory datum radiological material  hospitalize covid- patient confirm result sars cov- viral infection extract analyze result approximately ratio male .% female covid- patient find overall median age year patient community acquire case fever .% cough .% fatigue .% gastrointestinal symptom .% common clinical manifestation hypertension .% diabetes mellitus .% common comorbiditie drug hypersensitivity .% urticaria .% self report patient asthma allergic disease report patient chronic obstructive pulmonary disease copd .% patient current smoker .% rare bilateral ground glass patchy opacity .% common sign radiological finding lymphopenia .% eosinopenia .% observe patient blood eosinophil count correlate positively lymphocyte count severe r p nonsevere r p patient hospital admission significantly high level d dimer c reactive protein procalcitonin associate severe patient compare nonsevere patient p conclusion detailed clinical investigation  hospitalize covid- case suggest eosinopenia lymphopenia potential indicator diagnosis allergic disease asthma copd risk factor sars cov- infection old age high number comorbiditie prominent laboratory abnormality associate severe patient
